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Prevention, Diagnosis, and Management of Opioids, 
Opioid Misuse, and Opioid Use Disorder in Older 
Adults 
Structured Abstract 
Background. Opioid-related harms are increasing among older adults. Until we better 
understand the factors contributing to this trend, we will be unable to design and implement 
effective interventions to optimally manage opioid use and its potential harms among older 
adults. Although considerable research has been done in younger or mixed-age populations, the 
degree to which it is directly applicable to older adults is uncertain. 
 
Objectives. To provide a framework for understanding how to reduce adverse outcomes of 
opioid use among older adults, and to describe the evidence available for different factors 
associated with and interventions to reduce adverse outcomes related to opioid use in this 
population. 
 
Approach. With input from a diverse panel of content experts and other stakeholders, we 
developed a conceptual framework and evidence map to characterize empirical studies of factors 
associated with opioid-related outcomes and interventions to reduce opioid-related harms in 
older adults. We identified relevant literature among older adults (age ≥60 years) for an evidence 
map by systematically searching PubMed, PsycINFO, and CINAHL for studies published in 
English between 2000 and May 6, 2020. 
 
Findings. We identified 5,933 citations, from which we identified 41 studies with multivariable 
models of factors associated with opioid-related outcomes and 16 studies of interventions in 
older adults. More than half (22/41) of the multivariable analysis studies evaluated factors 
associated with long-term opioid use (which, though not a harm per se, may increase the risk of 
harms if not appropriately managed). Prior or early postoperative opioid use, or greater amounts 
of prescribed opioids (high number of opioid prescriptions or higher opioid dose), were 
consistently (100% agreement) and strongly (measure of association ≥2.0) associated with long-
term opioid use. Back pain, depression, concomitant use of nonsteroidal anti-inflammatory drugs 
(NSAIDs), and fibromyalgia also had consistent, but weaker, associations with long-term opioid 
use. Several factors were mostly associated (>75% agreement) with long-term opioid use, 
including benzodiazepine use, comorbidity scores, (generally undefined) substance misuse, 
tobacco use, and low income. However, studies were mostly consistent that alcohol abuse and 
healthcare utilization were not associated with long-term opioid use. Gender, age among older 
adults, Black race, dementia, rural/nonurban residence, prescription of long-acting opioids, 
unmarried status, and use of muscle relaxants were variably associated (<75% agreement) with 
long-term opioid use.  
Six studies examined factors associated with opioid-related disorders, although only one study 
evaluated factors associated with opioid use disorder. Alcohol misuse and gender were variably 
associated with opioid misuse (examined by three studies each).  
viii 
 
All other evaluations of specific pairs of associated factors and outcomes of interest were 
evaluated by only one or two studies each. These included analyses of factors associated with 
multiple opioid prescribers, mental health outcomes, physical health outcomes, all-cause 
hospitalization, opioid-related hospitalization, nonopioid-specific hospitalization, emergency 
department visits, opioid overdose, all-cause death, opioid-related death, and nonopioid-related 
death.  
The evidence on interventions directed at older adults is sparse. Of the 16 studies of opioid-
related interventions in older adults, six examined screening tools to predict opioid-related 
harms, but none of these tools was tested in clinical practice to assess real-world results. Two 
studies found that prescription drug monitoring programs are associated with less opioid use in 
communities. Other studied interventions include multidisciplinary pain education for patients, 
an educational pamphlet for patients, implementation of an opioid safety initiative, provision of 
patient information and pain management training for clinicians, a bundle of educational 
modalities for clinicians, free prescription acetaminophen, a nationally mandated tamper-
resistant opioid formulation, and motivational interview training for nursing students. Few 
intervention studies evaluated pain or other patient-centered outcomes such as disability and 
functioning. 
 
Conclusions. The evidence base that is directly applicable to older adults who are prescribed 
opioids or have opioid-related disorders is limited. Fundamental research is necessary to 
determine which factors may predict clinically important, patient-centered, opioid-related 
outcomes. Studies to date have identified numerous possible factors associated with long-term 
opioid use (whether appropriate or not), but analyses of other opioid-related outcomes in older 
adults are relatively sparse. Research is also needed to identify interventions to reduce opioid 
prescribing where harms outweigh benefits (including screening tools), reduce opioid-related 
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We developed a Conceptual Framework outlining the stages of care for older adults who 
require or use opioids, and factors impacting management decisions and patient outcomes (see 
Figure A). The framework prioritizes three potential targets to determine factors associated with 
and interventions for: (1) reducing opioid prescriptions where harms outweigh benefits, (2) 
preventing opioid misuse and opioid use disorder (OUD), and (3) reducing other opioid-related 
harms. 
• The current literature on risk factors is mostly sparse, particularly for the most relevant 
patient-centered outcomes. The studies were not designed to evaluate predictive models 
or screening tools for clinical decision making. We found 41 studies that used 
multivariable analyses assessing factors independently associated with opioid-related 
outcomes among older adults (≥60 years). 
o 22 multivariable studies evaluated long-term opioid use, which is not specifically 
a high-risk behavior and may indicate continuing pain symptoms, but does 
increase exposure and, therefore, potential for opioid-related harms. 
 All 9 studies that looked at prior or early postoperative opioid use found 
mostly strong associations (e.g., relative risk [RR] >2.0) with long-term 
opioid use. 
 All 9 studies that examined greater amounts of prescribed opioids (higher 
number of opioid prescriptions or higher opioid dose) found mostly strong 
associations with long-term opioid use. 
 Other factors with consistent (100% agreement), but largely weak 
associations (e.g., RR <2.0, but statistically significant), included back 
pain, depression, concomitant NSAID use, and fibromyalgia. 
 Studies were mostly consistent (≥75% agreement) that concomitant 
benzodiazepine use, higher comorbidity score, (generally undefined) 
substance misuse, tobacco use, and having a low income were each 
associated with long-term opioid use, but the associations were mostly 
weak. 
 In contrast, studies were mostly consistent that alcohol “abuse” and 
healthcare utilization were not associated with long-term opioid use.  
o Across 6 studies evaluating opioid-related disorders, including OUD and opioid 
misuse, 3 studies each had variable findings regarding the associations of alcohol 
misuse and of gender with opioid misuse.  
o All other evaluations of specific factors and outcomes of interest were evaluated 
by only one or two studies each. These included factors associated with opioid 
use disorder, high-risk obtainment of prescription opioids, procuring 
multiple opioid prescribers, mental health outcomes, physical health 
outcomes, all-cause hospitalization, opioid-related hospitalization, nonopioid-
specific hospitalization, emergency department visits, opioid overdose, all-
cause death, opioid-related death, and nonopioid-related death.  
• The literature on interventions specifically intended for or evaluated in older adults is 






disorders in older adults. Only 2 studies were randomized controlled trials. Each 
intervention was evaluated by one, or in two instances, two studies. 
o The most-studied interventions were screening tools to predict opioid-related 
harms, but none of these tools has been tested in large, national populations of 
older adults to assess real-world results or clinical outcomes related to their use.  
o 2 studies found that prescription drug monitoring programs have been 
associated with less opioid use (at the State level) but did not address appropriate 
use. 
o Other studied interventions include included multidisciplinary pain education 
for patients, an educational pamphlet for patients, implementation of an 
opioid safety initiative, provision of patient information and pain 
management training for clinicians, a bundle of educational modalities for 
clinicians, clinician education, free prescription acetaminophen, a nationally-
mandated tamper-resistant opioid formulation, and motivational interview 
training for nursing students.  
o Among studies that had the goal of reducing overall opioid prescriptions or 
use, none specifically assessed “appropriate” reduction of opioid prescriptions or 
use (e.g., when the risks of opioid use outweigh the benefits). Few evaluated 
patient-centered outcomes, including pain and functioning. 
• Future research is needed of studies in older adults to establish factors associated with 
clinically-important, patient-centered opioid-related outcomes in older adults and to 
identify interventions to improve primary prevention (reducing unnecessary opioid use), 
secondary prevention (reducing opioid-related harms), and treatment of existing opioid 
misuse or OUD. 
Background and Purpose 
Opioid-related hospitalizations, emergency department (ED) visits, and deaths are increasing 
among older adults, even as rates of nonopioid-related hospitalizations and ED visits are 
decreasing. Older adults make up a growing share of the U.S. population and are at a greater risk 
of opioid exposure due to higher incidences of pain and comorbidities that result in pain. Older 
adults are also more likely than younger adults to experience adverse drug reactions and opioid 
misuse (related to both prescription and nonprescription opioids) is an increasing source of 
opioid-related harms among older adults. To address these issues, we need to examine the 
evidence base of studies of older adults to better understand the factors driving opioid-related 
harms in older adults and the evidence-based interventions to reduce those harms. 
This Technical Brief provides a conceptual framework that diagrams the process of 
care to identify areas of risk and opportunities for intervention and describes the relevant 
evidence base. The framework and evidence map will support the Agency for Healthcare 
Research and Quality’s (AHRQ) and other agencies’ development of an evidence-based research 
agenda to answer the most important questions regarding prevention, diagnosis, health outcomes, 






Figure A. Conceptual framework 
 







We developed a Conceptual Framework based on existing frameworks and discussion with 
15 Federal and non-Federal stakeholders (see Figure A). The Conceptual Framework identifies 
Guiding Questions regarding factors potentially associated with opioid-related outcomes 
(featured in the octagons) and relevant interventions (featured in the triangles). Using the 
Conceptual Framework as a guide, we conducted a literature search of relevant studies published 
between January 2000 and May 6, 2020. The review was conducted in accordance with the 
AHRQ EPC Program Methods Guidance for Technical Briefs.  
 
Results 
The Conceptual Framework outlines the stages of care for older adults related to opioid use 
as well as the factors that impact management decisions and patient outcomes. These include 
assessment of pain, selection of pain treatment, choice of opioid regimen, assessment for opioid 
misuse or opioid use disorder (OUD), and management of misuse or OUD (featured in 
Rectangles B to F). Multiple potential patient, provider, health system, and societal factors (in 
the 8 ovals) may influence risks of adverse outcomes and the effect of interventions to reduce the 
adverse outcomes (Box O). The framework includes factors associated with interventions to (1) 
reduce opioid prescriptions where harms outweigh benefits, (2) prevent opioid misuse and OUD, 
and (3) reduce other opioid-related harms.  
Regarding factors related to opioid use and harms in older adults (≥60 years), we focused on 
the 41 studies that reported multivariable analyses to identify independent factors associated with 
the outcomes of interest. There were 22 studies that addressed long-term opioid use (categorized 
into Octagon R1 in the Conceptual Framework). Long-term opioid use is not specifically a high-
risk behavior, and may indicate continuing pain symptoms, but it does increase exposure and, 
therefore, can be a useful outcome to aid with opioid management. Eight studies that addressed 
opioid misuse or OUD (related to Octagon R2) examined two sets of outcomes: opioid misuse (6 
studies) and having multiple opioid prescribers (2 studies). While having multiple opioid 
prescribers is not an indication of opioid misuse, it may reflect a high-risk patient behavior 
and/or a lack of coordinated care. The 14 studies that addressed opioid-related harms (Octagon 
R3) had four sets of outcomes: mental or physical harms (4 studies), hospitalizations or ED visits 
(5 studies), opioid overdose (3 studies), and death (5 studies). Note that while we used 
standardized terminology to categorize factors and outcomes, to avoid distorting interpretation of 
each study’s results we maintained their original terminology, even if currently out of date. 
Among 22 studies evaluating long-term opioid use among older adults, 9 that examined 
opioid use prior to surgery or injury (or early use after surgery) and 9 that examined greater 
amount of opioid use (more prescriptions or higher dose) were consistent (in full agreement) that 
these factors are associated with long-term opioid use, with mostly strong associations (e.g., RR 
≥2.0). Other consistent associations, but with largely weak associations (RR <2.0, but 
statistically significant), were found with back pain (7 studies, 3 with strong associations), 
depression (11 studies, all weak associations), concomitant NSAID use (4 studies, all weak 
associations), and fibromyalgia (3 studies, all weak associations).  
Studies were mostly consistent (≥75% agreement) that benzodiazepine use (6 of 7 studies), 
higher comorbidity score (6 of 8 studies), variably or undefined substance misuse (9 of 10 






long-term opioid use, but these associations were mostly weak. Studies were also mostly 
consistent that alcohol “abuse” (4 of 5 studies) and healthcare utilization (3 of 4 studies) were not 
associated with long-term opioid use. Numerous factors had variable findings (<75% agreement) 
of association or were evaluated by only one or two studies. 
Only 16 studies addressed interventions to reduce opioid prescriptions, reduce opioid-
related harms, or identify or treat opioid-related disorders; only two were randomized controlled 
trials. Nine studies evaluated a variety of different interventions to reduce opioid prescribing or 
use (depicted in Triangle I1); although none specifically focused on or attempted to account for 
whether harms outweighed benefits. Eight studies evaluated interventions to identify or reduce 
opioid-related disorders (Triangle I2); six of these studies evaluated five screening tools to 
identify people at increased risk of opioid-related disorders; two of the studies evaluated 
interventions to reduce opioid misuse. Two studies addressed interventions to reduce opioid-
related harms in older adults (Triangle I3), one of which addressed management of a 
hypothetical patient with opioid misuse (Rectangle F). No study specifically addressed safe 
prescription practices to reduce harms among older adults appropriately using opioids (Rectangle 
D) or treatments of OUD.  
The studies provide some preliminary evidence that various screening tools and interventions 
may be effective to reduce opioid use, reduce the risk of opioid misuse, and manage opioid 
misuse among older adults, but replication in well-designed studies is needed. Two studies found 
that prescription drug monitoring programs were associated with less opioid use (at the State 
level) but did not evaluate whether the change in opioid use was beneficial to patients. Overall, 
there has been little replication of evaluations of interventions and none of the screening tools 
have been tested in large, broadly representative populations of older adults to assess their real-
world effects. No studies evaluated the management of actual (as opposed to hypothetical) older 
adults with opioid misuse or OUD (Rectangle F). 
Limitations 
Due to resource constraints, our literature search did not include studies published prior to 
2000 and did not include all potentially relevant literature databases. In keeping with the intent of 
a Technical Brief (which is to provide a high-level overview of the evidence base and identify 
gaps) we did not fully assess the quality of each eligible study or the strength of evidence for any 
of the Guiding Questions.  
Conclusions 
The evidence base that is directly applicable to older adults who are prescribed or use opioids 
or who have opioid-related disorders is relatively sparse. Fundamental research is necessary to 
determine which factors may predict opioid-related harms for older adults. Current studies 
largely focus on amounts or duration of opioid use among older adults, without assessment of 
whether the opioids are necessary to control pain or the effect of interventions on patient-
centered outcomes. Research is needed to identify interventions to reduce opioid prescribing 
where harms outweigh benefits, reduce opioid-related harms and disorders, and treat existing 
misuse or OUD among older adults. Future research should emphasize the adaptation of existing 
interventions for the general population specifically for use in older adults and should account 
for the heterogeneity of the older adult population. However, the development, validation, and 
evaluation of new interventions tailored to the needs of older adults will likely also be necessary 
to prevent and manage opioid misuse and OUD in older adults. 
 
 
   1 
Introduction 
Background 
Between 2010 and 2015, opioid-related hospitalizations among adults aged 65 years and 
older increased by 34 percent, from 199.3 to 267.6 per 100,000 individuals, while nonopioid-
related hospitalizations decreased by 17 percent.1 Over that same period, opioid related 
emergency department (ED) visits among older adults increased by 74 percent.1 Although 
younger age cohorts suffered larger absolute increases in opioid-related mortality between 2001 
and 2016, opioid-related mortality also increased among adults between the ages of 55 to 64 and 
those that are 65 and older.2 In addition, nonmedical prescription opioid use among individuals 
aged 65 years and older has doubled, from 0.4 percent in 2002 to 0.8 percent in 2014.3 These 
data raise concerns regarding the current approaches to pain management with opioids, and 
prevention, diagnosis, and management of opioid misuse and opioid use disorder (OUD) among 
older adults. 
Older Adults Are a Growing Population 
The U.S. and global population of older adults is increasing, further creating a critical need to 
understand opioid use among older adults. The U.S. population aged 65 years and older is 
forecast to increase from 48 million people in 2015 to 88 million people in 2050.4 The 
combination of the growing population of older Americans and the increasing rates of opioid-
related harms in this population will likely result in even larger increases in the absolute numbers 
of opioid-related hospitalizations, ED visits, and mortality among older adults. 
Pain in Older Adults 
Older adults are more likely than younger adults to be exposed to opioids due to their high 
incidence of pain and need for acute and chronic pain treatment for conditions such as diabetic 
neuropathy, large joint osteoarthritis, fractures, and cancer. In older adults, compared with 
younger individuals, episodes of acute pain are more likely to transition to chronic pain due to 
biological changes in the nervous system, contributing to their experiencing severe or persistent 
pain.5-7 Older adults may also have accumulated psychological (or emotional) trauma, resulting 
in anxiety and depression; loss of loved ones or other important individuals; an erosion of social 
roles; and occurrence of disability, all of which may increase the probability that an older adult 
uses opioids as a treatment for emotional and physical pain.3 For these reasons, and more, pain 
management in older adults is particularly challenging. 
Needs and Challenges of Pain Treatment in Older Adults 
Optimizing the balance of benefits and risks for different pain treatments is particularly 
important for older adults. Opioid medicationsa are commonly used to treat pain; however their 
use, especially at higher doses, is associated with risk of opioid-related harms, including 
overdose.8-12 Furthermore, data on the effectiveness of long-term opioid therapy are still 
unavailable for many sets of clinical circumstances.13-15 Prior published evidence and guidelines 
focused on the general population have suggested that restricting opioids to severe pain or pain 
                                                 
a See Definition of Terms section at the end of the Introduction. 
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that has not responded to nonopioid therapy, using the lowest effective dose of short-acting 
opioids for the shortest duration possible, and co-prescribing opioids with nonopioid analgesics, 
but not other interacting medications, is the optimal approach.16-19 At the same time, for many 
older adults, opioid use is an appropriate (or the only) option and may offer important benefits, 
such as improved quality of life and the ability to successfully conduct activities of daily living. 
For example, many older adults are unable to tolerate nonopioid analgesics (e.g., nonsteroidal 
anti-inflammatory drugs) due to impaired liver or kidney function, hypertension,20-22 other 
cardiac risks,23-29 concomitant anticoagulant therapy in atrial fibrillation or after stroke, risk of 
gastrointestinal bleeding,30-33 or other conditions.34 Since untreated pain has been associated with 
many negative consequences, including depression, anxiety, functional impairment, slow 
rehabilitation, decreased socialization, sleep and appetite disturbances, and greater healthcare 
utilization, the benefits of opioids may outweigh the risks.35 Appropriate use of opioids under 
clinicians’ supervision may provide many older adults with necessary pain relief, allowing them 
to remain active, independent, engaged in necessary therapy (e.g., rehabilitation or 
physiotherapy), and able to maintain a higher quality of life. In turn, opioids may help prevent or 
delay disability for years among many older adults. However, clinicians and other healthcare 
professionals need evidence-based information, education, and training to balance the benefits 
and risks of opioid use in their older patients. 
Older Adults Are at Higher Risk of Adverse Events Even With 
Appropriate Opioid Use 
Empirically, older adults are significantly more likely to experience adverse drug reactions 
than younger adults,36, 37 and are at increased risk of opioid-related falls and fractures,38-41 
hospitalizations, ED visits, and death,42 even when using opioids as directed and intended by the 
prescriber. The frequency of opioid-related hospitalizations and ED visits appears to vary 
geographically, presumably because of geographic differences in patients’ characteristics and 
access to healthcare and other services and structures.1  
Age-related physiological changes (e.g. in metabolism and body composition), drug-
condition interactions, and polypharmacy (resulting in drug-drug interactions) all increase older 
adults’ risk of opioid adverse effects, even when opioids are used as intended. Polypharmacy is 
highly prevalent in older adults and increases the risk of adverse drug-drug interactions. For 
example, combining opioids and benzodiazepines can result in respiratory depression and death.  
Opioids may exacerbate pre-existing conditions such as cognitive impairment, compromised 
respiration, hypogonadism, osteoporosis, frailty (or diminished physical reserve), and other 
substance (e.g., alcohol) use disorders.43-46 Reciprocally, unrecognized cognitive decline or 
dementia may lead to unintentional deviations from a prescribed opioid regimen, and accidental 
poisoning or overdose. These risks may be exacerbated by the high frequency at which older 
adults see multiple providers and specialists, who often do not coordinate their care and prescribe 
interacting or duplicative medications.47,48  
Misuse of Opioids May Also Be Responsible for Opioid Adverse 
Events in Older Adults 
It is unclear to what extent medical opioid use (as prescribed) versus nonmedical opioid use 
or misuse accounts for the increases in opioid-related harms over the past decade among older 
adults. Media coverage and research has focused almost entirely on opioid misuse among 
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younger individuals due to their higher prevalence of misuse.1,2,49 Older adults might misuse 
prescribed opioids by taking them in greater amounts, more often, or for longer than they were 
directed to by a prescriber, or even resort to illicit opioids to alleviate untreated or undertreated 
pain, increasing the risk of overdose.50 Opioid misuse, which may be in part due to inadequate 
pain management by clinicians, raises important questions about how to ensure that prescribers 
deliver adequate pain treatment to their older adult patients and thus avoid adverse events 
resulting from suboptimal treatment. Additionally, some older adults may attempt suicide via 
self-poisoning; suicide mortality appears to be increasing among older adults51 and social 
isolation, depression, chronic pain, disability, and loss of functioning are all factors associated 
with suicide that are prevalent among older adults.51 
As with younger individuals, opioid misuse may transition to OUD. Regardless of age, 
individuals may become physically dependent on opioids (i.e., the body adjusts its normal 
functioning around regular opioid use) and continue taking them to avoid uncomfortable 
withdrawal symptoms.52,53 Physical dependence on opioids may be a precursor to, but does not 
indicate, opioid misuse or OUD. Older adults may also develop psychological and other types of 
dependence on opioids. Long-term opioid use—use of opioids on most days for longer than 3 
months—may predispose individuals to developing OUD; although this connection has not been 
established in studies of younger or older adults. Some clinician-researchers have postulated that 
the identification of substance misuse problems in later life, such as opioid misuse or OUD, may 
be complicated by a clinical presentation that is similar to depression, delirium, or dementia in 
older adults.54-56 The similarities between the symptoms of OUD and other geriatric syndromes 
may hinder identification of OUD among older adults.  
Considering all of the aforementioned information, a better understanding of the current 
approaches to prevention, diagnosis, and management of opioids, opioid misuse, and OUD 
among older adults and the supporting evidence is necessary.  
Overview of the Technical Brief 
This Technical Brief comprises a conceptual framework and a focused evidence map of the 
current evidence base with the goal of understanding the issues that are driving the current rise in 
opioid-related morbidity, mortality, and other adverse events in older adults, and what evidence 
is needed to support effective interventions to prevent and manage harms from opioids in this 
population. The framework and evidence map will support the Agency for Healthcare Research 
and Quality (AHRQ) and other agencies to design an evidence-based research agenda to answer 
the most important questions regarding prevention, diagnosis, and management of opioid use, 
misuse, and OUD among older adults. The ultimate goals are to accelerate practice change and 
improve outcomes in older adults. This brief focuses on care management rather than societal or 
high-level system issues that are outside provider or health-system control.57 
Definition of Terms 
Opioid medications: All natural, synthetic, and semisynthetic substances that have effects 
similar to morphine, specifically those approved by the U.S. Food and Drug Administration 
(FDA) as medications (e.g., oxycodone). 
Medical opioid use: Use of an opioid for a condition or a disease (an indication) for which 
reasonable scientific evidence supports that an opioid is an effective treatment. 
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Recreational opioid use: Use of an opioid for its psychoactive effects in the absence of a 
condition or a disease (an indication) that reasonable scientific evidence supports that an opioid 
is an effective treatment. 
Multimodal Stepped Pain Therapy: A pain treatment approach that sequentially (1) combines 
medications from different pharmacologic classes and/or (2) combines pharmacologic and 
nonpharmacologic therapies or multiple nonpharmacologic therapies. 
Prescribers: Healthcare professionals from any discipline who have the legal authority to 
prescribe opioids and other medications. 
Long-term opioid use: Opioid use on most days for more than 3 months. Long-term use is 
defined regardless of the clinical appropriateness of the duration of opioid use.15 
Opioid-related disorders: For the purpose of this report, any problematic opioid use, including 
OUD and opioid misuse, defined next. 
Opioid use disorder (OUD): The diagnosis of problematic use of opioids as, for example, 
defined by DSM-V (Diagnostic and Statistical Manual of Mental Disorders) criteria.58 OUD is 
the clinical term for opioid addiction. OUD is typically characterized by loss of control of opioid 
use, risky opioid use, impaired social functioning, tolerance, and withdrawal. Tolerance and 
withdrawal do not contribute toward a diagnosis of OUD when individuals are using opioids 
appropriately and under medical supervision. Diagnosis of OUD is made when a person uses 
opioids and experiences 2 or more of 11 symptoms in a 12-month period. 
Opioid misuse: A problematic pattern of opioid use, distinct from OUD. Opioid misuse is not a 
clinical diagnosis. It is the use of opioids in any way (other than OUD) that is different than as 
directed by a prescriber (e.g., at higher doses, more frequently, or for longer duration than 
prescribed; for a reason other than indicated; without one’s own prescription) or the use of any 
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Methods 
We address three overarching research questions (“Guiding Questions”) related to opioids in 
older adults:  
1. What are the most important factors driving the increase in opioid-related 
hospitalizations and ED visits for older adults and what interventions are needed to 
reduce the risk of opioid-related adverse events, opioid misuse, and OUD in older 
adults without compromising pain control or quality of life? 
2. Among older patients taking opioids, what factors are most strongly associated with 
harms from opioids (adverse events, misuse, or opioid use disorder)? 
3. What interventions have been studied to help providers to 
a. reduce opioid prescription where harms outweigh benefits in older adults 
without compromising pain control or quality of life (e.g., shared decision-
making)?  
b. reduce the risk of adverse events, misuse or opioid use disorder in older adults 
for whom opioids are appropriate? 
c. identify and treat opioid misuse or opioid use disorder in older adults?  
 
In addition, we address the question of what research is necessary to develop interventions 
that improve the management of opioids and reduce the risk of opioid-related harms in older 
adults. The original Guiding Questions, which were more detailed, were developed by AHRQ in 
consultation with other federal agencies. The original questions can be found in Appendix B 
together with further details about the methods. 
To address the issues raised by the Guiding Questions, we developed a conceptual 
framework informed by stakeholder (Key Informant) discussions and generated an evidence map 
of the existing evidence base. The conceptual framework and evidence map summarize the 
evidence in a way that allows stakeholders to readily identify the next steps for research on 
opioid use and misuse in older adults. Here we give an overview of the methods; details can be 
found in the Appendices. 
Development of Conceptual Framework 
Initial Development 
A draft conceptual framework was developed to address Guiding Question 1 based on 
existing prior conceptual frameworks and systems maps, including those developed by Wakeland 
and colleagues,60,61 the U.S. Department of Health and Human Services Pain Management Best 
Practices Inter-Agency Task Force Report,62 and the National Academies of Sciences 
Engineering and Medicine report “Pain Management and the Opioid Epidemic: Balancing 
Societal and Individual Benefits and Risks of Prescription Opioid Use”.63 Existing frameworks 
and systems maps from other conditions not directly related to pain were considered to help 
inform alternative structures and formats for the framework.64,65 
Key Informants and Discussions 
We formed a 15-member panel comprising six individuals employed by Federal agencies and 
nine individuals employed by nonfederal entities. These individuals included experts in the care 
of older adults, experts in pain treatment and opioid use, nationally and internationally 
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recognized researchers, policy makers, and internationally recognized advocates for older adults 
with pain. The expertise of the Key Informants included geriatrics, pain medicine, addiction 
medicine, psychiatry, nursing, psychology, pharmacy, emergency medicine, and health policy. 
We had discussions with the 15 Key Informants to help us revise the conceptual framework. We 
solicited the panel’s input in three teleconferences and over email until we deemed that we had 
sufficiently discussed all of the most relevant themes. The interactions with the Key Informant 
Panel were facilitated by the EPC and included several structured prompts based on all Guiding 
Questions. The Key informants were asked about the draft Conceptual Framework and to 
identify peer-reviewed publications or other relevant literature related to the topics of interest. In 
Appendix C we provide an overview of our discussions with Key Informants that helped to 
shape the Conceptual Framework and to evaluate the evidence base. Appendix C also includes 
specific themes identified during the discussions. 
Evidence Map 
We conducted a literature search to find articles primarily addressing Guiding Question 2 
(factors associated with harms from opioids in older adults) and Guiding Question 3 
(interventions that either appropriately reduce opioid prescribing and risk of harms, or identify 
and treat misuse and OUD in older adults). We primarily sought studies that pertain to the 
likelihood of opioid use, preventing opioid misuse and OUD and reducing opioid-related harms 
(relating to the three Octagons and Triangles in the Conceptual Framework (Figure 1). 
The evidence map enumerates and describes the primary studies that directly address relevant 
questions pertaining to the management of opioid use and misuse in older adults. It forms a 
citation list and database for any future systematic review on the topic. In keeping with the intent 
of a Technical Brief, we did not assess their methodological quality. The literature search is 
described in Appendix A. Appendix B describes processes for abstract screening and further 
details about our methods to create an evidence map from full-text articles. 
Based on discussions with the Key Informants and the variable definitions of “older adults” 
across studies, we focused on studies that included adults aged 60 and over. There is no standard 
definition of “older adult.” Most studies, especially those based in the United States, used a 
threshold of 65 years, in keeping with Medicare eligibility criteria. To be more inclusive, we 
selected a threshold of 60 for our eligibility criteria; although, we recognize that some 
researchers consider adults 55 years, or even 50 years, to be potential thresholds to describe older 
adults in the context of opioid use. We restricted to studies conducted in high-income countries 
and excluded studies of older adults who were terminally ill, in hospice, or in similar situations 
where opioid harms, misuse, or OUD are of lesser concern. All factors associated with opioid 
misuse, harm, or OUD were considered and included, as were all factors and interventions 
regarding opioid use (including long-term opioid use), manage opioid use, or prevent opioid-
related harms, including misuse and OUD. Any outcome (person-, provider-, and system-level) 
was eligible for inclusion. All primary study designs, as well as systematic reviews and clinical 
practice guidelines, were eligible for inclusion.  
We searched PubMed, PsycINFO, and CINAHL, using terms related to older age or aging, 
crossed with terms for opioid use, opioid-related disorders, opioid misuse, and opioid-related 
adverse events. We did not include search terms for (and thus avoided excluding articles based 
on) interventions, outcomes, or study designs. We limited results to studies published in English, 
between January 1, 2000 and May 6, 2020. We restricted the time frame due to resource 
limitations (and, thus, feasibility). We chose a timespan of the past 20 years (specifically, since 
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1/1/2000), because older empirical data are less likely to be relevant to today’s setting. 
Demographic and clinical characteristics of older adults have shifted dramatically over the last 
20 years, so earlier evidence may not generalize well to a modern older adult population. Where 
earlier studies may also be applicable, important questions are often addressed by more recent 
replication studies, in which case they would be represented in the evidence map (with the 
possible exception of studies of pharmacological interventions, such as for treatment of OUD, 
that have not recently been investigated in older adults). Furthermore, the more recent literature 
is probably more relevant for informing the future research agenda. 
To screen the evidence base, we used the online software Abstrackr, which uses machine 
learning algorithms to predict and sort citations based on likely relevance; using these 
algorithms, we stopped screening when the remaining prediction values suggested no further 
relevant citations would be identified.  
We also searched ClinicalTrials.gov and PROSPERO to identify unpublished studies, 
ongoing studies, and unpublished systematic reviews. All potentially eligible citations were 
retrieved and screened in full text for eligibility by a single reviewer, after a training period to 
ensure consistency between all reviewers. Each eligible study was extracted for a limited set of 
elements on the population, the association variables (factors) or intervention, intent of 
interventions, examined outcomes, and study design features. All data were extracted into a 
predefined electronic form. Of note, we used standard terminology to categorize factors and 
outcomes, but we maintained the original wording used by the studies (e.g., “abuse”) during 
extraction and study-level summarization to avoid misrepresenting the original studies, even if 
the language used by the studies’ authors might currently be considered inappropriate or 
stigmatizing. 
We provide a high-level summary of the body of evidence that evaluated putative factors that 
predict adverse outcomes related to opioids in older adults. The summary focuses on only 
multivariable analyses within clearly specified cohorts of older adults since these studies are 
more likely to reliably identify independent variables (factors) than studies performing 
univariable analyses of a single variable in each model. We then organized the data from the 
studies by factor and opioid related outcome. The measure of association estimates from these 
multivariable analyses were each categorized according to the direction of the association and by 
following schema: 
• Strong association: a statistically significant association between a (categorical) 
factor and higher (or lower) risk of the outcome with a measure of association ≥2.0 
(or ≤0.5); e.g., relative risk (RR) or odds ratio (OR). 
• Weak association: a statistically significant association between a (categorical) 
factor and higher (or lower) risk of the outcome with a measure of association 
between 0.5 and 2.0 
• Statistically significant association: for evaluations of continuous factors (e.g., age, 
per year) for which we could not estimate a standardized measure of association 
where the association was statistically significant (we did not classify these 
associations as strong or weak) 
• No statistically significant association: for factors without a statistically significant 
association, regardless of magnitude of measure of association 
 
In partial determination of the strength of the body of evidence, we assessed whether findings 
were consistent across studies. We found no guidance on how to assess consistency of 
 
 
   8 
semiquantitative summaries of association studies. AHRQ guidance for assessing consistency 
across (primarily intervention) studies suggest consideration of direction and/or magnitude of 
effect (depending on the research question) and promotes the judgment of the researchers to 
determine consistency.66 For the purpose of the qualitative assessment of the evidence base for 
this report, we established the following arbitrary criteria for different levels of consistency: 
• A minimum of 3 studies had to evaluate the same factor category (e.g., age) for the 
same outcome (e.g., long-term opioid use). Associations with only one or two studies 
were not evaluated for consistency. 
• “Consistent” – All studies agreed in both direction and statistical significance of 
association (e.g., all found significant associations between history of depression and 
increased likelihood of long-term opioid use). Description of whether associations 
were strong or weak are noted. 
• “Mostly consistent” – At least 75 percent of studies agreed in both direction and 
statistical significance of association. No more than one study found a statistically 
significant association in the opposite direction (e.g., that men, not women, were at 
increased risk of outcome). Remaining studies found no significant association. 
o Note that where three studies evaluated a given association, a determination of 
“mostly consistent” was not possible. 
• “Variable” – Studies are neither consistent nor mostly consistent. 
 
We separately analyzed the studies of identifiable interventions used in (or for) older adults 
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Findings 
Conceptual Framework 
The Conceptual Framework (Figure 1) outlines the stages of care for older adults who use (or 
may use) opioids and factors that impact management decisions and patient outcomes, including 
assessment of pain, selection of pain treatment, choice of opioid regimen, assessment for opioid 
misuse or OUD, and management of misuse or OUD. The framework is intended to remain 
general enough to accommodate the considerable differences among older adults across the 
population. It incorporates “pathways” by which older adults start using (or misusing) opioids 
(namely, via a “pain pathway” [Box A1 in the figure] resulting in opioid prescription by a 
licensed healthcare professional or via a “recreational use pathway,” [Box A2] in which people 
start using opioids for recreational purposes).  
For patients who enter through the “pain pathway,” (Box A1) the clinician first assesses their 
pain to determine its cause (Rectangle B) using appropriate questions and possible screening 
tools that take into account older adults’ characteristics and expectations (e.g., using instruments 
validated in individuals with dementia to elicit an accurate response, or that overcome the 
common perception among some older adults that pain is part of the aging process). They then 
consider possible treatment options (Rectangle C). Providers can (or should) use the pain 
assessment to estimate the risks and benefits of various pain treatments in a given older patient. 
For example, kidney or liver disease identified during pain assessment influences the relative 
harms and benefits of using one treatment option versus another, such as nonsteroidal anti-
inflammatory drugs versus opioids.  
While opioids are an option (Rectangle C), nonopioid medications could be used to manage 
pain among older adults who do not have contraindications; although relative contraindications 
are commonly present among older adults (e.g., impaired liver or kidney function, hypertension). 
These medications include acetaminophen, nonsteroidal anti-inflammatory drugs (e.g., 
ibuprofen, naproxen), corticosteroids, antidepressants, antiepileptics, and others (e.g., topical 
capsaicin products). Nonpharmacological options are available as well and include a wide array 
of potential interventions, such as yoga, massage therapy, and acupuncture. Since older adults 
are often more susceptible to adverse drug events than younger adults, nonpharmacological 
treatment options may offer a lower risk of harms while providing an important benefit to older 
adults. Importantly, older adults may start “multimodal” treatment (of more than one 
intervention) that comprises a pain treatment approach that (1) combines medications from 
different pharmacologic classes and (2) combines pharmacologic and nonpharmacologic 
therapies or multiple nonpharmacologic therapies.  
The framework prioritizes three potential targets to determine factors associated with and 
interventions for (1) reducing opioid prescriptions where harms outweigh benefits, (2) preventing 
opioid misuse and OUD, and (3) reducing other opioid-related harms. 
Many factors play a role in the decision to use (or avoid using) opioids to manage pain 
(Octagon R1). A key consideration is whether the benefits of opioid treatment outweigh its 
harms. Such benefit-harm assessments are difficult and can be erroneous when information about 
key factors is lacking or not considered and can be skewed when there is limited access to 
effective nonopioid treatment alternatives. Interventions to support benefit-risk assessments 
(Triangle I1) could be employed at this point in the care pathway. For example, patient-level 
tools could, in theory, help clinicians assess the expected benefits and risks of opioid or other 
pain treatment use. These may be instruments that predict effectiveness or risks based on easily 
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assessable factors available to the clinician during the patient encounter. System-level 
interventions (at the clinic, hospital, pharmacy, healthcare system, or State levels) to increase 
access to and the affordability of effective nonopioid alternatives may also be impactful. 
If opioids are prescribed to an older adult (Rectangle D), prescribers must select a dose, 
schedule, form, and route of administration, and decide if and how they will monitor for opioid 
effectiveness, adverse events, misuse, and OUD. Age-related changes in metabolism of opioids 
are pronounced among older adults and clinicians may, for example, need to consider starting an 
opioid at the lowest tolerated dose (i.e., lower than employed in younger populations) and slowly 
titrating the dose up to achieve appropriate relief of pain with minimal adverse effects. Opioid 
use in older adults may eventually result in opioid misuse or OUD, and a variety of factors may 
predict transition to misuse, OUD, or both (Octagon R2). Pharmaceutical, non-pharmaceutical 
(e.g., behavioral), nonmedical (e.g., educational, community-based), and other interventions 
could help older adults to safely use prescription opioids and prevent or reduce the risks of 
transition to opioid misuse and OUD (Triangle I2). 
If older adults do engage in opioid misuse or develop OUD, the next stage in the care 
pathway (Rectangle E) relates to how misuse or OUD is identified. Similar to the idea that 
prediction tools could be used to assess likely benefits and harms at the time of opioid 
prescribing to reduce prescribing where harms outweigh benefits, tools could also help 
practitioners (and patients) determine who is at increased risk of opioid misuse and OUD. 
Rectangle E is where individuals from the “recreational use pathway” (Box A2) may enter into 
the Conceptual Framework. Identification of misuse or OUD among this group of older adults 
may require different methods or tools from those used to identify misuse or OUD among those 
in the “pain pathway.” 
Older adults identified with opioid misuse or OUD require management to reduce or stop 
associated harms (Rectangle F). Potential management options include interventions to 
coordinate care or improve healthcare transitions, pharmacological, nonpharmacological, and 
behavioral treatments, and combinations thereof.  
Each care pathway stage (Rectangles C through F) may ultimately give rise to an array of 
factors that predict opioid-related harms other than misuse or OUD (Octagon R3). Interventions 
(Triangle I3) could affect the factors that predict opioid-related harms (other than opioid misuse 
or OUD). If effective, they would prevent opioid-related adverse events and optimize other 
health outcomes (Box O). Rather than solely preventing harms, some intervention may also 
improve affected individuals’ quality of life, physical and cognitive function, and other 
outcomes, and ultimately reduce death. Improved knowledge of factors to predict these outcomes 
could inform an understanding of which interventions (in Triangle I3) might be most effective. 
As indicated by the light green rectangle that encompasses most of the conceptual 
framework, there are many interconnected variables or potential predictors (represented by green 
ovals P1-P8 at the top of the figure) that influence many aspects of the care management process 
and associated events, as well as each other. These relationships are too numerous, implicit, and 
complex to be depicted using arrows in the framework and thus are shown through the shaded 
rectangle. They include pain type, provider, patient, setting, guidance, and substance use factors 
(ovals P3-P8). Other predictors, included outside the light green rectangle, represent system and 
societal factors (ovals P1 and P2) outside the scope of this Technical Brief. These are likely to 
impact opioid use, misuse, and OUD, but are beyond the scope of research considered. 
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Evidence Map 
The literature search yielded 6,244 citations, of which 4,153 were screened in duplicate. The 
remaining citations were predicted to be of low probability of relevance by software. Additional 
details about screening can be found in Appendix D. Overall, we identified 191 articles of 
potential interest that addressed associations or interventions. From these, we included 41 studies 
that reported multivariable analyses of factors associated with outcomes of interest, and 16 
studies that evaluated interventions.  
Detailed information about these 57 studies are included in Appendix D, Tables D-3 to D-6. 
Another 121 articles reported unadjusted (univariable) or other analyses and were excluded. 
Appendix E lists the rejected articles and reasons for rejection. Appendix D (first paragraph) and 
Appendix Figure D-1 provide further details about the literature flow. 
We first present the evidence base of factors independently associated with outcomes of 
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Abbreviations: ED = emergency department, HCV = hepatitis C virus, HIV = human immunodeficiency virus, OUD = opioid use 
disorder. 
Relation of Evidence to Conceptual Framework 
Factors Associated With Opioid-Related Outcomes in Older Adults 
Overview of Literature 
We restricted our review to the 41 studies that reported multivariable analyses, since findings 
from unadjusted analyses are more likely to be spurious and therefore do not add much to the 
evidence base (for the purpose of determining likely candidates for independent predictors of 
outcomes of interest). None of the models (multivariable analyses) was designed or evaluated as 
a screening or prediction tool. 
We organized the 41 studies based on their analyzed outcomes. We categorized these into 
seven overall types of outcomes:  
1. long-term opioid use 
2. opioid-related disorders 
3. multiple opioid prescribers (or pharmacies) 
4. clinical harms, related to either mental or physical health conditions 
5. opioid-related hospitalization or ED visit 
6. opioid overdose 
7. death 
 
This categorization roughly corresponds to the temporal order that people interact with 
opioid use. Referring to the Conceptual Framework (Figure 1), category 1 aligns with opioid use 
(Octagon R1), categories 2 and 3 align with opioid misuse or OUD (Octagon R2 and Rectangle 
E) and categories 4 to 7 align with opioid-related adverse events and other health outcomes 





We also categorized the numerous specific evaluated factors into 31 categories that fell into 9 
factor types, which are depicted in the Conceptual Framework (Figure 1) as noted below. These 
factors are: 
• System factors: insurance feature (Oval P1) 
• Pain factors: cause and severity (P3) 
• Provider factors: specialty (P4) 
• Patient factors (P5) 
o Demographics: age, gender, race/ethnicity 
o Socioeconomic factors: income, employment, education, rural vs. urban, 
social factors, insurance status 
o Health conditions: comorbidities (physical health), mental health, activities of 
daily living, quality of life, healthcare utilization 
o Pharmaceutical treatments: nonopioid pain treatments, nonpain treatments 
• Guidance: opioid stewardship (P7) 
• Substance use (past or current): opioid-related disorders (opioid misuse, OUD, high-
risk behaviors), methadone use, number of opioid prescribers, substance misuse, 
tobacco use, benzodiazepine use or misuse (P8) 
• Opioid factors: history of opioid use, opioid duration, opioid amount, opioid type, and 
opioid prescription rates (addressed in Rectangles C and D) 
 
None of the factors evaluated by eligible studies related to societal factors, such as cultural biases 
for or against using opioids (Oval P2), or setting factors (Oval P6). Some factors that could be 
categorized as “setting” were categorized as patient factors (e.g., rural vs. urban) or provider 
factors (e.g., specialty). 
Very few analyses reported patient-centered outcomes. More than half (22 of 41) of the 
multivariable studies evaluated factors independently associated with long-term use of opioids. 
Many fewer studies evaluated outcomes pertaining to opioid-related harms (such as overdose or 
OUD) or high-risk or undesirable behaviors (such as opioid misuse). The factors most commonly 
evaluated included demographic factors, comorbidities, medication factors, history of pain or 
opioid use, social conditions, and history of substance use. All studies were based on 
retrospective (already collected) data. Three-quarters of the studies (31 of 41) were longitudinal; 
10 were cross-sectional, based on survey or registry data. Most included specific populations of 
patients (e.g., based on cause of pain, such as surgery or hip fracture), as noted in the tables 
describing the study findings. 
Roadmap for Reading the Description of the Evidence Map 
We describe the evidence pertaining to each “predictor” octagon in the Conceptual 
Framework (Figure 1) separately. Namely, we describe studies pertaining to “predictors” of 
opioid use (Octagon R1), “predictors” of opioid misuse and OUD (Octagon R2), and 
“predictors” of opioid-related harms (Octagon R3). While, we had hoped to find studies that 
evaluated predictors, many of these studies were either cross-sectional or otherwise did not 
evaluate whether the variables included in their models predicted future events. We use the term 
“factor” to cover any variable entered into the multivariable models (including true predictors, 
risk factors, or other measures). 
Within each “risk factor” category section (R1, R2, R3), we separately summarize particular 





the subcategories OUD, opioid misuse, and high-risk obtainment of prescription opioids). Within 
each (sub)section, we describe the evidence and discuss relevant research needs. Additional 
research needs are discussed at the end of this section on “Factors Associated with Opioid-
Related Outcomes in Older Adults.” 
To help frame the following detailed summaries of the various association studies, in Table 1 
we provide an overall summary of the factor-outcome pairs for which there were at least three 
studies, summarizing findings as well as consistency and strength of association (as defined in 
the Methods). Outcomes with only one or two studies are not included in Table 1 but are 






Table 1. Summary of consistency and direction of associations across multivariable analyses 






− Assn NS Total Consistency Association 
Long-term opioid use          
 Opioid use Early (or preoperative) 7 2    9 Consistent Strong (mostly) 
 Opioid amount More* 6 3    9 Consistent Strong (mostly) 
 Pain cause Back pain 3 4    7 Consistent Strong/weak 
 Mental health Depression  11    11 Consistent Weak 
 Nonopioid pain treatment NSAID  4    4 Consistent Weak 
 Pain cause Fibromyalgia  3    3 Consistent Weak 
 Benzodiazepine use  3 3   1 7 Mostly consistent Strong/weak 
 Comorbidities Comorbidity score † 2 4   2 8 Mostly consistent Strong/weak 
 Substance misuse Substance misuse ‡ 2 7   1 10 Mostly consistent Weak (mostly) 
 Tobacco Tobacco 1 4   1 6 Mostly consistent Weak (mostly) 
 Income Low income §  8   2 10 Mostly consistent Weak 
 Substance misuse Alcohol  1   4 5 Mostly consistent NS 
 Healthcare utilization Greater use 1    3 4 Mostly consistent NS 
 Gender Female  8 1 1 8 18 Variable  
 Age Younger § 2 6  2 4 14 Variable  
 Race Black  5  3 4 12 Variable  
 Comorbidities Dementia 1 1  2 1 5 Variable  
 Geography Rural/Nonurban  1  1 3 5 Variable  
 Opioid type Long-acting 2    1 3 Variable  
 Social Unmarried § 1 1   1 3 Variable  
 Nonopioid pain treatment Muscle relaxant  2   1 3 Variable  
Opioid misuse          
 Gender Female  1   2 3 Variable  
 Substance misuse Alcohol 1 1   1 3 Variable  
Note: This table includes only factor-outcome pairs that were reported by at least 3 studies. Broad (nonspecific) factor categories (e.g., pain cause) are omitted. Within each 
outcome, factors are sorted based by consistency, strength of association, and number of studies. Specific factors within broad factor categories are included (i.e., pain cause/back 
pain, pain cause/fibromyalgia, mental health/depression, nonopioid pain treatment/NSAID, substance misuse/alcohol, race/Black, comorbidities/dementia).  






Strong association: Measure of association (e.g., relative risk) ≥2.0 (or ≤0.5) and statistically significant. 
Weak association: Measure of association between 0.5 and 2.0 and statistically significant. 
 
NS = not statistically significant. 
+ = “positive” association (presence or magnitude of factor associated with increased likelihood of outcome). 
− = “negative” association (presence or magnitude of factor associated with decreased likelihood of outcome). 
 
Consistent:  100% agreement in direction and statistical significance across studies, irrespective of strength of association. 
Mostly consistent: ≥75% agreement (and <100%) across studies, irrespective of strength of association. 
Variable:    <75% agreement across studies.  
Other abbreviations: Assn = association, NSAID = nonsteroidal anti-inflammatory drug. 
* Number of prescriptions or opioid dose. 
† Charlson Comorbidity Index or Hierarchical Condition Category. 
‡ Variably (or not) defined. 
§ Note that this factor, and thus the directions of the associations, has been inverted compared with Tables 3 and 4. 
 
Factors Associated With Opioid Use (Octagon R1) 
None of the eligible studies evaluated factors associated with opioid use, per se. The largest 
number of eligible studies evaluated factors associated with long-term opioid use. Long-term 
opioid use is not a clinical harm in and of itself, since chronic, long-term pain may require long-
term analgesia, and thus appropriate long-term opioid use. Evidence from the general population 
is inconclusive regarding whether long-term opioid use is itself a predictor of opioid misuse or 
OUD.67 However long-term opioid exposure likely increases the risk of harm unless 
appropriately managed, and may indicate persistent pain that is not adequately controlled with 
other interventions. For these reasons, we determined that it is an outcome of interest. 
To help the reader interpret the subsequent summary tables, Table 2 provides a guide to the 
coding of study findings in Tables 3 to 14. The set of studies that evaluated factors associated 
with opioid use among older adults are summarized in Tables 3 to 6. 
Factors Associated With Long-Term Opioid Use 
Evidence Base 
More studies evaluated long-term opioid use than all other outcomes combined, possibly 
because the outcome is relatively easy to gather from pharmacy or insurance records. We found 
22 studies that reported multivariable models of long-term opioid use in older adults.68-89 
Definitions of long-term opioid use varied across studies: 11 evaluated at timepoints from 3 to 6 
months of use or more, two evaluated 9 to 12 month data, six evaluated approximately 1 year, 
one evaluated 1 month data, and two did not define long-term opioid use. 
In brief, several factor categories (and specific factors) have been found to be associated with 
increased likelihood of long-term opioid use. Furthermore, many of the associations are strong. 
Given the large number of specific factors evaluated, to help the reader, in addition to bolding 
the factor categories, in the text of this section we also underline the specific factor (although, we 
sometimes bold or underline both factor categories and specific factors within paragraphs to 
diminish visual clutter). 
Demographic Factors Associated With Long-Term Opioid Use 
Fourteen studies evaluated age (within the cohort of older adults) as a factor associated with 





older adults) is associated with increased likelihood of long-term opioid use; however, the 
majority of studies found (mostly weak) associations between older age and decreased likelihood 
of long-term opioid use. Among 18 studies evaluating gender, associations were also variable, 
but only two found that men were more likely to use opioids long-term. Notably, the only strong 
association was in a study of people with oropharyngeal cancer that, counter to most others, 
found that men were twice as likely to have continuous opioid use at 6 months. Twelve studies 
found variable associations between race and likelihood of long-term use, but all associations 
were weak or nonsignificant. Among the eight studies that reported statistically significant 
associations, five studies found that Blacks (or other non-White racial groups) had an increased 
likelihood of long-term opioid use, while three others found an association with decreased 
likelihood.  
Health Status Factors Associated With Long-Term Opioid Use 
Seventeen studies evaluated a large range of comorbidities, both within and between studies 
(Table 3). Studies were variable in their findings, but most found that there were associations 
between at least some comorbidities and the likelihood of long-term opioid use; these 
associations were mostly weak. The strong associations found were for presence of 3 to 4 
comorbidities, Hierarchical Conditional Category ≥1.20, and Charlson Comorbidity Index ≥3 
(but four of five studies found weak associations), and, separately, migraine, mild liver disease, 
and weight loss (not fully defined, but described in the study as a nutritional or medical 
comorbidity after total hip arthroplasty). A third study found a strong association between an 
AIDS diagnosis and a decreased likelihood of long-term opioid use. The evidence for dementia 
is variable among five studies: dementia was found to be strongly associated with increased 
likelihood of long-term use in one study and weakly associated in a second study, but, in contrast 
weakly associated with decreased likelihood in two other studies, and no significant association 
in the final study.  
Four studies of healthcare utilization were mostly consistent, with three finding no 
statistically significant association with likelihood of long-term opioid use (Table 3). The 
exception found a strong association between “any hospitalization” and increased likelihood of 
long-term use. Fourteen studies evaluated mental health factors. Eleven of these studies were 
consistent in finding weak associations between depression and increased likelihood of long-
term opioid use. Only psychosis, in a single study, was found to be strongly associated with 
increased likelihood of long-term opioid use. Three studies reported that people with 
schizophrenia or bipolar disease were less likely to use opioids long-term. 
Socioeconomic and Related Factors Associated With Long-Term Opioid Use 
Ten studies evaluated measures of income as factors associated with long-term opioid use 
(Table 4). Although definitions of income status varied, the 10 studies were mostly consistent, 
with eight of the studies finding weak associations between higher income and decreased 
likelihood of long-term opioid use. Five studies evaluated geographic location (categorized as 
rural in the table). The studies had variable findings. One study found that urban residents were 
(weakly) more likely to have long-term opioid use than “metropolitan” residents (they found no 
statistically significant association with rural residents). One found that nonurban residents were 
(weakly) more likely to have long-term opioid use. The other three studies found no statistically 
significant association with metropolitan residence. 
Four studies evaluated social factors (Table 4). Three studies evaluated marital status, 





unmarried and increased likelihood of long-term opioid use. The fourth study found that whether 
people dwelled in their home was not associated with long-term use. Two studies evaluated 
insurance status, with one study finding a weak association between Medicare Advantage 
coverage and increased likelihood of long-term opioid, relative to standard Medicare coverage 
and the second study founding a weak association between having supplemental Medicare 
coverage with relatively more copayments or deductibles, compared with coverage plans with 
minimal copayments or deductibles. 
Pain Factors Associated With Long-Term Opioid Use 
Nineteen studies evaluated a variety of causes of pain (Table 5). In brief, a large number of 
specific causes were associated with long-term use. The six strong associations found were 
mostly musculoskeletal conditions: back pain (in three studies, one with the strong association 
specifically for chronic back pain), bilateral total knee arthroplasty (TKA) (vs. unilateral TKA), 
and osteoporosis. One study found a strong association of long-term opioid use with higher than 
“very low” risk category of prostate cancer after radical prostatectomy. Two specific causes of 
pain were evaluated by at least three studies, each with consistent findings. Long-term opioid use 
was associated with back pain in seven studies (three strong [just chronic back pain in one 
study], three weak associations [just new back pain in one study]) and with fibromyalgia in three 
studies (all weak) 
Prescription Drug Treatment Factors Associated With Long-Term Opioid Use 
Seven studies evaluated (concomitant) nonopioid pain treatments as factors associated with 
long-term opioid use (Table 5). It should be noted that the concomitant use of nonopioid pain 
treatments may be a marker of less-well controlled chronic pain. The most frequently analyzed 
nonopioid pain treatment was nonsteroidal anti-inflammatory drugs (NSAIDs). The four studies 
were consistent in finding weak associations between NSAID use and long-term opioid use. 
Across the studies, the three strong associations were found with acetaminophen use (in one 
study), with antineuropathic pain treatments (either antidepressants or antiepileptics, in one 
study), and with muscle relaxants (in one study, but only weak associations in two other studies). 
Seven studies evaluated a variety of nonpain treatments. Individual studies found weak 
associations with rheumatoid arthritis treatments, anxiolytics, antipsychotics, sleep medication, 
and radiation and chemotherapy treatments.  
Opioid Use Factors Associated With Long-Term Opioid Use 
Nine studies evaluated different measures of opioid use as factors associated with long-term 
opioid use (Table 5). The studies consistently found that prior use (including preoperative use) or 
early use after surgery or an injury were associated with increased likelihood of long-term opioid 
use; seven of the nine studies found strong associations. Two studies disagreed regarding 
dependence as an associated factor. Neither study defined “dependence.” One study found a 
weak association between dependence as an independent variable and opioid use 9 to 12 months 
postoperatively (as the dependent variable). The second study, counterintuitively, reported that 
people with opioid dependence (as a comorbidity) were almost half as likely to be using opioids 
9 to 12 months postoperatively. No explanation for this finding was given. In contrast, nine 
studies were consistent in finding that increased opioid amounts (more prescriptions or higher 
dose opioids) were associated with long-term use (strong associations in six of the studies). This 
association was found for greater number of prescriptions (five studies), higher dose (three 





Four studies evaluated different opioid types (Table 5), both within and across studies. Three 
studies evaluated long-acting opioids, with different findings of either a strong (2 studies) or no 
association (1 study) with long-term opioid use. One study found a strong association 
specifically for use of the strong opioid oxycodone (compared with the weak opioid 
hydrocodone) with long-term opioid use, while another found only a weak association with the 
use of strong opioids (see Table 5 footnote). Another study found a strong association between 
use of the weak opioid tramadol (versus no tramadol) and long-term opioid use, while one study 
found no statistically significant associations with use of the weak opioid codeine. Finally, one 
study found that transdermal opioids were strongly associated with increased likelihood of long-
term use. 
Substance Use and Misuse Factors Associated With Long-Term Opioid Use 
A single study reported that methadone users were at strongly increased likelihood of long-
term use (Table 6). Fourteen studies evaluated (at least implicitly nonopioid) substance misuse 
as factors associated with long-term opioid use. The studies were variable in their findings, with 
ten finding (mostly weak) associations between substance (or “drug”) use (or “abuse”; mostly 
not specifically defined) and long-term opioid use, but four finding no significant association. 
However, most of the associations with specific substances were not statistically significant. In 
particular, five studies were mostly consistent in finding no significant association with alcohol 
“abuse”, with only one study finding a weak association. This study was also the only study to 
evaluate use of marijuana, cocaine, and amphetamines, finding that marijuana use was weakly 
associated with increased likelihood of long-term opioid use, but there were nonsignificant 
associations with cocaine and amphetamine use. 
Six studies evaluated tobacco use as a factor associated with long-term opioid use (Table 6). 
The studies were mostly consistent (5 of 6 studies) in finding that people who used tobacco had 
increased likelihood of long-term opioid use, but only one of the studies found a strong 
association. Seven studies were mostly consistent that people who used benzodiazepines also 
had increased likelihood of long-term opioid use. Three of these seven studies found strong 
associations, but one found no statistically significant association.  
Two studies evaluated proxy measures for opioid stewardship (Table 6). One found a strong 
association between prescribers being concordant with guidance and decreased likelihood of 
long-term opioid use. Based on evaluation of a claims database,78 the study found that those 
participants (not seen in an ED) whose opioid prescriptions were for no more than 3 days, no 
more than 50 mean morphine equivalents, and were not for a long-acting opioid were less than 
one-fourth as likely to use opioids for at least 12 months than patients who received regimens 
with a longer duration, higher dose, or use of a longer-acting opioid. A similar, but weak 
association, was found for those participants seen in the ED. In the second study,81 participants 
whose medical records indicated that they were provided with any type of tapering plan for their 
opioids had a (weakly) decreased likelihood of long-term opioid use. Neither study evaluated 
opioid stewardship as an intervention, per se. 
Summary of Factors Associated With Long-Term Opioid Use 
Overall, 22 multivariable models have evaluated a large number of potential factors 
associated with long-term opioid use among older adults. Table 1 highlights the findings for 
factor-outcome pair associations analyzed by at least three studies. 
Studies were consistent (in full agreement) that—in nine studies—opioid use prior to surgery 





prescriptions or higher dose) are the factors with mostly strong associations with long-term 
opioid use.  
Other consistent associations, but with largely weak associations, were found with back pain 
(7 studies, 3 with strong associations), depression (11 studies, all weak associations), 
concomitant NSAID use (4 studies, all weak associations), and fibromyalgia (3 studies, all weak 
associations).  
Studies were mostly consistent (≥75% agreement) that benzodiazepine use (6 of 7 studies, 3 
with a strong associations), comorbidity scores (6 of 8 studies, 2 with strong associations), 
variably or undefined substance misuse (9 of 10 studies, 2 with strong associations), tobacco use 
(5 of 6 studies, 1 with a strong association), and low income (8 of 10 studies, all with weak 
associations) were associated with long-term opioid use.  
Studies were also mostly consistent that alcohol “abuse” (4 of 5 studies) and healthcare 
utilization (3 of 4 studies) were not associated with long-term opioid use; however, one of these 
latter studies found a strong association between “any hospitalization” and long-term use. 
Factors with variable findings of association (evaluated by at least 3 studies) included gender 
(8 of 18 studies found weak associations with female gender; 2 found associations with male 
gender, 1 strong), age among older adults (8 of 14 studies found mostly weak associations with 
relatively younger age; 2 found weak associations with older age), Black race (8 of 12 found 
weak associations, but 5 associations were with increased and 3 were with decreased 
likelihoods), dementia (2 each, among 5 studies found associations with increased and with 
decreased likelihood), rural or non-urban residence (1 each, among 5 studies found associations 
with increased and with decreased likelihood), prescription of long-acting opioids (2 of 3 with 
studies found associations, both strong), unmarried relationship status (2 of 3 studies found 
associations, 1 strong), and use of muscle relaxants (2 of 3 studies found weak associations). 
Research Needs on Predictors of Long-Term Opioid Use  
The ability to predict which patients are more likely to use opioids long-term might help with 
management and harm prevention. However, more research is needed to determine how to 
identify these patients. In particular, additional research regarding how specific comorbidities, 
social determinants of health, insurance features (type, status), use of specific treatments for 
indications other than pain, specific opioid types and methadone, and opioid stewardship 
programs relate to long-term opioid use would be of value. More research is also needed to 
understand the role of stress, anxiety, depression, trauma, and other behavioral and mental health 
conditions in increasing the likelihood of long-term opioid use. Multimorbidity and associated 
polypharmacy have much higher prevalence rates in older adults and deserve attention as 
potential predictors. 
However, future studies would be more useful if they distinguished between problematic 
long-term opioid use (e.g., misuse, psychological dependence) and long-term use due to 
otherwise poorly controlled pain. Older adults with problematic opioid use may need 
interventions to reduce opioid use, whereas those with uncontrolled pain may require other 
interventions to better treat the underlying condition or other modalities of pain management. 
Specifically, research on how to successfully taper opioids, especially after long-term use, is also 
critically needed. Future studies should focus in particular on which factors are associated with 
the inability to taper opioids, including opioid dose, duration of opioid use, mental health 






Table 2. Code to interpret heat maps of multivariable analyses (in Tables 3 to 14) 







Bright pink  Strong Factor present associated with  higher risk of outcome P<0.05
† Categorical ≥2  
Light orange ↑ Weak Factor present associated with  higher risk of outcome P<0.05
† Categorical <2 
Light pink △ “Positive” Higher value of factor associated with  higher risk of outcome P<0.05
† Continuous Any 
Bright blue  Strong Factor present associated with  lower risk of outcome P<0.05
† Categorical ≤0.5 
Light blue ↓ Weak Factor present associated with  lower risk of outcome P<0.05
† Categorical >0.5 
Middle blue ▽ “Negative” Higher value of factor associated with  lower risk of outcome P<0.05
† Continuous Any 
Grey NS None No association between factor  and outcome P≥0.05
† Any Any 
Light yellow None Mixed Variable within study, as indicated Mixed Any Mixed 
* Note that color coding does not provide unique information in addition to the text provided within the heat map tables. 







Table 3. Heat map of multivariable analyses of demographic and health status factors and long-term opioid use* 
Study PMID  
Design (Specific Population) 
Outcome (Per Study) 
Mean or Median Age (Range) 
Age Gender Race Comorbidity HC Util Mental 
Health 
Al Dabbagh 2016 
2670794068  
Longitudinal retrospective  
(femoral fracture) 
Earlier discontinuation of opioid prescriptions  
(undefined) † 









New persistent long-term use (91-180 days) 











Longitudinal retrospective (TKA) 
Prolonged postoperative opioid use  
(3-6 months) 
NR (89% ≥60) 
 







Longitudinal retrospective  
(rheumatoid arthritis) 
Long-term opioid use (undefined) 

















Longitudinal retrospective  
(trauma) 
Opioid use 1 year after injury 










Longitudinal retrospective (TKA) 
Opioid use at 12 months 






Longitudinal retrospective  
(Alzheimer disease) 
Long-term opioid use (6 months) 










Longitudinal retrospective (THA) 
New chronic opioid use (3-4 months) 












Longitudinal retrospective  
(lumbar fusion for degenerative  
disease of the spine) 
Long-term opioid use (12 months) 













Prolonged opioid use (3 months) 












Longitudinal retrospective  
(without cancer) 
Opioid persistence (12 months) 














Study PMID  
Design (Specific Population) 
Outcome (Per Study) 
Mean or Median Age (Range) 




Longitudinal retrospective  
(hip fracture) 
Persistent opioid use (3-6 months) 
82 years (NR) NS NS 
 
NS 




Longitudinal retrospective  
(prostate cancer) 
New chronic opioid use (>2 months) 
64 years (NR)     Charlson CI ≥3   
McDermott 2019 
3039632183  
Longitudinal retrospective  
(oropharyngeal cancer) 
Continuous opioid use at 6 months 
NR (≥66 years)  (Older) 
 






Chronic opioid use >90 days 












Longitudinal retrospective (TKA) 
Number of prescriptions days 271-360  
postoperative 














Longitudinal retrospective  
(lung resection for NSCLC) 
Persistent opioid use (3-6 months) 
NR (≥66 years) ↓ 
(Older) 





Longitudinal retrospective  
(shoulder arthroplasty) 
Opioid use days 271-360 postoperative 














Longitudinal retrospective  
(surgery) 
New persistent opioid use (6 months) 


















Longitudinal retrospective  
(cancer) 
Prolonged opioid prescribing (3 months) 










Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article and the 
strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the cells indicates the 
factor that is at increased risk (e.g., females were at increased risk of opioid use 1 year after injury). Downward arrows are accompanied by text (in parentheses) that indicates the 
factor that is at decreased risk for the outcome, in keeping with the direction of the arrow (e.g., people in older age categories at decreased risk of long-term opioid use). In the 
Comorbidity column, dementia is also highlighted since it frequently, but not universally, was associated with decreased risk, in contrast with other comorbidities. 
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 





Abbreviations: ASA = American Society of Anesthesiologists, Charlson CI = Charlson Comorbidity Index (Score), DME = durable medical equipment use, HCC = Hierarchical 
Condition Category, HC Util = healthcare utilization, NR = not reported, NSCLC = nonsmall cell lung cancer, PMID = PubMed identifier, THA = total hip arthroplasty, TKA = 
total knee arthroplasty. 
* 2 studies that evaluated long-term opioid use did not evaluate the factors in this table: Alam 2012 (PMID 22412106), Jeffrey 2018 (PMID 28967517). 
† Note that this outcome is of short, not prolonged, duration of use. The arrows in this row are consistent with other studies (up arrows indicated increased risk of not early 
discontinuation). 
‡ Seven medical conditions were weakly associated with increased risk. Three medical conditions were weakly associated with decreased risk. 
§ Migraine, mild liver disease, weight loss. 







Table 4. Heat map of multivariable analyses of socioeconomic and related factors and long-term opioid use* 
Study PMID 
Design (Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 





New persistent long-term use (91-180 days) 




   
Curtis 2017 
2863517972  
Longitudinal retrospective (rheumatoid arthritis) 
Long-term opioid use (undefined) 
67 years (NR, Medicare) ↓ (High income) 
   
Hamina 2017 
2809232475 
Longitudinal retrospective (Alzheimer disease) 
Long-term opioid use (6 months) 
80 years (NR) ↓ (High SES) 
   
Jain 2018 
2956129877 
Longitudinal retrospective (lumbar fusion for  
degenerative disease of the spine) 
Long-term opioid use (12 months) 
66 years (NR) 




Longitudinal retrospective (general population) 
Prolonged opioid use (3 months) 
80 years (NR) ↓ (High SES) 
   
Lalic 2018 
2945167280  
Longitudinal retrospective (without cancer) 
Opioid persistence (12 months) 
NR (≥65 years) † ↓ (No subsidy) 
   
Lindestrand 2015 
2595225281  
Longitudinal retrospective (hip fracture) 
Persistent opioid use (3-6 months) 






Longitudinal retrospective (prostate cancer) 
New chronic opioid use (>2 months) 




Longitudinal retrospective (oropharyngeal cancer) 
Continuous opioid use at 6 months 







Longitudinal retrospective (general population) 
Chronic opioid use >90 days 








Longitudinal retrospective (lung resection for 
NSCLC) 
Persistent opioid use (3-6 months) 




Longitudinal retrospective (surgery) 
New persistent opioid use (6 months) 
NR (≥65 years) 
↓ 




Longitudinal retrospective (cancer) 
Prolonged opioid prescribing (3 months) 










Abbreviations: MCaid = Medicaid, MCare = Medicare, NS = not statistically significant, NSCLC = nonsmall cell lung cancer, PMID = PubMed identifier, SES = socioeconomic 
status. 
* 9 studies that evaluated long-term opioid use did not evaluate the factors in this table: Al Dabbagh 2016 (PMID 26707940), Alam 2012 (PMID 22412106), Cancienne 2018 
(PMID 28887020), Daoust 2018 (PMID 28767563), Hadlandsmyth 2018 (PMID 28927564), Inacio 2016 (PMID 27130165), Jeffrey 2018 (PMID 28967517), Namba 2018 
(PMID 29753617), Rao 2018 (PMID 29891412). 
† In reported subgroup analysis. 
 
Table 5. Heat map of multivariable analyses of pain, prescription drug, and opioid use factors and long-term opioid use* 
Study PMID  
Design  
(Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 










Al Dabbagh 2016 
2670794068  
Longitudinal retrospective  
(femoral fracture) 
Earlier discontinuation of opioid  
prescriptions (undefined) † 
75 years (16-102) 
NS 
(injuries) 





Opioid use ~10-14 months  
postoperative 
76 years (≥66) 
   ↑ 
Early 
use 





New persistent long-term use  
(91-180 days) 
71 years (NR, Medicare) 
↑ 
Back pain,  
arthritis, lung 
resection, other 







Longitudinal retrospective  
(TKA) 
Prolonged postoperative opioid use  
(3-6 months) 
NR (89% ≥60) 
↑ 















Longitudinal retrospective  
(rheumatoid arthritis) 
Long-term opioid use (undefined) 










    
Daoust 2018 
2876756373  
Longitudinal retrospective  
(trauma) 
Opioid use 1 year after injury 
79 years (>65) ↑ Various injuries 








Longitudinal retrospective  
(TKA) 
Opioid use at 12 months 













Study PMID  
Design  
(Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 












Longitudinal retrospective  
(Alzheimer disease) 
Long-term opioid use (6 months) 




      
Inacio 2016 
2713016576  
Longitudinal retrospective  
(THA) 
New chronic opioid use 
(3-4 months) 








    
Jain 2018 
2956129877  
Longitudinal retrospective  
(lumbar fusion for 
degenerative  
disease of the spine) 
Long-term opioid use (12 months) 
66 years (NR) ↑ Arthritis 
   
Pre-op 




Prolonged opioid use (3 months) 
80 years (NR) ↑ RA, cancer 
      
Lalic 2018 
2945167280  
Longitudinal retrospective  
(without cancer) 
Opioid persistence (12 months) 


















Longitudinal retrospective  
(hip fracture) 
Persistent opioid use (3-6 months) 
82 years (NR)  Osteoporosis 
   
Pre-op 
   
Loeb 2020 
3158484982  
Longitudinal retrospective  
(prostate cancer) 
New chronic opioid use (>2 months) 
64 years (NR)  
Prostate cancer 
risk category 




Longitudinal retrospective  
(oropharyngeal cancer) 




















Chronic opioid use >90 days 















, sleep drug 








Study PMID  
Design  
(Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 












Longitudinal retrospective  
(TKA) 
Number of prescriptions  
days 271-360 postoperative 
68 years (NR) 
↑↓ 
Back pain,  
fibromyalgia, 
others 












Longitudinal retrospective  
(lung resection for NSCLC) 
Persistent opioid use (3-6 months) 








    
Rao 2018 
2989141287  
Longitudinal retrospective  
(shoulder arthroplasty) 
Opioid use days 271-360  
postoperative 















Longitudinal retrospective  
(surgery) 
New persistent opioid use  
(6 months) 















Longitudinal retrospective  
(cancer) 
Prolonged opioid prescribing  
(3 months) 










Note: See Table 2 for description of association coding and Table 3 for additional legend information. 
Abbreviations: Bio-DMARD = biologic disease-modifying antirheumatic drug, MME = mean morphine equivalents, Nonop Pain Tx = nonopioid pain treatment (use of), Nonpain 
Tx = nonpain treatment (use of), NS = not statistically significant, NSAID = nonsteroidal anti-inflammatory drug, NSCLC = nonsmall cell lung cancer, PMID = PubMed identifier, 
Pre-op = preoperative use, PT = physical therapy, Rxs = (larger number of) prescriptions, RA = rheumatoid arthritis, THA = total hip arthroplasty, TKA = total knee arthroplasty 
(replacement) 
* 1 study that evaluated long-term opioid use did not evaluate the factors in this table: Jeffrey 2018 (PMID 28967517). 
† Note that this outcome is of short, not prolonged, duration of use. The arrows in this row are consistent with other studies (up arrows indicated increased risk of not early 
discontinuation). 
‡ In reported subgroup analysis. 
§ # The study also found a weak association with use of strong opioids. 
** Strong opioids included: morphine, oxycodone, buprenorphine, fentanyl, hydromorphone, and methadone. Weak opioids included single-ingredient codeine, combination 
codeine preparations, tramadol, and tapentadol. 
†† 2 prescriptions whose days’ supplies overlap by ≥7 days. 





Table 6. Heat map of multivariable analyses of substance use or misuse and related factors and long-term opioid use* 
Study PMID  
Design (Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 






New persistent long-term use  
(91-180 days) 








Longitudinal retrospective  
(TKA) 
Prolonged postoperative opioid  
use (3-6 months) 





Alcohol abuse,  
marijuana use 
[Cocaine use,  






Longitudinal retrospective  
(trauma) 
Opioid use 1 year after injury 




   
Hadlandsmyth 2018 
2892756474  
Longitudinal retrospective  
(TKA) 
Opioid use at 12 months 








Longitudinal retrospective  
(Alzheimer disease) 
Long-term opioid use (6 months) 








Longitudinal retrospective  
(THA) 
New chronic opioid use (3-4 months) 









Longitudinal retrospective  
(lumbar fusion for degenerative  
disease of the spine) 
Long-term opioid use (12 months) 










Long-term opioid use (12 months) 
73 years (NR, Medicare) 






Prolonged opioid use (3 months) 








Longitudinal retrospective  
(without cancer) 
Opioid persistence (12 months) 











Longitudinal retrospective  
(hip fracture) 
Persistent opioid use (3-6 months) 
82 years (NR) 
    ↓ 





Study PMID  
Design (Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 




Longitudinal retrospective  
(oropharyngeal cancer) 
Continuous opioid use at 6 months 
NR (≥66) 
 NS 









Chronic opioid use >90 days 
76 years (≥65)    
↑↓ 





Longitudinal retrospective  
(TKA) 
Number of prescriptions days  
271-360 postoperative 
68 years (NR) 
 ↑ 
Substance abuse 
   
Rao 2018 
2989141287  
Longitudinal retrospective  
(shoulder arthroplasty) 
Opioid use days 271-360  
postoperative 
NR (84% ≥60 years) 
 ↑ 
Substance abuse 
   
Santosa 2020 
3134999488  
Longitudinal retrospective  
(surgery) 
New persistent opioid use  
(6 months) 
NR (≥65 years)  
↑ 







Longitudinal retrospective  
(cancer) 
Prolonged opioid prescribing  
(3 months) 
77 years (≥66) 
  
Drug abuse 
[Alcohol abuse NS] 
   
Note: See Table 2 for description of association coding and Table 3 for additional legend information. 
Abbreviations: Benzo = benzodiazepine use, NS = not statistically significant, PMID = PubMed identifier, THA = total hip arthroplasty, TKA = total knee arthroplasty. 
* 5 studies that evaluated long-term opioid use did not evaluate the factors in this table: Al Dabbagh 2016 (PMID 26707940), Alam 2012 (PMID 22412106), Curtis 2017 (PMID 
28635179), Loeb 2020 (PMID 31584849), Nelson 2020 (PMID 31445908). 
† Administrative claims database determination that prescriptions were for ≤3 days, ≤50 mean morphine equivalents/day, and not a long-acting opioid. 
‡ In reported subgroup analysis. 







Factors Associated With Opioid-Related Disorders (Octagon R2) 
Six studies evaluated factors associated with opioid-related disorders (Tables 7 to 9). Two 
additional studies looked at predictors that older adults would receive opioid prescriptions from 
multiple opioid prescribers (Table 10). Although having multiple prescribers does not by itself 
indicate a disorder, it does indicate potential lack of coordination and therefore increased risk of 
harm to the patient. 
Factors Associated With Opioid-Related Disorders 
Evidence Base 
Six studies reported multivariable models of factors associated with opioid-related disorders, 
including opioid use disorder (OUD), opioid misuse, and high-risk obtainment of prescription 
opioids (Tables 7 to 9).90-95 The models evaluated a large number of factors related to 
demographics, patient health status, socioeconomic and related factors, insurance status, pain 
factors, opioid use factors, and substance use/misuse. 
Factors Associated With Opioid Use Disorder 
Only one study evaluated the risk of OUD, finding that the strongest factors were mental 
health (anxiety disorder; Table 7), pain severity (“interference,” whether one’s pain interferes 
with daily activities; Table 9), and other substance misuse (both marijuana and alcohol; Table 
9). The study also found evidence that younger age and Hispanic ethnicity (Table 7), being 
unemployed (Table 8), and using tobacco (Table 9) are associated with increased risk of OUD. 
Factors Associated With Opioid Misuse 
Four studies evaluated opioid misuse (or “abuse”; note: the original wording of the studies is 
maintained to avoid misrepresenting the original studies, even if the language used by the 
authors might currently be considered inappropriate or stigmatizing). Substance misuse and 
gender were the only factors evaluated by at least three studies. Three studies had variable 
findings regarding substance misuse, specifically alcohol (Table 9): one study found a strong 
association between a history of an alcohol-related healthcare visits and opioid misuse, another 
found a statistically significant association between higher scores on the CAGE Questions for 
Alcohol Use and misuse, but a third study found no statistically significant association between 
hazardous drinking and opioid misuse. Three studies also had variable findings regarding gender 
(Table 7): one study found a weak association that women were at increased risk of opioid use, 
but the other two found no statistically significant difference between genders.  
Rural versus urban residence was evaluated by two studies, both of which found no 
association (Table 8). Among the other factor categories evaluated by two studies (age, 
comorbidities, mental health conditions [Table 7], cause of pain, and pain severity [Table 9], 
in all cases one study found a statistically significant association and the second study found no 
statistically significant association). Other factors were evaluated by only a single study. 
Factors Associated With High-Risk Behaviors 
One study evaluated high-risk obtainment of prescription opioids as an outcome. The study 
found strong associations for older age (≥65, at various thresholds vs. 60-64; Table 7), college 
education (Table 8), and opioid misuse (recreational use; Table 9). Increased associations were 





statistically significant associations were found for quality of life (Table 7) or tobacco use 
(Table 9). 
Summary of Factors Associated With Opioid-Related Disorders 
Six studies have evaluated factors associated with opioid-related disorders among older 
adults, including OUD, opioid misuse, and high-risk behaviors, but since the researchers largely 
analyzed different sets of factors, there is little consistency or replication across models. Three 
studies each reported variable findings regarding the associations of alcohol misuse and of 
gender with opioid misuse. Only single studies have evaluated specific factors and OUD or high-
risk obtainment of prescription opioids among older adults. The OUD study reported strong 
associations with a history of anxiety, pain interference (a measure of pain severity), and both 
marijuana and alcohol use. Older age, college education, and a prior history of opioid misuse 
were each found to be associated with high-risk obtainment of prescription opioids (in one 
study). 
Research Needs on Predictors of Opioid-Related Disorders 
While several studies have evaluated the relationships between factors and opioid misuse in 
older adults, additional research is needed to confirm (or refute) the observed associations. To 
improve confidence and increase the strength of the evidence base, additional studies that include 
factors in common (i.e., analyzed by previously published studies) should be considered. In 
particular, research is needed to determine the risk of de novo (incident) opioid-related disorders 
among older adults, and what factors may predict new opioid misuse or OUD. More work should 
also focus on distinguishing opioid dependence from OUD in various data sources, and how 
changes in definitions and assessment methods over time have impacted the findings of research 
studies. When examining such questions, consideration must be given to the temporality and 
type of opioid use. For example, studies examining the relationship between OUD and risk of 
opioid overdose death would likely focus on prevalent opioid use, while studies examining the 
transition from initial opioid use to long-term use to OUD would likely focus on new use of 
opioids and follow individuals longitudinally over time. These decisions regarding opioid use 
definitions and study design merit consideration in future work to maximize the ability of studies 
to address research needs. 
Furthermore, there is a need to develop and validate accurate measures of opioid misuse 
among older adults. Studies have used multiple concurrent or proximal dispensing of opioid 
medications (drawn from claims data) as a measure of opioid misuse, but research validating 
such measures was not identified, and questions remain about the appropriateness of such 
measures. Provider factors, such as poor communication and coordination, could be an equally 
plausible explanation for the presence of multiple opioid prescriptions or dispensing in an older 
adults’ drug claims. The use of multiple prescribers and pharmacies as a proxy for opioid misuse 
was also common, especially in large administrative database studies. Research should explicitly 
focus on the performance characteristics of various measures combining number of days of 
overlap between opioid prescriptions, number of different opioid prescribers, and number of 
different opioid dispensing pharmacies. If many such measures are, in fact, not a good proxy for 
opioid misuse (e.g., because these are actually palliative care patients appropriately using 
opioids), then much of the limited evidence base on factors associated with opioid misuse in 
older adults is unlikely to be provide information useful for identifying actual opioid misuse. 
In addition, more research is necessary to understand the role of stress, anxiety, depression, 





misuse and development of OUD. If these conditions are associated with opioid misuse and 
OUD among older adults, stress, mental health conditions, and behavioral conditions may serve 






Table 7. Heat map of multivariable analyses of associations between demographic and health status factors and opioid-related 
disorders* 
Outcome Study PMID 
Design (Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 
Age Gender Race Comorbidity ADL QoL Mental Health 
Opioid use  
disorder 
Choi 2017 2869982991  
Cross-sectional survey 
(general population) 
Opioid use disorder 




NS    
Anxiety 
Opioid misuse Carter 2019 3086379690  
Cross-sectional registry † 
(opioid-related ED visit) 
Opioid misuse 






   
Cochran 2017 2848949192  
Cross-sectional survey 
(general population) 
Prescription Opioid Misuse Index 
NR (≥65 years) ‡ 
 NS  NS   NS 




73 years (65-90) 






Gold 2016 2756440793  
Cross-sectional survey 
(general population) 
High-risk obtainment of  
prescription opioids 





   NS  
Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article (or 
outcome) and the strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the 
cells indicates the factor that is at increased risk (e.g., people in older age categories were at increased risk of high-risk obtainment of prescription opioids). Downward arrows are 
accompanied by text (in parentheses) that indicates the factor that is at decreased risk for the outcome, in keeping with the direction of the arrow (e.g., people in older age 
categories were at decreased risk of opioid use disorder). 
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 
healthcare specialist, opioid factors, other medication factors, opioid misuse, other substance use/misuse, and opioid stewardship. This heat map is organized by type of outcome 
(reason for hospitalization, reason for ED visit). Studies are presented in alphabetical order within outcome categories. 
Abbreviations: ADL = activities of daily living, ED = emergency department, PMID = PubMed identifier, QoL = quality of life. 
* 1 study that evaluated opioid misuse did not evaluate the factors in this table: Hoffman 2017 (PMID 28531306). 
† Described as a cross-sectional study, but includes death as an analyzed outcome. 







Table 8. Heat map of multivariable analyses of associations between socioeconomic and related factors and opioid-related disorders* 
Outcome Study PMID 
Design (Specific 
Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 
Income Employment Education Rural Social Insurance 
Opioid use  
disorder 
Choi 2017 2869982991  
Cross-sectional survey 
(general population) 
Opioid use disorder 
NR (≥50 years) 
 ↑ 
Unemployed 
NS  NS  
Opioid misuse Carter 2019 3086379690  
Cross-sectional registry † 
(opioid-related ED visit) 
Opioid misuse 
NR (≥65 years) ↑ Poorer 
  NS  ↑ 
Medicaid 
Medicare ‡ 
Cochran 2017 2848949192  
Cross-sectional survey 
(general population) 
Prescription Opioid Misuse Index 
NR (≥65 years) ‡ 
  NS NS   




73 years (65-90) 
    NS  
High-risk 
behaviors 
Gold 2016 2756440793  
Cross-sectional survey 
(general population) 
High-risk obtainment of prescription 
opioids 
NR (≥60 years) 





Note: See Table 2 for description of association coding and Table 7 for additional legend information. 
Abbreviations: NS = not statistically significant, PMID = PubMed identifier. 
* 1 study that evaluated opioid misuse did not evaluate the factors in this table: Hoffman 2017 (PMID 28531306). 
† Described as a cross-sectional study, but includes death as an analyzed outcome. 






Table 9. Heat map of multivariable analyses of associations between pain and substance use disorder factors and opioid-related 
disorders 
Outcome Study PMID 
Design (Specific 
Population) 
Outcome (Per Study)  












Opioid use  
disorder 
Choi 2017 2869982991  
Cross-sectional survey 
(general population) 
Opioid use disorder 
NR (≥50 years) 
NS  
Interference 





Opioid misuse Carter 2019 3086379690  
Cross-sectional registry* 
(opioid-related ED visit) 
Opioid misuse 
NR (≥65 years) 
 
Injury 
    
Alcohol 
 
Cochran 2017 2848949192  
Cross-sectional survey 
(general population) 
Prescription Opioid Misuse Index 
NR (≥65 years) † 





Hoffman 2017 2853130694  
Longitudinal retrospective  
(polyneuropathy) 
Opioid abuse 
68 years (NR) 
  NS    
Opioid dependence (per ICD 
codes, 
not further defined) 
68 years (NR) 
   
≥90 days 
   




73 years (65-90) 
NS △ 
Severity 





Gold 2016 2756440793  
Cross-sectional survey 
(general population) 
High-risk obtainment of 
prescription opioids 
NR (≥60 years) 
    
Misuse 
 NS 
Note: See Table 2 for description of association coding and Table 7 for additional legend information. 
Abbreviations: NS = not statistically significant, PMID = PubMed identifier. 
* Described as a cross-sectional study, but includes death as an analyzed outcome. 






Factors Associated With Multiple Opioid Prescribers 
Evidence Base 
Only two studies reported a multivariable model of factors associated with having multiple 
opioid prescribers in older adults (Table 10).96, 97 The models evaluated a variety of factors 
related to demographics, patient health status, socioeconomic and related factors, insurance 
status, pharmaceutical treatments, and substance use/misuse. While having multiple opioid 
prescribers is not in itself an indication of opioid misuse, it might reflect a high-risk patient 
behavior of intentionally seeking out multiple providers to procure more than recommended 
prescriptions (i.e., “doctor shopping”). It also might indicate fragmented or uncoordinated, and 
thus high-risk, patient care.98-101 In the general population of all adults, multiple opioid 
pharmacies has been strongly associated with opioid abuse,102 which raises the concern that it 
may also be associated with opioid misuse among older adults. 
The two models largely overlapped in their evaluated factors; however, consistency varied 
both across and within models. Both models evaluated age and found that among older adults, 
the younger individuals (i.e., 65 to 74 and 75 to 84 years of age compared to ≥85 years;96 each 
age decile compared to ages 66 to 70 years97) were at increased risk of using multiple prescribers 
(or as shown in the table, that older age groups were at decreased risk), with either strong or 
weak associations. Similarly, both found that insurance coverage (lower copays, Medicare 
Advantage vs. traditional Medicare, and Medicare Part D benefit in addition to Veterans Affairs 
[VA] insurance only) was associated with increased risk, strongly for no copay versus full copay, 
weakly for Medicare Advantage versus other Medicare coverage.  
One of the two studies found weak associations for gender and race, such that men and  
non-Hispanic Blacks were at increased risk; however, the other study did not find these 
associations to be statistically significant. The first study also found that rural residents were at 
decreased risk (weak association) with multiple prescribers, but the second study found the 
opposite (also weak association). Regarding income, one study found weak associations between 
various measures of higher income and increased risk of multiple prescribers; the second study 
reported seemingly contradictory findings that higher median income was associated with lower 
risk, but that increased percentage of households below the poverty level (a poorly defined 
variable) was also associated with lower risk. 
Among the factors evaluated by a single study only, strong associations were found for 
mental health conditions (sleep disorder and psychiatric diagnoses, but not suicide or self-
injury), other associations were found for comorbidities (Hierarchical Condition Category risk 
score), health utilization (number of days), and substance misuse. No statistical association 
was found for tobacco use. 
Summary of Factors Associated With Multiple Opioid Prescribers 
Two multivariable models have identified a number of potential factors associated with 
having multiple opioid prescribers among older adults. Both found that younger age (among 
older adults) and specific insurance coverage factors (lower copays, Medicare Advantage vs. 
traditional Medicare, and Medicare Part D benefit in addition to VA only) were associated with 
having multiple prescribers. Other variables were inconsistently associated with having multiple 





Research Needs on Predictors of Multiple Opioid Prescribers  
As will be described in the section Factors Associated with Hospitalizations or ED Visits, 
below, a single study in older adults has found a strong association between the number of opioid 
prescribers and an increased risk of opioid-related hospitalizations. However, additional studies 
are needed to establish whether having multiple opioid prescribers is associated with harms. 
Regardless of whether this association may be due to harms caused by lack of coordination 
among prescribers or to high-risk patient behaviors (such as doctor shopping), determining the 
predictors that are associated with having multiple opioid prescribers would be of value. 
However, since only two studies are available, and they report some inconsistencies in findings, 
additional research is necessary to identify the predictors (or risk factors) for having multiple 
opioid prescribers in older adults. Additional studies should aim to include the factors examined 
by the prior two studies, in addition to other putative predictors, and assess the consistency of 
reported associations. 
Furthermore, polypharmacy, not just coprescribing, deserves additional focus. Understanding 
the relationship between the number of medications an older adult is taking and subsequent 
opioid-related hospitalizations and ED visits would be a reasonable next step. Subdividing 
polypharmacy into potentially appropriate and inappropriate subtypes would then offer 
additional information valuable information. Medication appropriateness criteria like the Beers 
List might play a role in this future research.103 Employing alternative measures of drug burden 
such as the Drug Burden Index, cumulative anticholinergic burden, and number of medications 
























































































  ↑ 
Abuse 
NS 
Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article (or 
outcome) and the strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the 
cells indicates the factor that is at increased risk (e.g., non-Hispanic Blacks are at increased risk of having multiple prescribers). Downward arrows are accompanied by text (in 
parentheses) that indicates the factor that is at decreased risk for the outcome, in keeping with the direction of the arrow (e.g., people in older age categories at decreased risk of 
having multiple prescribers). 
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 
healthcare specialist, opioid factors, other medication factors, opioid misuse, other substance use/misuse, and opioid stewardship. Studies are presented in alphabetical order. 
Abbreviations: HC Util = healthcare utilization, HCC = Hierarchical Condition Category risk score, MC = Medicare, Nonop Pain Tx = nonopioid pain treatment (use of), Nonpain 
Tx = nonpain treatment (use of), PMID = PubMed identifier, Psych Dx = psychiatric diagnosis, Sleep d/o = sleep disorder. 






Factors Associated With Opioid-Related Harms (Octagon R3) 
Four sets of studies have evaluated factors associated with opioid-related harms (Octagon R3 
in Figure 1: Conceptual Framework):  
1. Mental or physical health harms (Table 11) 
2. Hospitalizations or ED visits (Table 12) 
3. Opioid overdose (Table 13) 
4. Death (Table 14) 
Factors Associated With Mental Health or Physical Health Harms 
Evidence Base 
Four studies reported eight multivariable models of associations between opioid-related 
factors and mental or physical health outcomes (harms) (Table 11).94, 105-107 The models analyzed 
six mental health outcomes, including depression, suicidal ideation, and substance misuse 
(alcohol or nonalcohol, nonopioid substance misuse), and two physical health outcomes (hip 
fracture and respiratory exacerbation). The models evaluated the association between these 
factors and opioid use, opioid use duration, opioid type, and opioid misuse. 
Given that each study reported a different outcome (or set of outcomes), there is a lack of 
replication of findings across studies. Across studies (and outcomes), there were disparate 
associations related to opioid use. There was a strong association between status as an opioid 
user and risk of hip fracture in one study, but a weak association that new opioid users were at 
decreased risk of respiratory exacerbations compared with nonusers. However, this study 
(Vozoris 2016,107) found strong associations between new opioid use and chronic obstructive 
pulmonary disease (COPD) or pneumonia-related death, and weak associations with COPD or 
pneumonia-related ED visits and all-cause mortality (see sections Factors Associated With 
Hospitalizations or ED Visits and Factors Associated With Death). The third study that evaluated 
opioid use found no statistically significant association between past-year opioid use (without 
misuse) and suicidal ideation. 
Opioid use duration was evaluated by two studies across six outcomes. Longer duration of 
opioid use was strongly associated with increased risk of hip fracture and weakly associated with 
depression and other substance (nonalcohol, nonopioid) dependence, but not “alcohol abuse,” 
other “substance abuse,” or other substance overdose.  
Opioid type and opioid misuse were each evaluated by a single study. Opioid type 
(buprenorphine and, separately, strong opioids) was found to be strongly associated with 
increased risk of hip fracture. Opioid misuse was found to be weakly associated with increased 
risk of suicidal ideation. 
Summary of Factors Associated With Mental Health or Physical Health Harms 
Multivariable models have identified various measures of opioid use and misuse as potential 
factors associated with mental and physical health harms, but given the heterogeneity of 






Table 11. Heat map of multivariable analyses of opioid-related factors and opioid-related harms 
Outcome Study PMID  
Design (Specific Population) 
Outcome (Per Study)  
Mean or Median Age (Range) 
Opioid Use Opioid Duration Opioid Type Opioid Misuse 
Mental health Hoffman 2017 2853130694  
Longitudinal retrospective  
(polyneuropathy) 
Depression 




Alcohol abuse  NS   
Other substance dependence  ↑ 
Long-term use 
  
Other substance abuse  NS   
Other substance overdose  NS   




NR (≥50 years) NS 
  ↑ 
Misuse 
Physical health Taipale 2019 30325873106 
Cross-sectional registry  
(Alzheimer disease) 
Hip fracture 









Vozoris 2016 27418553107 
Longitudinal retrospective  
(COPD) 
Respiratory exacerbation 
77 years (≥66) ↓  (New use) 
   
Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article (or 
outcome) and the strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the 
cells indicates the factor that is at increased risk (e.g., those with long-term opioid use were at increased risk of depression). Downward arrows are accompanied by text (in 
parentheses) that indicates the factor that is at decreased risk for the outcome, in keeping with the direction of the arrow (e.g., new opioid users were at decreased risk of 
respiratory exacerbation compared to no opioid use). 
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 
healthcare specialist, opioid factors, other medication factors, opioid misuse, other substance use/misuse, and opioid stewardship. This heat map is organized by type of outcome 
(mental and physical health harms). Studies (and outcomes) are presented in alphabetical order within outcome category. 






Research Needs on Predictors of Mental Health or Physical Health Harms 
Few studies have evaluated the factors predicting mental or physical health harms associated 
with opioids specifically in older adults, and those that did each evaluated a unique set of 
outcomes. Additional studies are needed that focus on replication or better establish associations 
and replicate observed associations. 
Furthermore, additional research is necessary on the relationships between isolation, 
psychiatric or mental health conditions, and caregiver support (lack thereof) and opioid-related 
harms. Efforts to link measures of isolation and caregiver support to medication data, or to 
employ existing datasets that have already combined this information, may be an effective way 
to generate more empirical evidence.  
Factors Associated With Hospitalizations or ED Visits 
Evidence Base 
Five studies reported 11 multivariable models of opioid use-related factors associated with 
hospitalization and ED visits in older adults (Table 12).96, 107-110 The models analyzed outcomes 
pertaining to all-cause hospitalization, opioid-related hospitalization, nonopioid-specific 
hospitalization, all-cause ED visit, and nonopioid-specific ED visit. The models evaluated factors 
associated with number of prescribers and opioid use, type, and misuse.  
Outcomes varied across studies. Two studies evaluated all-cause hospitalization and, 
separately, all-cause ED visits, but they evaluated different types of factors (opioid use and 
opioid type). Another two studies evaluated three different nonopioid-specific hospitalization 
outcomes (pulmonary-related hospitalization and intensive care admission, and postsurgical 
hospital readmission). Each of the other outcomes was evaluated by a single study. 
The most commonly evaluated factor category was opioid use (8 analyses/outcomes in 3 
studies), although it was variably defined (new opioid use; history of opioid use, not misuse; 
frequency of preoperative opioid use; opioids “on hand” at surgery admission; and opioids 
prescribed postoperatively). Most analyses found associations between opioid use and risk of 
hospitalization or ED visit. One study found no statistically significant association with COPD or 
pneumonia-related hospitalizations or intensive care unit admissions. 
No other factor category was analyzed by more than a single study. One study found that 
opioid type (schedule II opioids, see Table 12 abbreviation list) was weakly associated with 
increased risk of all-cause hospitalization and ED visits. One study found that opioid misuse was 
strongly associated with all-cause hospitalization and ED visits, but not statistically significantly 
associated with number of nights in the hospital or number of ED visits. One study found that 
increased number of opioid prescribers was strongly associated with increased risk of opioid-
related hospitalizations. 
Summary of Factors Associated With Hospitalizations or ED Visits 
Five studies have reported multivariable analyses of opioid-related factors associated with 
hospitalization or ED visits among older adults with no replication of analyses. Overall, there is 
an indication that opioid use, opioid type, opioid misuse, and the number of opioid 
prescribers are all associated with increased risks of hospitalization and ED visits, but no 
specific analysis (between a given factor category and outcome category) was evaluated by more 






Table 12. Heat map of multivariable analyses of factors associated with hospitalization or emergency department visits 
Outcome Study PMID  
Design (Specific Population) 
Outcome (Per Study) 
Mean or Median Age (Range) 
Opioid Use Opioid Type Opioid Misuse No. Prescribers 
All-cause  
hospitalization 
Choi 2019 30585135109 
Cross-sectional survey and registry 
(general population)  
All-cause hospitalization 






Number of nights in the hospital ↑ 
Use 
 NS  
Kuo 2016 26522794108  













69 (NR, Medicare) 




Vozoris 2016 27418553107  
Longitudinal retrospective  
(COPD) 
COPD or pneumonia-related hospitalization 
77 years (≥66) 
NS    
ICU admission during COPD or  
pneumonia-related hospitalization 
NS    
Dasinger 2019 30879796110  
Longitudinal retrospective  
(surgery) 
Postsurgical 30-day readmission 
64 years (NR) ↑ Use 
   
All-cause ED visit Choi 2019 30585135109 
Cross-sectional survey and registry 
(general population)  
All-cause ED visit 






Number of ED visits ↑ 
Use 
 NS  
Kuo 2016 26522794108  
Longitudinal retrospective  
(without cancer) 
All-cause ED visit 






Vozoris 2016 27418553107  
Longitudinal retrospective  
(COPD) 
COPD- or pneumonia-related ED visit 
77 years (≥66) 
↑ 
New use 
   
Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article (or 
outcome) and the strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the 
cells indicates the factor that is at increased risk (e.g., opioid users were at increased risk of all-cause hospitalization).  
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 
healthcare specialist, opioid factors, other medication factors, opioid misuse, other substance use/misuse, and opioid stewardship. This heat map is organized by type of outcome 
(reason for hospitalization, reason for ED visit). Studies (and outcomes) are presented in alphabetical order within outcome categories. 
Abbreviations: COPD = chronic obstructive pulmonary disease, ED = Emergency Department, ICU = Intensive Care Unit, PMID = PubMed identifier, Schedule II = opioid with a 





Research Needs on Predictors of Hospitalizations or ED Visits  
Each of the identified studies evaluated different combinations of factors and outcomes. 
Thus, additional studies are needed that focus on replication or better establish or reproduce 
observed associations. 
Factors Associated With Opioid Overdose 
Evidence Base 
Three studies reported multivariable models of factors associated with opioid overdose in 
older adults (Table 13).94,111,112 The models each evaluated a unique set of factors related to 
demographics, patient health status, opioid factors, and substance use/misuse. 
One study, Lo-Ciganic 2019,112 reported a unique analysis of a machine-learning algorithm, 
which produced a “prediction score” for 268 “predictor” candidates. They report the 50 
predictors with the highest prediction scores. However, they do not report association estimates 
that are comparable to other studies. Upon reviewing their bar graph of the 50 highest predictor 
scores, we noted that six predictors had scores of 0.6 or higher and the rest had scores <0.4. We, 
thus, categorized the top scores as strong associations. These included age (direction not 
reported), comorbidities (disability status), opioid amount (separately, average and total mean 
morphine equivalents and number of opioid fills), and substance misuse (combined substance or 
alcohol use disorder). Of note, several of the factors analyzed were area-level measures (e.g., 
percentage of unemployment in the participant’s area of residence). Interpretation of these 
factors are subject to ecological fallacy (where a spurious association is made about an individual 
based on aggregate data for a group). However, the six highest predictor scores were measured at 
the level of the individual participant. 
We did not extract or tabulate the other 44 reported predictors; however, these included: race 
(not defined), other comorbidities (falls, fractures, and other injuries; area-level percentage of 
poor to fair health), mental health (mood disorders, anxiety disorders, psychoses), low income 
(low-income subsidy, area-level percentage of children in poverty), area-level percentage of 
unemployment, insurance status (area level penetration of Medicare Advantage, area level 
percentage of women in fee-for-service Medicare), opioid type (not defined; duration of short-
acting opioid use, duration of long-acting opioid use), nonpain treatments (antidepressants), 
opioid misuse (days from last overdose event), other substance misuse (early refills, area-level 
percentage of excessive drinking, drug use disorders), and benzodiazepine use (and days of 
concurrent opioid and benzodiazepine use). 
Also of note, as implied above, many of the predictors were poorly defined, such as age (for 
which no direction of association was indicated), type of opioid, and race (for which there was 
no indication of which category was at increased risk).  
The second study reported only that long-term opioid use was strongly associated with 
opioid overdose. The third study found that opioid misuse (supplied opioids exceeded daily 
prescription) and increased numbers of prescribers or, separately, pharmacies were both 









Outcome (Per Study)  
Mean or Median Age 
(Range) 













NR (NR, Medicare) 





Hoffman 2017 2853130694  
Longitudinal retrospective  
(polyneuropathy) 
Opioid overdose 
68 years (NR) 
   
Long-term use 






68 years (NR, Medicare) 
ND † ‡  ‡ 
Disability status 
  ‡ 
MME 
Opioid fills 




Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article and the 
strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the cells indicates the 
factor that is at increased risk (e.g., those with comorbidities are at increased risk of opioid overdose). 
Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and related factors, pain cause and severity, 
healthcare specialist, opioid factors, other medication factors, opioid misuse, other substance use/misuse, and opioid stewardship. Studies are presented in alphabetical order.  
Abbreviations: MME = mean morphine equivalents, ND = no data reported, PMID = PubMed identifier. 
* In total, 50 “predictors” are ranked; only those with the highest prediction scores are reported here. Several ranked predictor (not among those with the highest scores) were 
based on regional measures (e.g., “area level percentage of unemployment”), which are subject to ecological fallacy. 
† The study does not indicate the directionality of the association. 






Summary of Factors Associated With Opioid Overdose 
Three studies evaluated factors associated with opioid overdose in older adults. One study 
ranked numerous (often poorly defined) factors by strength of association; the other two 
evaluated nonoverlapping sets of factors. Nevertheless, one study each reported strong 
associations for opioid overdose among older adults with age (however, the direction of the 
association was not reported), disability status, opioid use duration, amount of opioids used, 
opioid misuse, other substance misuse, and number of opioid prescribers. 
Research Needs on Predictors of Opioid Overdose  
Most results are from various machine learning algorithms reported by one large study, so a 
need likely exists for researchers to replicate the findings of this study through the use of 
parametric statistical regression models. This will require at least one or more confirmatory 
studies. 
Factors Associated With Death 
Evidence Base 
Five studies reported nine multivariable models of factors associated with opioid-related 
mortality or opioid-related factors associated with nonopioid-related deaths in older adults (Table 
14).90,107,113-115 The models analyzed all-cause death; opioid-related death; nonopioid-specific 
death, including COPD- or pneumonia-related death; and drug overdose death (any drug). The 
models evaluated factors related to demographics; opioid use, misuse, and prescription; 
socioeconomic and related factors; clinician factors; and other substance use. Of note, two of the 
studies were conducted based on measures (of factors and outcomes) at the county or state level 
(as opposed to at the individual participant level). Both Grigoras 2018 and Zoorob 2018 
evaluated death rates in counties (or states) and rates or percentages of people in a given category 
(e.g., White race) within the same counties (or states). These analyses are subject to ecological 
fallacy (where a spurious association is made about an individual based on aggregate data for a 
group). 
Across outcomes, no factor category was reported on by more than two studies. Race and 
income were each examined by two studies (but as percentages of people in a race/ethnicity 
category or who were in poverty), both of which found associations between these factors and 
rates of death. The two studies reported models for five separate outcomes, and both found that 
higher percentages of people who were White (or non-Black/non-Hispanic) in a given area were 
associated with higher death rates. The same two studies reported that higher poverty rates were 
also associated with increased rates of death.  
Three studies (reporting on three outcomes) evaluated different aspects of opioid use. Two 
studies found associations between opioid use (either new use—weak association—or tramadol 
use specifically—strong association) and all-cause death. One of these studies also found that 
new users of opioids were (strongly) at increased risk of COPD or pneumonia-related death. 
Another study found a statistically significant association between the percentage of opioid users 
among older adults in a county and drug-overdose death rate. 
Single studies identified the following factors as being associated with higher risk of death: 
lower level of education (more residents without a high school diploma in a given area), not 
rural residency, specialty of the opioid prescriber (various, including emergency medicine), and 
rate of benzodiazepine use in a given area. Possibly counterintuitively, one study found that 





versus routine discharge. Only the association between tramadol use and risk of COPD or 





Table 14. Heat map of multivariable analyses of opioid-related associations between factors and death 
Outcome Study PMID Outcome (Per 
Study)  
Mean or Median Age 
(Range) 
Race Income Education Rural Specialty Opioid Rx 
Rate 
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NR (≥65 years) 









77 years (≥66) 
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All-cause death 
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NR (NR, Medicare) 
△ 
% White ‡ 
△ 
% Poverty ‡ 
  △ 
Various 
△ 
Higher rate ‡ 
   
Synthetic opioid-
related death rate △ 
% White ‡ 
△ 
% Poverty ‡ 
   △ 
Higher rate ‡ 
   
Natural and 
semisynthetic opioid-
related death rate 
△ 
% White ‡ 
△ 
% Poverty ‡ 
   △ 
Higher rate ‡ 
   
Methadone-related 
death rate △ 
% White ‡ 
△ 
% Poverty ‡ 
   △ 
Higher rate ‡ 










77 years (≥66) 
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New use 
  






Drug overdose death 
rate 






% Poverty ‡ 
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% <HS ‡ 
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Note: The heat map lays out each analyzed outcome within each article across rows. The colors and arrows indicate which factor categories were reported in each article (or 
outcome) and the strength and direction of the association, as described in Table 2. Direction of the arrows indicates the direction of the association. Accompanying text within the 
cells indicates the factor that is at increased risk (e.g., Whites were at increased risk of death). Downward arrows are accompanied by text (in parentheses) that indicates the factor 





Across heat map tables, the columns are presented in the same order: demographics, markers of health status, socioeconomic and 
related factors, pain cause and severity, healthcare specialist, opioid factors, other medication factors, opioid misuse, other 
substance use/misuse, and opioid stewardship. This heat map is organized by type of outcome (cause of death). Studies are 
presented in alphabetical order within outcome categories. 
Abbreviations: <HS = less than a high school education; Benzo = benzodiazepine use, COPD = chronic obstructive pulmonary 
disease, ED = emergency department, HS = high school education, NSAID = nonsteroidal anti-inflammatory drug, Op Rx Rate = 
rate of opioid prescribing, PMID = PubMed identifier, Specialty = prescriber specialty. 
* Described as a cross-sectional study but includes death as an analyzed outcome. 
† Crossed with a death registry. 
‡ All variables (factors and outcomes) are based on county-level (or state-level) rates (or percentages). Thus, the whole analysis 
is subject to ecological fallacy. 
 
Summary of Factors Associated With Death 
Across five studies, multivariable models have identified a number of potential factors 
associated with death related to opioid use (or among older adults using opioids). Associations 
have been replicated only for race, income, and opioid use, but only by two studies each and the 
studies of opioid use evaluated different opioids. However, these factors applied to communities 
at high risk, not necessarily to individuals. Two factors have been found to be strongly associated 
with death (new opioid use and tramadol prescription), but each by only a single study and for 
different outcomes (all-cause death and nonopioid related death, respectively). 
Research Needs on Predictors of Death 
Since the associations between most factors and death have been evaluated by only a single 
study, additional studies are needed to determine likely candidates as predictors of death 
pertaining to opioid use in older adults. In particular, studies employing a specific and, if 
possible, validated definition of opioid-related death are needed. 
Additional Research Needs and Gaps Pertaining to Predictors 
Based on discussions with Key Informants and within the research team, we identified a 
number of research needs that are not addressed by published multivariable risk factor analyses 
or that do not cleanly fit within Octagons R2 or R3 in the Conceptual Framework. These are 
discussed in roughly the temporal order that people interact with opioid use, starting with patient 
demographics. 
Research Needs About the Definition of “Older Adult” 
Future research should consider whether it is appropriate to identify individuals aged 50 to 60 
or 50 to 65 as “older.” If that term is applied to individuals younger than 60 or 65 years of age, 
researchers should consider providing a clear justification or rationale (e.g., biological aging) for 
the application of one age threshold versus another. Research into the impact of varying the age 
threshold used to define adults as “older” might be warranted for many of the questions related to 
opioid use, misuse, and OUD in older adults. The rationale is that intergenerational or birth 
cohort differences could result in qualitatively different inferences depending on the age groups 
chosen for a given study. Individuals currently aged 50 to 65 years (Baby Boomers II and 
Generation X) are likely to have different predictors of opioid-related harms compared to 
individuals aged 65 and older (Baby Boomers I), in part due to differences in age and 
comorbidities, but in part due to different life and cultural experiences. Thus, an important gap in 





or overall populations spanning many age groups is generalizable to older adults. Similarly, 
individuals aged 85 or older (sometimes referred to as the “oldest old”) may have unique 
predictors related to age-related physiological changes that are not present in younger subgroups 
of the older adult population. Complicating the issue of deciding who most appropriately could 
be grouped as being “older” is that socioeconomically disadvantaged individuals (and others 
with health care disparities) have higher rates of chronic diseases, functional limitations, and 
high-risk behaviors (such as smoking), along with poorer access to healthcare. Thus, they may 
physiologically age earlier than their more-advantaged peers.116 
Research Needs About Birth Cohort, Age, and Substance Use 
Research has not explicitly quantified the interaction or interplay between birth cohort, age, 
and nonopioid substance use (e.g., alcohol) as predictors of opioid misuse and OUD. The aging 
of the “baby boomer” cohort, along with the differing patterns of substance use and misuse 
among these individuals, might result in unique patterns of opioid misuse compared to the prior 
birth cohort (born in the early 1940s or before). In addition to nonopioid substance use and use 
disorders, baby boomers may have unique characteristics that result in an increased rate of opioid 
misuse, OUD, and overdose as they age into the older adult cohort over time. More research is 
necessary to distinguish between these potential age and birth cohort influences. Such research 
should also take into account temporal trends in other important factors that might influence 
opioid use and misuse, such as demographic changes, increased life expectancy, greater illicit 
drug availability, improved access to healthcare, and the development and implementation of 
harm reduction and substance use disorder treatment services. 
In addition, more research is necessary to understand the differences that may exist between 
older adults with lifelong risk factors for substance use disorders and mental health conditions 
who develop OUD versus older adults who experience a stressful event later in life and develop 
OUD. Some forthcoming research may help to provide some evidence on these topics. American 
Institute for Research investigators have recently tested the use of the Current Opioid Misuse 
Measure (COMM) for use with people with disabilities caused by arthritis, severe spinal 
osteoporosis and spinal stenosis who use opioids to manage chronic pain. Preliminary results 
suggest that a subset of the COMM items is valid for assessing opioid misuse in this population. 
Finally, the associations between age and opioid-related outcomes must be interpreted 
carefully in the absence of data and studies that have examined age-period-cohort associations. It 
is possible that age may operate as a proxy for historic experience (e.g., more opportunity to 
experience events like surgeries that require opioids) and trends (e.g., increasing numbers of 
prescriptions for opioids during some time periods). Age-period-cohort research is necessary to 
disentangle the associations between age, period, birth cohort, and opioid-related outcomes 
before any associations between age and opioid-related outcomes can be properly interpreted.  
Summary of Evidence Base on Predictors Across Outcomes 
This section repeats observations from preceding sections. 
Most of the current evidence base regarding factors associated with opioid-related outcomes 
is sparse, particularly for definitive opioid-related harms. Table 1 summarized the evidence base 
for factor-outcome associations with at least three studies. (More detailed summaries of the 
evidence base for association studies are provided in Appendix D, Tables D-3, D-5, and D-6.) 





for some individuals might indicate high-risk behavior or even opioid misuse, but for many 
individuals may indicate appropriate treatment of chronic pain. 
Summary of Factors Associated With Opioid Use (Octagon R1) 
One set of studies has evaluated factors associated with opioid use (Octagon R1 in Figure 1: 
Conceptual Framework). The only outcome pertaining to opioid use among eligible studies was 
long-term opioid use. The largest set of studies evaluated this outcome. No study evaluated 
opioid use where benefits outweigh harms. 
Overall, 22 multivariable models have evaluated a large number of potential factors 
associated with long-term opioid use among older adults. Table 1 highlights the findings for 
factor-outcome pair associations analyzed by at least three studies. 
Studies were consistent (in full agreement) that—in nine studies—opioid use prior to surgery 
or injury (or early use after surgery) and—in nine studies—greater amounts of opioids (more 
prescriptions or higher dose) are the factors with mostly strong associations.  
Other consistent associations, but with largely weak associations, were found with back pain 
(7 studies, 3 with strong associations), depression (11 studies, all weak associations), 
concomitant NSAID use (4 studies, all weak associations), and fibromyalgia (3 studies, all weak 
associations).  
Studies were mostly consistent (≥75% agreement) that benzodiazepine use (6 of 7 studies, 3 
with a strong associations), comorbidity scores (6 of 8 studies, 2 with strong associations), 
variably or undefined substance misuse (9 of 10 studies, 2 with strong associations), tobacco use 
(5 of 6 studies, 1 with a strong association), and low income (8 of 10 studies, all with weak 
associations) were associated with long-term opioid use.  
Studies were also mostly consistent that alcohol “abuse” (4 of 5 studies) and healthcare 
utilization (3 of 4 studies) were not associated with long-term opioid use; however, one of these 
latter studies found a strong association between “any hospitalization” and long-term use. 
Factors with variable findings of association (evaluated by at least 3 studies) included gender 
(8 of 18 studies found weak associations with female gender; 2 found associations with male 
gender, 1 strong), age among older adults (8 of 14 studies found mostly weak associations with 
younger age; 2 found weak associations with older age), Black race (8 of 12 found weak 
associations, but 5 associations were with increased and 3 were with decreased likelihoods), 
dementia (2 each, among 5 studies found associations with increased and with decreased 
likelihood), rural or non-urban residence (1 each, among 5 studies found associations with 
increased and with decreased likelihood), prescription of long-acting opioids (2 of 3 with studies 
found associations, both strong), unmarried relationship status (2 of 3 studies found associations, 
1 strong), and use of muscle relaxants (2 of 3 studies found weak associations). 
Summary of Factors Associated With Opioid Misuse and Related Outcomes 
(Octagon R2) 
Two sets of studies have evaluated factors associated with opioid misuse (Octagon R2 in 
Figure 1: Conceptual Framework): opioid-related disorders and multiple opioid prescribers. 
Six studies have evaluated factors associated with opioid-related disorders among older 
adults, including OUD, opioid misuse, and high-risk behaviors, but since the researchers largely 
analyzed different sets of factors, there is little consistency or replication across models. Three 
studies each reported variable findings regarding the associations of alcohol misuse and of 





risk obtainment of prescription opioids among older adults. The OUD study reported strong 
associations with a history of anxiety, pain interference (a measure of pain severity), and both 
marijuana and alcohol use. Older age, college education, and a prior history opioid misuse were 
each found to be associated with increased risk of high-risk obtainment of prescription opioids 
(in one study). Only two studies evaluated factors associated with having multiple opioid 
prescribers (potentially an indication of misuse or a risk factor for harms related to 
uncoordinated care). Both found that younger age (among older adults) and specific insurance 
coverage factors (lower copays, Medicare Advantage vs. traditional Medicare, and Medicare Part 
D benefit in addition to VA only) were associated with having multiple prescribers. Other 
variables were inconsistently associated with having multiple opioid prescribers or were only 
evaluated by one model. 
Summary of Factors Associated With Opioid-Related Harms (Octagon R3) 
Four sets of studies have evaluated factors associated with opioid-related harms (Octagon R3 
in Figure1: the Conceptual Framework): mental or physical health harms, hospitalizations or ED 
visits, opioid overdose and death. 
Few studies (two each) have evaluated opioid-related factors associated with mental health 
or physical health harms in older adults. A single study found that opioid use, duration of use, 
and opioid type are strongly associated with increased risk of hip fracture, but other studies 
found weak or no associations with outcomes. Each of the four studies evaluated different 
outcomes and no factor-outcome association was replicated. Additional research is needed. 
Outcomes related to hospitalizations or ED visits have been evaluated in multivariable 
models in five studies. Strong associations were reported between opioid use or misuse and both 
all-cause hospitalization and ED visits, as well as between increased number of opioid 
prescribers and opioid-related hospitalizations. However, the five studies each evaluated 
different combinations of factor categories and outcome categories, such that no finding has been 
replicated. Additional research is needed. 
Three studies evaluated factors associated with opioid overdose in older adults. One study 
ranked numerous (often unclearly defined) factors by strength of association; the other two 
evaluated nonoverlapping sets of factors. Nevertheless, one study each reported strong 
associations for opioid overdose among older adults with age, disability status, opioid use 
duration, amount of opioid use, opioid misuse, other substance misuse, and number of opioid 
prescribers. Additional research is needed. 
Among five studies that have evaluated factors associated with death related to opioid use in 
older adults, two reported that counties with higher percentages of people who are White or in 
poverty are associated with higher risks of opioid-related or drug overdose deaths. Notably, these 
measures apply to communities, not necessarily individuals, at high risk. Other specific 
associations have each been evaluated by only a single study (including strong associations for 
new opioid use and tramadol prescription). Additional research is needed. 
Interventions Related to Opioid Use in Older Adults 
Overview of Literature 
We identified 16 studies (in 17 articles) that address interventions to appropriately reduce 
opioid prescriptions, reduce harms, identify misuse, or treat misuse in older adults. A summary 
of the identified intervention studies is presented in Table 15.117-133 The descriptions are 





patient, clinician, and healthcare system), then by study. Appendix D Tables D-4 to D-6 include 
further details of each study.  
Only two were randomized controlled trials. In both trials clinicians, not patients, were 
randomized.119,122 Most studies were secondary database or registry analyses (e.g., among 
Medicare Part D enrollees) or cross-sectional survey studies. Five studies were pre-post studies 
(with data collected and compared before and after an intervention was introduced). Two studies 
were conducted specifically among caregivers, in one study as a focus group and in the other for 
training of motivational interviewing. Further descriptions are provided below. 
Nine of the studies evaluated interventions to reduce opioid prescriptions or use, which align 
with Triangle I1 in the Conceptual Framework (Figure 1), and primarily address the stage at 
which decisions are being made about which treatment(s) to use (Conceptual Framework 
Rectangle C). One of these interventions also was designed to minimize patient activities that 
may lead to opioid misuse (Triangle I2). Six additional studies evaluated screening tools to 
identify people at increased risk of opioid-related disorders (also Triangle I2). Two studies 
evaluated clinician-level interventions to reduce harms related to opioid use or misuse in older 
adults (Rectangle F and Triangle I3 in the Conceptual Framework). Few studies evaluated 
patients’ pain. No studies addressed safe prescription practices among older adults appropriately 
using opioids (Rectangle D) and no studies evaluated either management of opioid misuse in real 
(as opposed to hypothetical) older adults or treatments for OUD in older adults (Rectangle F). 
There are numerous gaps in the evidence base related to the various stages depicted in the 
Conceptual Framework (Rectangles B to F) and the types of interventions (Triangles I1 to I3), 
not to mention issues related to applicability or heterogeneity of treatment effect suggested by 
the various potential predictors (or effect modifiers). Even where there is evidence, almost none 






Table 15. Studies that evaluate interventions of interest 




Intervention Design Sample Size Result* 
Reduce opioid prescriptions or 




Patient-level Darchuk 2010 
20735746117 





Patient education pamphlet† NRCS, prospective 172 NS 
Clinician-level Pasquale 2017† 
29199396119 







Bundle of educational 
modalities 



















PDMP NRCS, retrospective  
(registry) 
6920 Improved 
Moyo 2017, 2019 
28498498124, 
31372990125 





Tamper-resistant oxycodone NRCS, retrospective  
(registry) 
5055 NS 




Screening Park 2011 
21143370127 
PMQ Single group, 
prospective 
150 Useful tool 
Tiet 2019  
30947051128 










Henderson 2015  
26056833130 












ASSIST Single group, 
retrospective 
210 Unclear 
Clinician-level Pasquale 2017† 
29199396119 





Patient-level Rose 2016† 
26431852118 
Patient education pamphlet† NRCS, prospective 172 Improved 
Reduce opioid-related harms 
(Conceptual Framework 
Rectangle F and Triangle I3) 



















Abbreviations: ASSIST = Alcohol, Smoking and Substance Involvement Screening Test, AUDIT-C = Brief Alcohol Use 
Disorders Identification Test, NRCS = nonrandomized comparative study, PDMP = prescription drug monitoring programs, 
PDUQp = Prescription Drug Use Questionnaire, patient version, PMID = PubMed identifier, PMQ = Pain Medication 
Questionnaire, RCT = randomized controlled trial, SDS = Severity of Dependence Scale, SoDU = Screen of Drug Use. 
* Qualitative assessment of effect of intervention, categorized as statistically nonsignificant (NS), Improved (statistically 
significant effect of intervention to reduce harm or to increase benefit), Worsened (statistically significant effect of 
intervention to increase harm or to decrease benefit), Mixed (benefit for some outcomes, harm for others). 
† Note that this study is in the table multiple times. 
‡ The older adults with opioid misuse were, in fact, hypothetical patients that the students used as case examples. 
§ The clinicians’ patients were, in fact, those who were predicted to be at increased risk for opioid abuse, not patients diagnosed 
with opioid misuse (or opioid use disorder). 
 
Interventions To Reduce Opioid Prescribing for Older Adults for 
Whom Harms Outweigh Benefits (Triangle I1) 
Evidence Base 
We identified nine studies of interventions to reduce opioid prescribing or use in older adults 
(first set of subrows in Table 15). These studies align with Triangle I1 in the Conceptual 
Framework (Figure 1) at the stage where decisions are being made regarding treatment. 
Interventions were aimed at patients (rehabilitation and education), clinicians (providing 
information and education), hospital systems (an opioid safety initiative), and healthcare systems 
(free acetaminophen prescriptions, prescription drug monitoring programs (PDMP), and tamper-
resistant opioids). Of note, among studies that had the goal of reducing overall opioid 
prescriptions or use, none specifically assessed “appropriate” reduction of opioid prescriptions or 
use (e.g., for patients whose risks of harms outweigh benefits). However, only four studies also 
evaluated effects of the interventions on pain (and/or mental health and quality of life) outcomes. 
Only the hospital systems-level study assessed reducing opioid prescriptions or use specifically 
in the context of maintaining adequate pain control 
Training Patients 
Two studies assessed training or education of patients with the goal of reducing opioid use 
(identified as “Patient-level” in Table 15).  
Darchuk 2010117 described the Mayo Clinic Comprehensive Pain Rehabilitation Center 
program, an intensive 3-week, group-based, outpatient interdisciplinary pain rehabilitation 
program. As described by the authors, the cognitive–behavioral model serves as the basis for 
treatment, which incorporates physical therapy, occupational therapy, biofeedback and relaxation 
training, stress management, wellness instruction (e.g., sleep hygiene, healthy diet), chemical 
health education, and pain management training (e.g., activity moderation, elimination of pain 
behaviors). The program's goals emphasize functional restoration and self-management of 
chronic pain symptoms. An important treatment goal for all patients in this program is the 
discontinuation of opioid and simple analgesics taken for relief of chronic pain. The study was 
conducted as a pre-post design, without a separate concurrent comparator group. The authors 
reported on an older adult subgroup comprising 78 individuals aged ≥60. The study found a large 
reduction in opioid use after discharge from the program, which occurred in parallel with 
reduced depression, catastrophizing, pain severity, and pain interference, and increased perceived 
control, and physical and social functioning. 
Rose 2016118 evaluated the effect of a patient education pamphlet on opioid use. The pre-





with a mean age of 63 years. The goal of the education was not specifically designed to reduce 
opioid use. The pamphlet covered educational domains about safe opioid storage, opioid 
weaning, and opioid disposal. However, the study also reported on postoperative opioid 
cessation, finding no difference in opioid cessation rates between groups. Furthermore, no 
differences were found in pain outcomes. 
One systematic review is ongoing that, at least tangentially, will address issues related to 
appropriate prescriptions. The ongoing systematic review by Alvan et al.134 is investigating 
risks and benefits of pharmacological treatment of older (≥65 years) patients with common pain 
conditions. They are also looking for qualitative research studies that assessed the experiences of 
older adults with pain. The review is expected to be published in 2020. 
Clinician-Level Interventions (Information and Training) 
Two studies assessed education of or providing information to clinicians with the goal of 
reducing opioid use (identified as “Clinician-level” in Table 15).  
A cluster-randomized trial assessed the value of providing information to physicians about 
Medicare patients’ opioid “abuse” risk. Pasquale 2017119 used a regression model to predict that 
2,391 patients enrolled in Medicare plans were at increased risk for opioid “abuse” and then 
linked the patients with their prescribing physicians (N=4,353). Those physicians were 
randomized to be sent either “patient information,” educational materials for diagnosis and 
management of pain, both patient information and educational materials, or there was no 
communication. The study evaluated patients’ opioid prescriptions, “chronic high-dose opioid 
use” (multiprescriber, multipharmacy, high-dose use ≥90 days), “uncoordinated opioid use” 
(multiprescriber), among other opioid-related outcomes. The study found that the interventions 
did not affect these outcomes, but they did not evaluate patient-level outcomes, including pain 
and functioning. 
Gugelmann 2013120 evaluated a “bundle” of interdisciplinary educational modalities 
provided to ED nurse practitioners with the specific goal of decreasing opioid discharge pack use 
in patients treated and released from the ED, particularly those at risk for dependence. These 
included: lectures, journal clubs, case discussions, and an electronic medical record decision 
support tool.” In a larger evaluation of all ED patients, they report the results for a subgroup of 
2212 individuals aged 65 years or older who were treated before (N=1360) or after (N=852) the 
training (interrupted pre-post design). The single result reported for this older adult subgroup 
related to prescription of oxycodone/acetaminophen “4-packs,” with a statistically significant 
decrease in prescriptions during the postintervention period. The study did not report 
comparative pain outcomes for older adults. Of note, Gugelmann et al. was the only pertinent 
study related to opioid use found by a 2016 systematic review, by Maree et al.,54 of opioid (and 
benzodiazepine) misuse in older adults. 
Hospital System-Level Intervention 
One study assessed implementation of an opioid reduction program in a hospital system 
(identified as “Hospital system-level” in Table 15).  
The study, conducted in the VA Health Care System, evaluated rollout of an “Opioid Safety 
Initiative” nationwide. The initiative included training and education of physicians and “active 
support” of patients and physicians.135 The initiative has a goal of reducing non-cancer pain 
opioid treatment to <200 morphine-equivalent mg daily, with active monitoring of patients with 
higher prescribed dosages. Chen 2019121 compared patients undergoing total knee arthroscopy 





and nonopioid prescriptions. The study found substantial decreases in chronic opioid use 
together with “minimal” impacts on pain scores (i.e., no worsening of pain, despite decreased 
opioid use). 
Healthcare System-Level Interventions 
Four studies evaluated the association of national or State-level systems changes and changes 
in opioid prescriptions (at a population level). None evaluated pain outcomes. 
One trial randomized clinicians to being able to prescribe acetaminophen at no charge to 
their patients with knee osteoarthritis (as opposed to providing recommendations for over-the-
counter acetaminophen). Among 117 patients (all ≥65 years, 32% using opioids prior to the 
trial), Vicentini 2019 found no difference in average daily opioid dose or number of opioid uses 
between groups.122 The study did not report patient-centered outcomes such as pain or 
functioning. 
Two studies evaluated prescription drug monitoring programs (PDMP) in the U.S. 
Yarbrough 2018123 evaluated data on Medicare enrollees in all 50 states, comparing states with 
PDMPs that (1) allowed both prescribers and dispensers to have access to the program, (2) 
provided online access to the program, and (3) required reporting of all pharmacy prescriptions 
with states whose PDMPs did not meet these criteria. The number of opioid prescriptions were 
compared between states. The study concluded PDMPs had a modest effect on oxycodone use. 
Moyo 2017124 and 2019125 also evaluated data on Medicare enrollees (with data reported 
specifically for those ≥65 years), initially (in 2017) in 21 states that either did or did not have 
PDMPs, expanded nationwide (in the 2019 publication). The study reported opioid prescriptions 
at the state level, as measured by kilograms of opioids dispensed, number of dispensed 
prescriptions, and opioid dose per prescription. This study also found significant reductions in 
opioid prescriptions and daily doses associated with PDMP. Neither study evaluated whether the 
amounts of opioids prescribed were “appropriate” or adequate to manage pain. 
The third study evaluated the effect of the introduction of a tamper-resistant formulation of 
oxycodone CR (controlled release) on opioid use in Australia. As part of a larger study of 
individuals prescribed controlled-release oxycodone, Schaffer 2018126 evaluated 5,055 older 
adults ≥65 years. The study compared prescriptions for oxycodone CR specifically, changes to 
“strong” opioids, and switches to other opioids related to the change in formulation but found no 
significant association between oxycodone formulation and opioid use. No patient-level 
outcomes, including pain, were reported. 
Research Needs Regarding Interventions To Reduce Opioid Prescribing for 
Older Adults for Whom Harms Outweigh Benefits (Triangle I1) 
With the exception of PDMP, each of the interventions to reduce opioid use was evaluated by 
only a single study; thus, there is a need to replicate the findings and expand upon the research 
base. Furthermore, the studies all evaluated overall opioid use, instead of aiming to reduce opioid 
use where harms outweigh benefits. Future studies should attempt to better focus on minimizing 
“inappropriate” use. Such attempts might first require ethics research to define “appropriate 
reductions” in opioid use, as well as policy research to understand the unintended adverse 
consequences of policies that aim to reduce potentially inappropriate opioid use. 
Research Needs Specific to Multidisciplinary Pain Treatment Teams 
Significantly more research is needed on care models that organize multiple providers (e.g., 





treatment team (e.g., as in interdisciplinary pain programs or clinics). While the ED intervention 
described in Gugelmann 2013120 addressed the portion of the conceptual framework related to 
reducing suboptimal opioid prescribing, it did not involve any formal efforts to organize 
providers into a pain treatment team. Furthermore, no interventions appear to address how 
exactly to establish clear delineations of responsibility for pain management in a 
multidisciplinary pain team. Furthermore, Key Informants and others believe that 
interdisciplinary pain teams could or should include a pharmacist capable of performing a 
comprehensive geriatric medication evaluation, who would then either make recommendations 
to prescribers or function semi-autonomously under a collaborative practice agreement (i.e., 
protocol) to make modifications to an older adult’s medication regimen. Studies of this potential 
care model would be highly valuable. 
Research Needs Specific to Deprescribing Protocols and Sharing Responsibility 
Related to care models that organize multiple providers, one of the most important areas for 
future research is understanding who is responsible for prescribing an opioid, monitoring its 
continued use, and deprescribing the opioid. Deprescribing is the clinically supervised process of 
dose-reducing or completely stopping medications that could cause harm or that no longer 
provide benefits that outweigh potential risks.136-138 It is not an action that the patient and/or 
caregiver takes independent of the prescriber. It occurs under the guidance and direction of the 
healthcare provider. The decision to deprescribe should also be made with the patient. Forced or 
nonconsensual deprescribing without patients’ explicit agreement is not recommended, 
especially for pain treatments. In particular, research is necessary on how to address 
deprescribing of an opioid by a provider who did not prescribe the drug. Furthermore, 
recognizing that older patients often have many providers due to their multiple chronic 
conditions, deprescribing protocols should explicitly address how responsibility will be shared 
for deprescribing of an opioid. Future research should therefore (1) identify what providers 
perceive as their set of responsibilities and locus of control, (2) develop interventions that 
explicitly address provider responsibility, and (3) test interventions to determine if explicitly 
incorporating provider responsibility into deprescribing protocols and other interventions is 
effective, especially in comparison with protocols that do not address how to divided or share 
responsibility among multiple providers. It is possible that deprescribing or tapering opioids may 
cause adverse events or confer a risk of harms (e.g., suicide). Research is necessary to better 
understand the causal effects of deprescribing and tapering approaches on harms to ensure that 
all approaches employed are safe in addition to being effective. Antecedent noninterventional 
research using secondary data might be necessary to understand the relationships between real-
world discontinuation or tapering patterns and subsequent outcomes. Such information, if 
obtained using methods that properly account for biases (e.g., confounding and selection biases), 
could be valuable for informing the design of interventions. Information is also necessary to 
identify for which conditions deprescribing might be inappropriate because it represents a 
deprivation of important, medically necessary therapy. For example, deprescribing opioids for 
older adults with refractory dyskinesias might be highly inappropriate and result in severely 
impaired quality of life, extreme insomnia, and suicidal depression. Qualitative research could 
help to confirm that opioids are essential and equipoise does not exist for interventional research 





Research Needs Specific to Multimodal Stepped Care Pain Therapy 
Research specific to older populations is necessary on the outcomes of interventions related 
to multimodal stepped care pain therapy—a pain treatment approach that (1) combines 
medications from different pharmacologic classes and (2) combines pharmacologic and 
nonpharmacologic therapies or multiple nonpharmacologic therapies.  
In particular, research on how to implement this approach in resource-constrained clinical 
settings should be conducted. More evidence is also necessary to confirm that multimodal 
stepped therapy improves older adults’ outcomes, including functioning, disability (especially 
related to pain), quality of life, and any other outcomes valued by older adults. While opioids are 
more effective if they are combined with nonpharmacologic treatments, more evidence is 
necessary to provide a better understanding about how, given a specific source of pain or 
combination of sources, different interventions should be combined and modified for older 
adults.139 The number of treatment combinations is nontrivial considering that in addition to 
medications, multimodal stepped therapy may also include cognitive-behavioral therapy, 
massage, physical therapy, rehabilitation, exercise, acupuncture, meditation, and more. Since 
many different research questions will need to be answered to establish the role, feasible designs, 
and ideal implementation of multimodal and multidisciplinary care interventions for older adults, 
qualitative research involving key stakeholders may be necessary to establish a structured 
research agenda and sequential steps. 
Interventions To Identify or Reduce Opioid-Related Disorders in Older 
Adults (Triangle I2) 
Evidence Base 
As listed in the second set of subrows in Table 15, we identified eight studies pertaining to 
identifying or reducing opioid-related disorders (including misuse). These align with Triangle I2 
in the Conceptual Framework (Figure 1). Six of the studies evaluated screening tools (at the 
patient level) to predict risk of opioid-related disorders. While we have aligned these with 
Triangle I2, one could equally argue that they align with Triangle I1 (reducing opioid prescribing 
where harms may outweigh benefits) since the tools may be used during decision making 
regarding choice of treatment. Two studies (Pasquale 2017 and Rose 2016) also addressed issues 
related to Triangle I1 and are described in the section above (Interventions to Reduce Opioid 
Prescribing). 
Screening Tools 
Six studies evaluated tools to identify older adults either at risk of, or with, opioid misuse, 
dependence, or OUD, but only two assessed the same tool. 
Park 2011127 analyzed a validated tool (for the general population) to develop a tool 
specifically for older adults with chronic pain. They modified the existing Pain Medication 
Questionnaire (PMQ) into a 7-item version and evaluated it in 150 older adults (≥65 years) who 
had chronic pain (≥3 months) and were using opioids for at least 30 days. The tool was evaluated 
to predict opioid misuse. The authors concluded that the modified PMQ may be useful in 
assessing opioid misuse in community-dwelling older adults with chronic pain, but that future 
studies are needed to confirm the reliability, validity, and factor structure. 
Tiet 2019 evaluated a 2-item instrument they had previously developed,140 the Screen of 
Drug Use (SoDU) tool, in patients seen at primary clinics in the VA system, with a mean age of 





purpose of the tool was to screen and identify those with any drug use disorder (including 
stimulants, cocaine, narcotics, hallucinogens, inhalants, marijuana, tranquilizers, and 
miscellaneous). Among 1,283 patients, the researchers evaluated the tool to identify OUD as 
diagnosed by the Mini International Neuropsychiatric Interview (MINI) structured diagnostic 
interview.141 The SoDU tool was found to have perfect sensitivity (100%) and high specificity 
(86%). In subgroup analyses, for “older” participants (undefined, but likely >62.2 years), the tool 
had even higher specificity (94%). The authors concluded that the 2-item SoDU tool had 
excellent statistical properties and is suitable for primary care practices. 
Beaudoin 2016129 validated an existing tool, the Prescription Drug Use Questionnaire, 
patient version (PDUQp) in a set of patients known to have used opioids in the previous 30 
days. The article reported on a subgroup of 38 patients aged ≥65 years. The tool was validated 
for opioid misuse and OUD. Henderson 2015130 also assessed the PDUQp in 88 older adults (≥65 
years) with subcritical illnesses or injuries seen in the ED who were using opioids daily. The 
study assessed the population for opioid misuse and “abuse.” The authors concluded that the 
PDUQp may be a viable instrument to screen for prescription opioid misuse and OUD, but likely 
requires modifications to optimize its predictive ability in adults over age 50 years. 
Cheng 2019131 evaluated a different existing tool (validated in the general population), the 
Severity of Dependence Scale (SDS) in 246 older adults (aged 65-90 years) who were 
prolonged users of central nervous depressants, including opioids (and benzodiazepines and 
hypnotics). The study evaluated medication misuse or dependence (as a combined outcome), 
specific to opioid use (and specific to other drugs). The authors concluded that the SDS is 
reliable, valid and capable of detecting medication misuse and dependence among hospitalized 
older patients, with good diagnostic performance. 
Finally, Draper 2015132 categorized 210 older adults (≥60 years) who were receiving 
outpatient clinical care at an urban hospital based on their score on the Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST) and their opioid (and alcohol and 
benzodiazepine) misuse status. However, only two included individuals were classified as having 
opioid misuse. The authors did not appear to make recommendations about the use of ASSIST 
and noted that there may be several important complexities with using the tool as a screen. 
Two ongoing systematic reviews may be pertinent to the evaluation of screening tools in 
older adults. Raposo Galindo et al.142 are conducting a systematic review of validated assessment 
tools for measuring the risk of behavior suggestive of opioid “abuse” in adults with noncancer 
pain. The review, as a whole, does not focus on older adults, but plans to focus on “different age 
groups” including older adults, as data allow. Listed outcomes include opioid use. The 
researchers planned to publish in 2018, but we found no record of the finalized review. Pask et 
al.143 also have an ongoing systematic review of how opioids affect cognition in older adults 
(≥65 years). In particular, they are investigating which “screening and assessment tools can be 
used to detect and assess opioid-induced cognitive impairment in older adults,” excluding those 
with opioid misuse. Listed outcomes include cognitive function and cognitive impairment. The 
researchers planned to publish in early 2019, but we found no record of the finalized review. 
Clinician-Level Intervention To Reduce Misuse 
As described above, Pasquale 2017119 randomized clinicians managing patients enrolled in 
Medicare determined to be at increased risk for opioid “abuse” to be sent either “patient 
information,” educational materials for diagnosis and management of pain, both patient 





lack of effect on outcomes opioid prescriptions, the study also found no effect on diagnosis of 
OUD. Of note, about 10 percent of patients had new diagnoses of OUD during the study. 
Patient-Level Intervention To Reduce Misuse 
As described above, Rose 2016118 evaluated a patient education pamphlet in 172 patients 
undergoing major joint replacement (mean age 63). The goal of the pamphlet was to inform 
patients about safe opioid storage, opioid weaning, and opioid disposal. Reported outcomes 
included ease of weaning off opioids, opioid withdrawal symptoms, opioid disposal, opioid 
storage, and opioid use cessation. The authors concluded that the pamphlet improved self-
reported proper opioid disposal rates in postoperative patients. 
Research Needs Regarding Interventions To Reduce Opioid-Related 
Disorders in Older Adults (Triangle I2) 
Studies of interventions that clinicians, patients, healthcare systems, or other entities can use 
to reduce either inappropriate opioid prescriptions or the risk of opioid misuse are sparse or 
lacking for older adults. Although we did not evaluate the effectiveness of interventions in the 
studies, overall, the reported results are not impressive, suggesting that new tools, methods, and 
specific interventions are needed to ensure more appropriate opioid prescribing among older 
adults and to minimize the risk of older adults becoming dependent on their opioid prescriptions. 
Research Needs Specific to Validation of Existing Tools To Identify Opioid Misuse 
or OUD 
Several tools have been validated and/or evaluated to identify older adults at increased risk of 
opioid misuse or OUD, but there has been little to no replication of findings. Validation of 
existing screening tools for opioid misuse or OUD in large, national populations of older adults 
is a clear research need to ensure that the tools are feasible to use and accurate for populations 
other than the small, limited ones in which the tools were developed and tested. It is also unclear 
to what extent many of the tools can be implemented in multiple care settings, as well as whether 
setting might modify the accuracy (i.e., discriminative ability) of the tools. Another key related 
research need is validation of the Opioid Risk Tool (ORT) and Screening, Brief Intervention, and 
Referral to Treatment (SBIRT) tool in older adults. Whether the findings from studies of ORT 
and SBIRT among younger or middle-aged adults can be extrapolated to older adults is 
unknown. Given the multitude of unique characteristics of older adults, it is unclear if the tools 
will generalize well without any modifications. It is possible that the items of the ORT are 
unlikely to be impacted by age, but this remains unknown without further study. Studies of the 
tools are particularly needed for primary care settings. Such studies should carefully document 
the validity and reliability in the overall population of older adults and within strata of older age 
(e.g., 60 to 69.9 years, 70 to 79.9 years). If an alternative tool were to be developed specifically 
for older adults, research should focus on the brevity of the tool as a key feature that is necessary 
for it to have meaningful uptake among clinicians caring for medically complex older patients in 
busy primary care settings.b An assessment of the cultural appropriateness of various tools and 
their performance across subgroups of race and ethnicity is a remaining research need. Given 
                                                 
b Some discordance existed among Key Informants about the generalizability of available screening tools, 
with some experts arguing that the screening tools developed in younger adults can be readily applied 
to older adults (without needing replication in studies of older adults) while others arguing that further 





existing evidence that suggests race and ethnicity are potentially important predictors of opioid-
related outcomes, a rational next step is to study how tools (and management of opioids more 
broadly) might need to differ for older racial/ethnic minority adults with pain. 
Research Needs Specific to Implementation and Effectiveness of SBIRT 
In addition to foundational research on the implementation and effectiveness of SBIRT for 
OUD in older adults, there is a need for research on how to integrate SBIRT into existing care 
management for older adults. Medication reviews are a prime target because SBIRT could be 
integrated into regular medication reviews for older adults. How exactly this should be done, 
though, remains empirically unstudied. Research identifying the optimal and most effective ways 
to combine SBIRT with medication reviews and other routine care management is highly 
important. There is also a need for more empirical evidence about which medications 
(methadone, buprenorphine, naltrexone) and treatment regimens for OUD are most effective and 
safe for older adults. A related need is information on how to implement SBIRT and medications 
for OUD in settings where older adults often receive care, but that may not have the necessary 
resources or infrastructure to implement interventions to treat OUD in older adults. Post-acute 
care settings like skilled nursing facilities and nursing homes are likely to be one such setting. 
Research Needs Specific to Provider Perception of OUD Risk 
We did not identify any studies documenting providers’ beliefs about OUD risk in older 
adults. Providers may prescribe opioids long-term to older adults because they believe that the 
risk of OUD is particularly low in this population, especially considering the marketing materials 
providers received from pharmaceutical companies in the 1990s and possibly beyond suggesting 
that OUD and addiction risk were low. Qualitative, survey, or other research may necessary to 
empirically document provider beliefs and understand provider perceptions. These perceptions 
may be an important predictor of prescribing and opioid-related harms. If true, that information 
could eventually inform the development or tailoring of behavioral interventions aimed at 
reducing suboptimal opioid prescribing for older adults. Key Informants also noted that many 
caregivers and patient family members do not believe older adults are at a high risk, or any risk, 
of misusing opioids or developing OUD. These beliefs and perceptions could be very important 
to study as potential predictors of misuse and OUD as they would inform future interventions 
attempting to incorporate caregivers or family members into misuse or OUD surveillance efforts. 
The perceptions and beliefs of various stakeholders are also important because they might result 
in erroneous expectations about the effects of mandatory system-wide interventions to reduce 
opioid prescribing. While such system-wide interventions could potentially reduce the risk of 
OUD across all age groups, they might also result in significant harms to older adults who 
require opioids and are unable to substitute alternative nonopioid treatments.  
Research Needs Specific to Care Coordination 
Research is needed on whether interventions to improve care coordination between providers 
can help to reduce misuse and OUD (and also opioid-related harms). The lack of communication 
about what medications are being prescribed by providers in one setting to providers in other 
settings can either directly result in harms (e.g., through therapeutic duplication resulting in 
overdose) or facilitate opioid misuse. Research on how interventions to improve coordination 
between an older adult’s primary care provider and other providers (i.e., collaborative capacity) 
impact the risk of opioid misuse and OUD is particularly necessary. A better understanding of 





on communication; in particular, understanding the relationship between co-location or 
geographic proximity of primary care, pain management, mental health, and substance use 
services. Finally, the development of integrated approaches or interventions involving healthcare 
(e.g. pharmacists) and social care (e.g. social workers) professionals may help to prevent 
problematic opioid use or to identify it earlier than would have been possible otherwise. 
Research Needs Specific to Safe Storage and Disposal 
While we found a single study about educating older adult opioid users about safe handling 
of opioid prescriptions, further evaluation of safe storage and disposal programs to reduce opioid 
misuse may be a topic for future examination in research studies.  
Interventions To Reduce Opioid-Related Harms (Triangle I3 and 
Rectangle F) 
Evidence Base 
Two studies evaluated interventions designed to reduce opioid-related harms (as shown in the 
last rows of Table 15). Both studies evaluated interventions aimed at clinicians, one set of 
interventions was designed to reduce opioid misuse (and related harms) among Medicare patients 
deemed to be at high risk, and the other was an intervention to manage opioid misuse in older 
adults. 
Clinician-Level Intervention To Reduce Misuse 
As described above, Pasquale 2017119 randomized clinicians managing patients enrolled in 
Medicare determined to be at increased risk for opioid “abuse” to be sent either “patient 
information,” educational materials for diagnosis and management of pain, both patient 
information and educational materials, or there was no communication. In addition to the 
lack of effect on outcomes opioid prescriptions and risk of new OUD, the study found no effect 
of the interventions on risk of opioid-associated ED visits. 
Clinician-Level Intervention To Manage Opioid-Related Disorders 
The only study that pertained to management of older adults with opioid misuse, Chang 
2019,133 was an evaluation of motivational interviewing training for 31 doctorate of nursing 
practice students. The training used as an example a hypothetical older adult who took more 
prescription opioids than prescribed (thus, misuse), and then evaluated the students’ motivational 
interviewing knowledge, confidence, attitude, skills, and their substance “abuse” knowledge. The 
authors concluded that the preliminary findings suggested motivational interviewing education 
with standardized patient simulation could improve nursing students' knowledge of and 
confidence in motivational interviewing techniques to manage prescription opioid “abuse” 
among older adults. The study did not measure the effect of the educational approach on 
subsequent clinical practice or older adults’ outcomes. 
Patient-Level Interventions To Manage Opioid-Related Disorders 
Of note, a systematic review, by Wylie et al.,144 is ongoing and evaluating opioid agonist 
therapy in older adults. However, it is unclear whether the review is specifically addressing 
interventions. Their protocol describes the goal “to gain an understanding of older adult (50+) 
service user experiences during opioid agonist therapy” and to “assess the [opioid agonist 
therapy] experiences of older adults with an opioid disorder.” Their reported primary outcomes 





improvement of [opioid agonist therapy] for an older adult population.” They expect to publish 
their results in 2019, but we have found no record of the finalized review. 
Research Needs Regarding Interventions To Reduce Opioid-Related Harms 
(Triangle I3 and Rectangle F) 
Research Needs Specific to Tools To Predict Harms During Appropriate Opioid 
Use 
Distinct from validation of existing tools to identify misuse or OUD (addressed in the prior 
section pertaining to Triangle I2 in the Conceptual Framework), tools are necessary to help 
providers identify older adults who are likely to experience opioid-related adverse events despite 
using opioids appropriately (which address Triangle I3 in the Conceptual Framework). While the 
evidence map suggests some potential tools may exist for identifying opioid misuse and related 
harms that occur during misuse, we identified no person-level screening or prediction tools that 
attempted to identify older adults who were most likely to experience an opioid-related harm 
despite using opioids as prescribed by a provider. Accordingly, there were no tools that explicitly 
calculated the tradeoffs between expect benefits and harms to derive a benefit-harm ratio for a 
given person. Research is necessary to develop these tools, which are foundational for expanding 
efforts to avoid or mitigate adverse events when an older person truly requires opioids for pain 
management. In addition to research that helps to answer how benefits and harms should be 
assessed, research is also necessary to identify exactly who is poised to best perform the benefit-
harm assessment. It is possible that some individuals may become well-poised to assess the 
balance of benefits and harms of opioids through education or formal educational interventions. 
Families and caregivers, for example, might be such persons. Clinicians, direct care workers, 
health profession students, and faculty are likely to be identified as persons for whom 
educational interventions might be impactful. Educational intervention studies should focus on 
training these individuals to quantify the benefits and risks of opioids, and then reduce opioid 
prescribing where harms outweigh benefits. They will also need to train individuals to better 
understand how to increase access to nonopioid treatments, prevent opioid misuse or OUD, and 
reduce the risk of opioid-related harms when opioid use is necessary. Educational interventions 
focused on helping social care providers (e.g., social workers) to screen, assess, and diagnose 
substance use disorders among older adults might be particularly impactful for identifying opioid 
misuse or OUD. 
Research Needs Specific to Self-Management 
Self-management is becoming a more prevalent component of pain treatment approaches. 
This raises important questions how self-management (and interventions more broadly) might 
need to be adapted for older adults, especially those with cognitive impairment or other 
challenges to self-management. The challenges that cognitive impairment and dementia might 
pose are unique to the older adult population and are a major and important challenge that 
prevents generalizing evidence from younger cognitively-intact populations to older ones. A 
particular program, the Chronic Pain Self-Management Program (CPSMP), may be in use by 
some National Aging Network partners, but studies were not identified in the evidence map that 
report on the effectiveness or outcomes of this program in an older adult population.3 Studies of 
the outcomes of CPSMP may help advance our understanding of the role of self-management in 





Research Needs Specific to Settings for OUD Treatment 
There is no empirical information about management of older adults with opioid misuse or 
OUD, and, more specifically, the comparative effectiveness of various settings for treatment of 
OUD for older adults. Standard outpatient versus more controlled residential treatment facilities 
are both options for OUD treatment and provision of medication assisted treatment, but the 
comparative effectiveness of these settings, especially when taking into account the severity of 
older patients’ OUD or medical complexity, is unknown. Each setting and the way they provide 
medication assisted treatment may have important differential effects on subsequent outcomes, 
including relapse prevention. More information is also necessary to understand whether certain 
settings are more effective for specific subgroups of older adults. For example, while more 
research is necessary in general about the management of OUD for diverse racial and ethnic 
minority older adults, research might be particularly helpful on which settings result in the best 
outcomes for racial/ethnic minority older adults with OUD.  
Research Needs Specific to Naloxone Kits 
While emergency naloxone rescue kits are now recommended for all patients receiving 
medication assisted treatment, research is necessary to confirm that older adults have also been 
receiving these kits. Perhaps even more importantly, research is necessary to understand how 
family members and other caregivers are engaged and educated about the use of these kits. Older 
adults often have complex caregiving circumstances and unique strategies may be necessary to 
engage all of their caregivers in opioid overdose prevention through education or other means. In 
the event of an overdose, it is unclear if caregivers are prepared to use the rescue kit.  
Research Needs Specific to Care Coordination 
As suggested by other portions of the conceptual framework and evidence map, interventions 
that organize multiple providers from different specialties or disciplines and provide training in 
pain medicine or related principles are likely to be particularly fruitful topics for future research. 
Poor pain-related care coordination is a likely driver of hospitalizations and ED visits. The 
development and assessment of interventions that improve care coordination for older adults 
with pain may therefore reduce the risk of opioid-related hospitalizations and ED visits. 
Research Needs Specific to Tailoring Opioid-Related Information 
Since providers need to discuss the benefits and risks of opioids with their older patients, but 
have little information about how benefits and risks may manifest and result in a future opioid-
related hospitalization or ED visit for a particular patient, research is necessary on how to 
individualize and tailor information about opioids during discussions with older patients, both 
prior to starting opioids and while they are continued. The provision of relevant information or 
education may help older patients avoid hospitalizations or ED visits by avoiding or minimizing 
the adverse events of opioids. An important area of future research might explore how best to 
provide patients with information about their opioid prescription (e.g., with follow-up phone 
calls made by a pharmacist or health professional) and what information might be most relevant 
(e.g., information focused on modifiable patient risk factors like alcohol use and how to avoid 
falls). 
Research Needs Specific to Coprescribing and Polypharmacy Tools 
Screening for coprescribing and drug-drug interactions alone is an important component of 





necessary to formally develop and validate screening or prediction tools to quantify the risk of 
opioid-related events due to coprescribing, drug-drug interactions, and polypharmacy. This is 
especially true for circumstances where older adults are taking medications as prescribed (i.e., 
not misusing opioids). Key Informants noted that some providers simply screen for coprescribed 
medications or drug-drug interactions (usually followed by stopping ≥1 medications or 
modifying treatment regimens) as their primary approach in clinical practice to reduce opioid-
related hospitalizations or ED visits. Research would be helpful to develop a systematic 
interventional approach that formalizes this practice and examines its effectiveness using the 
outcome measure of subsequent risk of opioid-related ED visits or hospitalizations.  
Research Needs Specific to Other Opioid Outcomes 
It is possible to take a broader view on what constitutes an “opioid-related” hospitalization or 
ED visit. Beyond respiratory depression and overdoses, opioids have been associated with a 
variety of outcomes, many of which are surprisingly understudied. For instance, high-quality 
empirical evidence on motor vehicle crashes associated with opioid use is surprisingly scarce. 
Beyond overdoses and respiratory depression, further research on some of these opioid-related 
events that result in hospitalizations or ED visits could result in novel interventions, such as 
programs that intervene to balance an older adult’s need to drive for mobility against their need 
to take opioids for pain management. Suicide, violent deaths, falls and other injuries may all be 
particularly valuable foci for future studies. 
Research Needs Specific to Peer Support and Mutual Help Meetings 
Narcotics Anonymous (NA) and other mutual help meetings are popular sources of support 
for individuals who use illicit opioids like heroin. The role of NA and other mutual help 
meetings or organizations is poorly understood for older adults with OUD. The social support 
provided through those venues could have a beneficial effect on outcomes. More research is 
necessary to understand the role of NA or similar organizations in the care of older adults with 
OUD. Related to NA and mutual help, more research is necessary about the effects of peer 
support programs, which have been employed to engage and retain middle-aged adults in 
substance use disorder and mental health treatment, but for which no studies were identified by 
the evidence map for older adults. 
Research Needs Specific to Recovery 
No studies of older adults were identified that addressed recovery—the process of change 
through which older adults overcome their OUD, regain their health and social function, and live 
self-directed lives while reaching their full potential. It is thus unknown whether recovery 
support services for OUD exist for older adults and if they are effective. Additionally, identifying 
the features of such services that might best promote recovery is a major research need. For 
example, older adults often have important individual needs and strong unique preferences; 
interventions that reflect these may be more effective at promoting engagement in OUD 
treatment and recovery from OUD among older adults. 
Other Research Needs Pertaining to the Management of Opioid Use in 
Older Adults 
Although our evidence review did not cover several of the topics below, there were clear 
needs to fill gaps in knowledge about them to address the topic of the review. Many of these 





Research Needs Specific to Management of Cancer Pain for Older Adults 
Experts believe that older adults with cancer and those at end-of-life frequently require 
opioids for pain management. However, there are concerns among stakeholders that many 
providers consider cancer as a condition that provides an exemption from the application of pain 
management principles; in particular, for individuals who have treatable cancers versus those for 
whom cancer is end-stage. As a result, cancer patients may not receive an adequate examination 
of the cause of their pain. For example, some older adults with cancer may have neuropathic pain 
from the malignancy while others may have postsurgical pain, each of which might respond 
better to different treatments. Furthermore, providers may be more willing to prescribe opioids 
and to prescribe them at higher doses than they ordinarily would for patients without cancer. 
Individuals with cancer are excluded from some opioid prescribing guidelines.139 Prescribing 
guidelines that are not specific to older adults do exist for individuals with cancer.145 Research is 
likely necessary to understand whether cancer presents a unique set of factors that influence 
opioid prescribing and outcomes, and if yes, to ultimately develop more rigorous pain 
assessment tools to guide opioid prescribing for older adults with cancer. 
Research Needs Specific to Comparative Effectiveness of Opioids and 
Nonopioids in Older Adults 
Our evidence map did not include studies that evaluated the effectiveness of interventions to 
reduce pain, per se. However, discussions with stakeholders raised several concerns about the 
lack of evidence regarding which interventions are adequately, or most, effective to treat pain in 
older adults. The following research needs discussions are primarily based on those discussions. 
Research is necessary to fill the gap in knowledge about the comparative effectiveness of 
opioid versus nonopioid interventions in older adults. Selecting nonopioid therapies in place of 
opioids requires comparative effectiveness and safety evidence that is lacking, especially for 
nonpharmacologic interventions. Research to develop tools or algorithms that help providers 
better understand which of their older patients are likely to derive benefits from opioids in excess 
of any harms, especially compared to nonopioid alternatives, is also lacking. Some of this 
research has been recently funded (in September 2019) by the National Institutes of Health 
(NIH), in part under the Helping to End Addiction Long-term (HEAL) Initiative launched in 
April 2018, and results will become available in coming years, though these studies were not 
considered for the current technical brief. These investments by NIH in understanding the role of 
nonopioid and nonpharmacologic treatments is important and will likely be relevant for older 
adults. Nonetheless, research may still be necessary to answer questions such as “What are the 
unintended harms of implementing mandatory system-wide interventions to reduce opioid 
prescribing and substitute alternative nonopioid treatments?” It is highly important to study the 
premise that increased access to nonopioid treatments will prevent or reduce suboptimal opioid 
use. For many subpopulations of older adults, the premise may be false and system-wide 
interventions may cause considerable harm if they do not exempt such subpopulations. 
Therefore, in addition to understanding the comparative effectiveness of opioids and nonopioids 
in older adults, research is necessary to both identify subgroups of older adults for whom long-
term opioid may be the only viable option and how to best ensure that system-wide interventions 





Research Needs Specific to Adapting Nondrug Interventions for Older Adults and 
Frail Patients 
A broad knowledge gap exists about what, if any, evidence on interventions in younger 
adults is transferrable to older adults or can be tailored to meet the specific needs of older adults. 
In particular, research will likely be necessary on how to adapt nondrug (and, thus, nonopioid) 
interventions for the older adult population. For example, exercise, physical therapy, and 
complementary and alternative medicine interventions studied in younger adults will likely 
require geriatric modifications, especially for older adults who are frail, multimorbid, or have 
disability and functional limitations. These medically complex older adults are often excluded 
from most randomized controlled trials of drug and nondrug interventions, even among those 
that included older adults. Therefore, frail individuals and those with multimorbidity should be a 
crosscutting focus of many future research studies. In particular, more research is needed on 
cognitive behavioral therapy for pain in older adults to answer questions about how it might 
work (i.e., the mechanisms underlying any observed effects), how it should be combined with 
exercise and other therapies in a multimodal treatment approach, and how multidisciplinary 
teams can successfully incorporate principles of cognitive behavioral therapy into their clinical 
practice. 
Research Needs Specific to Cost and Reimbursement of Nonopioid Therapies 
Major cost barriers may exist to accessing nonopioid therapies, especially nonpharmacologic 
ones. Most of these (e.g., massage therapy) are often not reimbursed by insurers. If they are 
reimbursed, patients may frequently be responsible for paying a large proportion of the cost out 
of pocket. Evidence was unavailable about how interventions to improve access to 
nonpharmacologic therapies might be implemented and what the effects on patient utilization 
and outcomes would be among older adults. Along with comparative effectiveness and safety 
research, information on reimbursement and access to nonpharmacologic therapies is 
fundamentally necessary to decrease opioid use through the substitution of alternative therapies. 
Additionally, research into how older adults’ income, financial assets, and socioeconomic status 
influence use of nonpharmacologic therapies may also be necessary. Such information could be 
used to identify older adults who are forced to select alternative interventions that are relatively 
more affordable (e.g., cannabis or marijuana) and target interventions to them. Finally, research 
is necessary on the costs of opioid misuse and OUD at the individual and society levels, though 
this topic was outside the scope of the current report. Cost could be studied as either as an 
outcome of nonopioid therapy use (e.g., cost savings through avoidance of misuse or OUD) or as 
a stand-alone topic. 
Research Needs Specific to Marijuana and Cannabis as Cointerventions 
Greater research is likely necessary to understand the role, if any, that cannabis and 
marijuana have in a pain treatment plan for older adults. Comparative effectiveness research 
focused on comparing the safety and effectiveness of cannabis/marijuana and other therapies is 
likely a key area for future research. This need exists partly because some older patients perceive 
cannabis and marijuana as being more readily accessible than other nonopioid therapies like 
acupuncture, especially in terms of cost, since many insurers do not cover acupuncture, massage, 
and other alternative nonopioid therapies. Research into the safety of combining opioids and 
cannabis is likely also urgently necessary since older adults are currently combining these 





Research Needs Specific to Goal-Setting and Shared Decision Making 
Tools have not been reported that could explicitly help providers establish opioid-related 
treatment goals for pain, function, and other relevant outcomes through shared decision making 
with their older patients or caregivers. Such tools could, in theory, help to avoid opioid 
prescribing entirely or promote the use of lower and/or less frequent doses. Evidence is also 
necessary to address how providers and patients should come to an agreement about when opioid 
use should be stopped, how often that plan or agreement should be discussed, and to what extent 
patients might self-manage their opioid regimen to make adjustments in response to inadequate 
pain relief or adverse events without engaging in misuse. Related to goal-setting and shared 
decision making is the need to identify how to best measure the outcomes of pain management 
that are of utmost importance to older adults. In particular, research on outcome measures that 
relate to older adults’ goals of pain treatment could help to optimize opioid use and pain 
treatments more broadly. Some older adults have more severe pain at times when they must be 
more active or mobile (e.g., when they must transfer into or out of a wheelchair), yet few studies 
have examined outcomes like transfers or the ability to perform activities of daily living without 
pain. Such outcomes are essential for understanding when opioids might provide benefits that 
outweigh harms, and are important to older adults. More research is also necessary to understand 
the effectiveness of dosing strategies that maximize patient-centered outcomes; for example, 
research to understand the comparative effectiveness of taking opioids at times when more 
mobility or activity is necessary versus taking opioids at scheduled times regardless of activities 
of daily living or other activities that might increase the presence or severity of pain. 
Additional Pertinent Ongoing Research 
In fiscal year 2019 alone, several hundred studies of opioids have been funded by the NIH. 
Many of these studies were funded through the NIH HEAL Initiative that coalesced in April 
2018.146 The studies covered by this initiative address different aspects of opioid use and misuse 
across a wide variety of populations. These newly funded studies were not considered for the 
current technical brief unless they had registered in ClinicalTrials.gov between the years 2000 
and 2019. The number of newly funded studies that specifically address older adults is therefore 
unclear. However, it is important to note that these investments by the NIH are likely to advance 
our understanding of different subtopics address by this current report. For example, projects 
have been funded to optimize new targeted, nonaddictive medications and nonpharmacological 
treatments for various types of pain, which could be highly relevant for older adults with limited 
treatment options due to prevalent comorbidities and contraindications. Some of this research 
might also provide information about the comparative effectiveness of opioid and nonopioid 
therapies on outcomes of high importance to older adults, such as quality of life and functioning. 
Other funded projects might provide more information about cognitive behavioral therapy for 
pain, including the mechanisms underlying how it works, how to combine it with other 
treatments (e.g., exercise, stress management), and who can successfully implement it (e.g., 
physical therapists, psychologists, nurse practitioners). 
On August 31, 2018, the Centers for Disease Control and Prevention (CDC) provided over 
150 million dollars to U.S. states and territories to address opioid overdose with the explicit 
goals of advancing the understanding of the opioid overdose epidemic and scaling up prevention 
and response activities to make an immediate impact and save lives.147 Several of these grants 
may address relevant subtopics that are the focus of this technical brief. For example, under 





Benzodiazepines to Reduce Older Adult Falls,” more information is likely to become available in 







Summary and Implications 
Summary of Conceptual Framework and Evidence Base 
As part of this technical brief on prevention, diagnosis, and management of opioid use, 
misuse, and opioid use disorder in older adults, we created a Conceptual Framework that outlines 
the stages of care for older adults who use (or may use) opioids and factors that impact 
management decisions and patient outcomes, including assessment of pain, selection of pain 
treatment, choice of opioid regimen, assessment for opioid misuse or OUD, and management of 
misuse or OUD (Rectangles B to F in the Conceptual Framework, Figure 1). Multiple potential 
patient, provider, and societal predictors (Ovals P1 to P8) may influence opioid-related harms 
and other outcomes, and the Framework at large. Predictors and interventions to reduce opioid 
prescriptions where harms outweigh benefits (Octagon R1 and Triangle I1), prevent opioid 
misuse and OUD (Octagon R2 and Triangle I2), and reduce other opioid-related harms (Octagon 
R3 and Triangle I3) are included. 
This broad overview of the evidence base identified 41 studies with multivariable models of 
factors associated with opioid-related outcomes. We believe it is likely that only (or mostly) the 
multivariable analyses could provide adequate evidence that putative factors are likely to be 
reliable predictors of outcomes. The studies addressed one outcome (long-term opioid use) 
related to factors that are predictors of opioid use (Octagon R1 in the Conceptual Framework), 
two sets of outcomes (opioid misuse and multiple opioid prescribers) related to factors that are 
predictors of opioid use or OUD (Octagon R2) and four sets of outcomes (mental or physical 
harms, hospitalizations or ED visits, opioid overdose, and death) related to factors that are 
predictors of opioid related harms (Octagon R3).  
The largest body of evidence (22 studies) evaluated factors associated with long-term opioid 
use. Of note, however, is that the outcome long-term opioid use does not address whether the 
harms associated with use outweigh the benefits. Long-term use may be a poor proxy for 
potential harms or problematic opioid use and may simply be an indicator of incomplete 
treatment of the underlying condition causing pain and thus long-term need for pain control. 
Nevertheless, the studies were consistent (in full agreement) that opioid use prior to surgery or 
injury (or early use after surgery) and greater amount of opioids (more prescriptions or higher 
dose) are the factors with mostly strong associations. Other consistent associations, but with 
largely weak associations, were found with back pain, depression, concomitant NSAID use, and 
fibromyalgia. Studies were mostly consistent (≥75% agreement) that benzodiazepine use, higher 
comorbidity scores (such as the Charlson Comorbidity Index), “substance misuse” (although, 
generally poorly or not defined in studies), tobacco use, and low income were associated with 
long-term opioid use. Studies were also mostly consistent that alcohol “abuse” and healthcare 
utilization were not associated with long-term opioid use. Factors with variable findings of 
association included gender, age among older adults, Black race, dementia, rural or nonurban 
residency, prescription of long-acting opioids, unmarried relational status, and use of muscle 
relaxants. 
Across six studies of factors associated with developing opioid-related disorders, three 
studies each had variable findings regarding the associations of alcohol misuse and of gender 
with opioid misuse. All other evaluations of specific associated factors and outcomes of interest 
were evaluated by only one or two studies each. These included analyses of opioid use disorder, 
high-risk obtainment of prescription opioids, procuring multiple opioid prescribers, mental health 





nonopioid-specific hospitalization, emergency department visits, opioid overdose, all-cause 
death, opioid-related death, and nonopioid-related death.  
Only 16 studies addressed interventions of any kind to appropriately reduce opioid 
prescriptions (Triangle I1 in the Conceptual Framework, 9 studies), prevent opioid-related 
disorders like OUD in older adults (Triangle I2, 8 studies), or reduce opioid-related harms 
(Triangle I3, 2 studies). The most-studied interventions (in 6 studies) are screening tools to 
predict opioid-related harms but none has been tested in clinical practice to assess real-world 
results. Two studies found that PDMPs are associated with less opioid use (at the State level), 
although they did not address the effect of the PDMPs on patients (e.g., their level of pain 
control). Other studied interventions to reduce opioid use included a patient-level pain 
rehabilitation program and a patient-education pamphlet, different clinician-level educational 
modalities, a hospital system-level opioid safety initiative, provision of free (to patient) 
acetaminophen, and a nationally-mandated tamper-resistant opioid formulation. Few studies 
evaluated the parallel effect of the interventions on patient-centered outcomes, including daily 
functioning or activities of daily living, disability, quality of life, and pain control. One study 
each evaluated clinician- and patient-level educational materials. With the goal of reducing 
opioid-related harms, one study evaluated motivational interviewing training of nursing students 
to help manage older adults with opioid-related disorders and one study evaluated clinician-level 
educational materials. Of note, the recreational pathway (Box A2) was not specifically addressed 
by the empirical evidence.  
Future Research Needs 
As noted, there are many gaps in the evidence base regarding factors associated with opioid-
related outcomes and of the effectiveness of interventions for older adults. We describe 
numerous research needs derived from clear gaps in the evidence base and based on issues raised 
by a range of stakeholders. In particular, future research should emphasize the adaptation of 
existing interventions for use in older adults, account for the heterogeneity in characteristics of 
the older adult population, incorporate outcomes of greatest importance to seniors, and determine 
how caregivers can help to actively implement interventions. To date, all studies have evaluated 
groups of older adults with little if any attempt to parse out benefits and harms among subgroups 
(e.g., by age within the category of “older adults,” by generational cohort, or by underlying 
condition). As a precursor to that work, it may be necessary to define “older adult” in a 
principled way and better understand the relationship between age, period, and birth cohort. The 
question of how to deprescribe opioids safely, especially when individuals are dependent on 
opioids and experiencing pain, is especially complex in older adults and deserves a special focus. 
Studies among older adults to confirm the reliability, validity, and factor structure of screening 
tools for detecting opioid misuse are an especially salient and attainable next step. The 
development, validation, and evaluation of new interventions tailored to the needs of older adults 
will likely also be necessary to manage opioid misuse and OUD in older adults.  
Limitations 
We developed an evidence map to describe the amount and type of practically available 
evidence related to the core of the Conceptual Framework, but in keeping with the scope of a 
Technical Brief, we did not fully assess studies (e.g., their risk of bias) or the body of evidence 
(e.g., strength of evidence). For feasibility, we did not consider research published more than 20 





relevant to today’s setting. Demographic and clinical characteristics of older adults have shifted 
dramatically over the last 20 years, so earlier evidence may not generalize well to a modern older 
adult population. Where earlier studies may also be applicable, important questions are often 
addressed by more recent replication studies, in which case they would be represented in the 
evidence map (with the possible exception of studies of pharmacological interventions, such as 
for treatment of OUD, that have not recently been investigated in older adults). 
It is important to note that we did not review articles to determine whether they would meet 
any specific set of eligibility criteria for a systematic review of a specific Key Question. In our 
estimation, it is likely that many of these articles would be rejected for a given systematic review 
based on the specific populations of interest, the eligible definitions of predictors (or risk factors) 
and outcomes, study design features, and analytic methods. For example, although we assessed 
whether studies performed a multivariable (versus univariable) analysis when examining factors 
associated with opioid-related harms, we did not assess whether studies adequately controlled for 
all potentially important covariates in a given multivariable model. Thus, it is likely that many 
studies we identified in the evidence map would not be relevant to address a specific, well-
formulated research question. Furthermore, the reader should be reminded that our literature 
search, screening, and eligibility criteria did not allow for us to delve into the large number of 
studies that did not focus on older adults or opioids that may have had relevant, potentially 
eligible, subgroup analyses. If the abstract provided no indication of an analysis regarding opioid 
use in older adults, it was not included. Undoubtedly, we thus missed pertinent studies that 
would have required more in-depth searching and screening. 
While we did include studies conducted in other countries besides the U.S., we restricted to 
those countries with high-income economies where opioid misuse and OUD were anticipated as 
being most prevalent.  
Finally, we did not include studies of older adults in palliative care, those who were 
terminally ill, those in hospice care, or others with limited life expectancy because opioid 
misuse, harms, or OUD were of significantly less concern in such populations. This should not 
be interpreted as a suggestion that these populations are not important.  
Conclusions 
Prevention, diagnosis, and management of opioids, opioid misuse and OUD in older adults 
are significant and challenging issues for which a greater understanding is necessary. The 
evidence base that is directly applicable to older adults who are prescribed opioids or have 
opioid-related disorders is sparse. Fundamental research is necessary to determine which factors 
may predict opioid-related harms; studies to date suggest that the amount of prescribed opioids, 
prior use of opioids, musculoskeletal conditions, and substance misuse are potentially important 
factors. Research is also needed to identify interventions to reduce opioid treatment where harms 
outweigh benefits, to reduce opioid-related harms and disorders, and to treat existing misuse or 
OUD among older adults. The preponderance of evidence has evaluated the “risk” of long-term 
opioid use without evaluation of whether such use is appropriate (e.g., to manage ongoing pain) 
or indicative of misuse. Similarly, current studies of interventions have focused largely on 
quantities or duration of opioid use, without assessment of whether pain is being adequately 
managed. Future research should emphasize the adaptation of existing interventions for use in 
older adults and account for the heterogeneity of the older adult population with a goal of 





evaluation of new interventions tailored to the needs of older adults will likely also be necessary 
to manage opioid misuse and OUD in older adults. 
In summary, two immediately actionable next steps are (1) to conduct additional research 
focused on predictors of and interventions to improve clinically-important, patient-centered 
outcomes (not only amount or duration of opioid use), and (2) to further validate and adapt 
screening tools for identifying opioid misuse in older adults. Intermediate-term next steps should 
include developing interventions to (1) increase the uptake of best practices for safer opioid 
prescribing that does not compromise pain control in older adults, (2) overcome barriers to 
screening for opioid misuse and OUD in older adults, and (3) expand treatment for OUD in all 
settings where older adults receive care. Ultimately, developing the evidence base will enable 
policymakers, healthcare providers, and older adults to reduce inappropriate opioid use and the 
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This list of does not include abbreviations used only in tables or figure. 
 
AHRQ Agency for Healthcare Research and Quality 
ASSIST Alcohol, Smoking and Substance Involvement Screening Test 
CDC Centers for Disease Control and Prevention 
COPD chronic obstructive pulmonary disease 
CPSMP Chronic Pain Self-Management Program 
CR controlled release 
ED emergency department 
EPC Evidence-based Practice Center 
FDA Food and Drug Administration 
HEAL Helping to End Addiction Long-term 
NA Narcotics Anonymous 
NIH National Institutes of Health 
NSAID nonsteroidal anti-inflammatory drug 
ORT Opioid Risk Tool 
OUD opioid use disorder 
PDMP prescription drug monitoring program 
PDUQp Prescription Drug Use Questionnaire, patient version 
PMQ Pain Medication Questionnaire 
SBIRT Screening, Brief Intervention, and Referral to Treatment 
SDS Severity of Dependence Scale 
SoDU Screen of Drug Use 
TKA total knee arthroplasty (replacement) 
TOO Task Order Officer 




Appendix A. Search Strategies 
PubMed run 7/9/19 
(“Opioid-Related Disorders”[Mesh] 
OR “Prescription Drug Misuse”[Mesh] 
OR ((“Analgesics, Opioid”[Mesh] OR Opioid* OR opiate* OR opium OR “Methadone”[Mesh] 
OR methadone OR “Narcotics”[Mesh] OR Narcotics OR “Morphine Derivatives”[Mesh] OR 
Codeine OR Hydrocodone OR Oxycodone OR Dihydromorphine OR Ethylmorphine OR 
Hydromorphone OR Morphine OR “Prescription Drugs”[Mesh] OR Prescription Drug*) AND 
(abuse OR misuse OR dependence OR addiction OR diversion OR “use disorder” OR “Drug-
Seeking Behavior”[Mesh] OR “long term use” OR “nonmedical use” OR “non-medical use” OR 
multiple providers OR multiple prescriptions)) NOT ((“Alcoholism”[Mesh] OR 
“Benzodiazepines”[Mesh] OR “Heroin Dependence”[Mesh]) NOT (“Opioid-Related 
Disorders”[Mesh] or Opioid*))) 
AND 
(“Aged”[mesh] OR “elderly”[tw] OR “elder”[tw] OR “elders”[tw] OR geriatr*[tw] OR “Homes 
for the Aged”[mesh] OR “Health Services for the Aged”[mesh] OR older person*[tw] OR old 
person*[tw] OR older patient*[tw] OR old patient*[tw] OR “older women”[tw] OR “old 
women”[tw] OR “older men”[tw] OR “old men”[tw] OR old adult*[tw] OR older adult*[tw] OR 
“Older individual”[tw] OR “Older individuals”[tw] OR “old people”[tw] OR “older people”[tw] 
OR “Oldest Old”[tw] OR “Nonagenarians”[tw] OR “Nonagenarian”[tw] OR 
“Octogenarians”[tw] OR “Octogenarian”[tw] OR “Centenarians”[tw] OR “Centenarian”[tw] OR 
“septuagenarian”[tw] OR “septuagenarians”[tw] OR “Aging”[mesh] OR “aging”[tw] OR 
“ageing”[tw] OR “older population”[tw] OR “aging population”[tw] OR “aging population”[tw] 




CINAHL/PsycINFO run 7/9/19 
(Opioid* OR opiate* OR opium OR methadone OR Codeine OR Hydrocodone OR Oxycodone 
OR Dihydromorphine OR Ethylmorphine OR Hydromorphone OR Morphine OR Prescription 
Drug* OR Narcotic*) AND (abuse OR misuse OR dependence OR addiction OR diversion OR 
“use disorder” OR “Drug-Seeking Behavior" OR “long term use” OR “nonmedical use” OR 
“non-medical use” OR multiple providers OR multiple prescriptions ) 
Narrow by SubjectAge: - aged: 65+ years 




Prospero run 8/27/19 
(opioid OR opiate OR "prescription abuse" OR diversion) AND (older OR elderly OR aged OR 
old OR veteran OR medicare OR medicaid) AND (older or elderly or aged or old or veteran or 
medicare or medicaid) 
 
ClinicalTrials.gov run 8/27/19 




Appendix B. Additional Description of Methods 
Methods 
The following four Guiding Questions were developed by AHRQ in consultation with other 
federal agencies. After discussion wit the Key Informants, the phrasing of the questions was 
revised and simplified, as presented in the main report. 
Guiding Questions 
1. What are the most important factors driving the increase in opioid-related hospitalizations 
and ED visits for older adults and what interventions are needed to reduce the risk of 
opioid-related adverse events, opioid misuse, and opioid use disorder (OUD) in older 
adults without compromising pain control or quality of life?  
a. Are there interventions developed for the general population that could be applied 
to older adults without modification? 
b. Are there interventions developed for the general population that could be studied 
in older adults? 
c. Is there a need for interventions specifically designed or adapted for older adults? 
d. What outcomes should be captured specifically for older adults (falls, cognitive 
function, cardiovascular events, etc.)? 
2. Among older patients taking opioids, what factors are most strongly associated with 
harms from opioids (adverse events, misuse, or opioid use disorder)? 
a. Underlying patient factors, such as fall risk, cognitive impairment, frailty, liver 
disease, etc. 
b. Medication factors (opioid dosing and preparation; co-prescribing; etc.) 
c. Environmental factors (presence of a caregiver, etc.) 
3. What interventions have been studied to help providers— 
a. reduce opioid prescription where harms outweigh benefits in older adults without 
compromising pain control or quality of life (e.g., shared decision-making)?  
b. reduce the risk of adverse events, misuse or opioid use disorder in older adults for 
whom opioids are appropriate? 
c. identify opioid misuse or opioid use disorder in older adults?  
d. treat opioid misuse or opioid use disorder in older adults, including facilitating 
transitions across the continuum of care and across institutional and community 
settings? 
For each subquestion, describe studies by the following populations and settings: 
● Different care scenarios (acute, chronic, cancer) 
● Age, sex, race/ethnicity, income, and geography (urban, rural)  
● Settings (inpatient, primary care, long-term care) 
● Early versus late onset OUD 
4. What studies are needed to develop evidence based interventions (for providers, patients, 
or systems) to reduce opioid prescription where harms outweigh benefits, misuse, and 
opioid use disorder in older adults? What should the design of these studies be?  
 
To address the issues raised by the Guiding Questions, we developed a conceptual 
framework informed by stakeholder (Key Informant) discussions and conducted an evidence 
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map of the existing evidence base. The conceptual framework and evidence map summarize the 
evidence in a way that allows stakeholders to readily identify the next steps for research on 
opioid use and misuse in older adults. 
Development of Conceptual Framework 
Initial Development 
A draft conceptual framework was developed based on existing prior conceptual frameworks 
and systems maps, including ones from Wakeland and colleagues,38,39 the U.S. Department of 
Health and Human Services Pain Management Best Practices Inter-Agency Task Force Report,40 
and the National Academies of Sciences Engineering and Medicine text Pain Management and 
the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription 
Opioid Use.41 Existing frameworks and systems maps from obesity and other conditions not 
directly related to pain were considered to help inform alternative structures and formats for the 
framework.42,43 The draft conceptual framework was revised based on feedback from a panel of 
invited Key Informants.  
Key Informants 
We formed a 15-member panel comprised of six individuals employed by federal agencies 
and nine individuals employed by non-federal entities. These individuals included experts in the 
care of older adults, experts in pain treatment and opioid use, nationally and internationally 
recognized researchers, policy makers, and internationally recognized advocates for older adults 
with pain.  
There were several stakeholder types that we explicitly sought non-federal Key Informants to 
represent. These individuals were selected based on their complementary perspectives on 
potential predictors of opioid-related harms and interventions to reduce harm among older adults. 
To form our panel, we sought  
• A patient or patient advocate because it was important to represent the perspective of 
older patients who have received care for pain in a variety of healthcare settings and 
who could inform on what interventions would have been most helpful for them to 
manage their pain and opioid use.  
• A practicing geriatrician since geriatrics healthcare professionals are frequently 
responsible for managing pain in older adults.  
• A pharmacist specializing in geriatrics because pharmacists often lead clinical and 
quality improvement efforts to manage opioids in older adults as a member of the 
patient’s care team.  
• A pain and addiction medicine expert because they, like geriatrics healthcare 
professionals, are often responsible for managing opioids in older adults but have 
orthogonal expertise to clinicians with geriatrics expertise.  
• A pain medicine specialist practicing in an outpatient or community setting because 
we anticipated that interventions may be particular important in outpatient settings 
and we expected that outpatient patient specialists would have unique insights about 
how pain differs among older adults and how such differences might be risk factors 
for opioid-related harms, as well as how such differences could be exploited to 
develop future interventions for older adults.  
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• A state-level health policymaker or policy advisor because that perspective was 
thought to be essential to understand risk factors and possible interventions to manage 
opioid use in older adults at the population level.  
• An expert in psychiatry because pain, mental health, and opioid use (and misuse) are 
strongly related, and psychiatry healthcare professionals have often led efforts to 
prevent and treat opioid misuse and addiction.  
• A non-pharmacist (because pharmacists were explicitly sought) allied (non-physician) 
healthcare professional or who had expertise in alternative medicine expertise 
because such individuals, including nurses, chiropractors, and acupuncturists, often 
manage a large portion of the routine care for older adults with pain, and were 
expected to have unique perspectives about risk factors as well as interventions that 
could be implemented by allied healthcare professionals.  
• An expert in psychology because the transition from appropriate opioid use to misuse 
or OUD among older adults may be strongly related to behavior, and since many 
potential non-pharmacological interventions to intervene on opioid use may arise 
from the field of psychology, this perspective was viewed as essential. 
Key Informant Discussions 
We solicited the panel’s input in three teleconferences and over email until we deemed that 
we had sufficiently discussed all of the most relevant themes. The interactions with the Key 
Informant Panel were facilitated by the Brown EPC and included several structured questions 
about the Guiding Questions. The Key informants were also asked about the draft Conceptual 
Framework and to identify peer-reviewed publications or other relevant literature related to the 
topics of interest. All teleconferences were audio-recorded and transcribed by a member of the 
EPC team.  
All Key Informants were provided with an equal opportunity to speak and all were 
encouraged to provide input to ensure that no single perspective was over-represented or 
dominated the discussions. 
Based on input and feedback from the Key Informants during discussions, we refined the 
study eligibility criteria and data extraction items for the evidence map (see section Evidence 
Map below). To summarize the information collected during the Key Informant discussions, we 
used a combination of notes and transcripts created from audio recordings to map the concepts 
and themes identified by the Key Informants to the draft conceptual framework. We employed a 
Systems Mapping (i.e., “Systems Framework”) approach to perform the mapping, which 
involved identifying what care management or other behaviors the Key Informants were 
speaking about, who was performing those behaviors from the perspective of the Key 
Informants, and how the behaviors fit within the complex “system” that exists to prevent, 
diagnosis, and manage opioids, opioid use, and OUD in older adults.27, 28 The Systems 
Framework approach to coding the Key Informant discussions was selected because it 
emphasizes identifying opportunities for change and designing future interventions to targeted 
specified behaviors.27 
For a given concept or theme spoken about by the Key Informants, we first identified which 
person or organization the Key Informant was referring to. In a Systems Framework, this would 
be the “Actor”. We then identified actions that could be directly or indirectly observed. These 
actions are performed by the actors and referred to as “Behaviors” in the Systems Framework. 
Finally, we identified circumstances and factors that affected whether a behavior was likely to 
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happen, which often involved elements of capability, opportunity, and motivation. These 
circumstances and factors are “Influences” in the Systems Framework. We attempted to maintain 
the statements made by Key Informants in as close to an original form as possible so as to avoid 
altering the meaning intended by the Key Informant.  
In addition to identifying themes, we focused on which parts of the conceptual framework 
were spoken about most and least by the Key Informants, and what research Key Informants 
identified as being most or least urgent and of greatest or least interest.  
Further Development of Framework 
We iteratively added to and revised our draft framework through discussions with Key 
Informant panel members. Key Informants also gave input to guide the search process for 
literature to inform the framework. With each iteration, we used the updated framework to search 
for new domains, concepts, and factors. These were incorporated into the framework to develop 
a next iteration. We also continued to search for potentially relevant existing conceptual 
frameworks and systems maps. During development, we also considered frameworks and 
systems maps created for older adults with conditions other than pain or opioid use to ensure no 
relevant concepts are omitted. 
Finalization of Framework 
The framework was considered final when (1) no new domains, concepts, or factors arose 
from discussions with the Key Informant panel members and (2) new items offered only small 
incremental gains in information over previously encoded items because they were primarily 
derivatives of existing concepts or factors. Informational redundancy between the Key Informant 
input and conceptual framework figure thus was a key measure of progress toward finalization.  
Evidence Map 
We conducted a literature search to find articles primarily addressing Guiding Questions 2 
and 3 (pertaining to predictors of harms from opioids in older adults and interventions to 
appropriately reduce opioid prescription, to reduce risk of harms, to identify misuse and OUD, 
and to treat misuse and OUD in older adults). The literature search and abstract screening 
processes are described below under Literature Search Strategies for Identification of Relevant 
Articles. We then created a preliminary evidence map from full-text articles. The evidence map 
enumerates the number of primary studies (along with systematic reviews and clinical practice 
guidelines) that directly address relevant questions pertaining to the management of opioid use 
and misuse in older adults. It describes the characteristics of these studies (e.g., their design, 
basic population descriptors, interventions). It does not summarize the quantitative findings of 
the studies, nor does it assess either the quality of the studies or the strength of the evidence. The 






Evidence Map Eligibility Criteria 
Eligible Populations 
● Older adults with or without pain prescribed or otherwise using (or having used) opioids 
(or for whom opioid prescription/use may be warranted) 
o For abstract screening, we used an age threshold of mean or median age ≥50 
years. For the evidence map (full-text screening), we used a mean or median age 
threshold ≥60 years (or analysis of a subgroup ≥60 years within the study) 
▪ During abstract screening we also included studies of the Veterans Health 
Administration (and databases) or that used Medicare databases, 
regardless of age data in the abstract (unless the study was clearly focused 
on adults <50 years old) 
▪ During abstract screening we also included studies of surgical or health 
conditions that primarily affect older adults (e.g., hip arthroplasty, 
coronary artery bypass, prostate cancer; unless the study was clearly 
focused on adults <50 years old) 
▪ During abstract screening we also tagged, but excluded large (N>5000) 
population-based studies that did not explicitly report on an older adult 
subgroup in their abstracts because they may report sub-analyses of older 
adults in the full-text article 
● Other criteria, applied during both abstract screening and full-text review, included: 
o Any timeframe of opioid use in relation to pain (whether past, present, or none) 
o Any cause of pain (including acute, subacute, chronic, neuropathic, somatic; any 
severity), including no pain 
o Any use of opioids, whether prescribed or not, legally obtained or not 
▪ Exclude nonopioids use, misuse, or use disorder (e.g., benzodiazepines, 
anesthetic narcotics) without concomitant use of opioids 
o Study conducted in high-income countries (as defined by the World Bank 
(https://data.worldbank.org/income-level/high-income) 
o Exclude terminally ill, those in hospice care, or others in whom opioid misuse, 
harms, or OUD are of little concern 
Eligible Interventions and Predictors 
● Any intervention to predict or manage opioid use, including: 
o Screening questionnaires 
o Prediction tools 
o Clinical decision support tools 
o Quality improvement initiatives / implementation strategies to promote evidence-
based care 
o Models of care 
o Other related interventions 
● Opioid prescriptions to manage pain 
o Nonopioid medications and non-pharmacologic treatments for pain control (as a 
comparator) 
● Interventions to prevent opioid harms, misuse, or OUD 
o Pharmacologic or non-pharmacologic 
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● Any predictor (or risk factor or associated variable) of opioid use, misuse, harm, or OUD, 
including: 
o Patient demographic features (e.g., age, race/ethnicity, sex) 
o Patient social conditions (e.g., housing status, social contacts, employment) 
o Patient setting (e.g., outpatient, inpatient, long-term care) 
o Patient morbidities (e.g., cause of pain, other clinical conditions) 
o Patient cognitive function, quality of life, function 
o Patient history of pain, history of opioid use and misuse 
o Clinic and clinician descriptors (e.g., primary vs. specialty care, specific 
specialty) 
o Clinical team members (e.g., physician only, nurse outreach, home health aide, 
pain clinic) 
Eligible Outcomes  
● Person-level 
o clinical outcomes (e.g., death, falls, cognitive function, cardiovascular events, 
respiratory function) 
o clinical resources (e.g., ED visits, clinic visits, hospitalizations) 
o living status (e.g., residence, work, activities of daily living, social function) 
o quality of life or function (however measured) 
o pain and pain control 
o opioid use (including long-term use, appropriate dose reduction), misuse, and 
OUD 
o opioid-related adverse events 
● Provider-level outcomes, including but not limited to: 
o barriers/facilitators to/of appropriate opioid prescription 
o provider knowledge 
o attitudes and beliefs 
● System-level outcomes, including but not limited to: 
o likelihood of provider adherence to interventions 
o changes in the proportion of providers prescribing opioids appropriately 
Eligible Study Designs  
● Any primary study design, including  
o Randomized and nonrandomized comparative studies (including intervention 
comparisons of interest from registry, database, or other cohort studies) 
o Single-group studies (including registry, database, or other cohort studies) 
o Case control studies 
o N-of-1 studies 
o Prospective or retrospective studies 
o Cross-sectional or longitudinal studies 
o Surveys or qualitative research analyses 
o Data reports (e.g., from FDA or pharmacopeia) 
● For the question of associations between risk factors and outcomes, in the first screening 




● Systematic review 
● Clinical practice guideline (whether or not evidence-based) 
● For the Conceptual Framework, we also tagged narrative articles of potential interest 
including narrative reviews, editorials, opinion pieces, comments, letters, etc. 
● Any timing 
● Any setting (in high-income countries) 
● English language publication 
Rationale for Evidence Map Eligibility Criteria  
Eligible Populations 
Eligible populations are older adults who use, or may use, opioids for pain management or 
recreational purposes. Although ≥60 or ≥65 years of age are more traditional age thresholds for 
identifying older adults, for our preliminary screen of the evidence base we populations as young 
as 50 years of age for two reasons. First, many studies of opioid misuse and opioid use disorder 
deviate from traditional age cutoffs and consider individuals aged 50 years or older to be “older 
adults.” Second, the lower age threshold could allow researchers to understand how predictors of 
opioid use and how opioid use itself changes as individuals transition from middle age to older 
age.  
However, since a primary purpose of this Technical Brief is to inform policymakers in the 
Centers for Medicare & Medicaid Services (CMS), we focused the evidence map on the 
population of adults age 65 years or older. Furthermore, fully reviewing studies of populations 
younger than 65 years would more than double the evidence base, which would not have allowed 
a feasible review given time and resource constraints for this Technical Brief.  
Studies of younger patients and large population-based studies are enumerated briefly. Lists 
of these studies are available from the Brown EPC. 
Eligible Interventions and Predictors 
The evidence map aimed to describe all available interventions, both those developed for a 
younger or general population that have been adapted for older adults and those that were 
specifically designed for older adults. We were inclusive, in terms of interventions and predictors 
so that we could describe what has been studied (and what there may be evidence for). 
Therefore, all interventions and predictors were eligible.  
Eligible Outcomes  
The Technical Brief aimed to identify what outcomes should (and could) be captured 
specifically for older adults. Therefore, all patient-level and system-level outcomes were eligible 
for the evidence map. 
Eligible Study Designs 
We included all primary study designs along with systematic reviews and clinical practice 
guidelines.  
For the question of predictors of outcomes, we sought to capture independent factors that are 
most likely to be true predictors. Thus, we limited to multivariable analyses. 
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Literature Search Strategies for Identification of Relevant Articles  
The literature searches were designed to capture articles of interest to support the Conceptual 
Framework and to be included in the evidence map. 
We searched PubMed, PsycINFO, and CINAHL using terms related to older age or aging, 
crossed with terms on opioid use, opioid-related disorders, opioid misuse, and opioid-related 
adverse events. We did not include search terms for (and thus avoided excluding articles based 
on) interventions, outcomes, or study designs. We limited results to studies published in English, 
between the years 2000 and 2019, inclusive. The rationale underlying the date limits was that 
opioid prescribing for pain, as it currently occurs in modern clinical practice, began in the 1990s, 
which is also when opioid prescribing rates dramatically accelerated. 
To screen the evidence base, we used the online software Abstrackr, which uses machine 
learning algorithms to predict and sort citations based on likely relevance. We trained the team in 
the study eligibility criteria by going through several training cycles where all team members 
screened the same citations and reconciled conflicts as a group. The training cycles were 
performed until all screeners were uniform in their assessments. After that pilot phase, citations 
were double-screened by two reviewers. Based on our experience with the software (and soon-
to-be-completed empirical research), we stopped screening citations when the software predicts 
that no further (unscreened) abstracts are likely to be relevant. We also searched 
ClinicalTrials.gov and PROSPERO to identify unpublished studies, ongoing studies, and 
unpublished systematic reviews. We did not record reasons for exclusion at the abstract level.  
All potentially eligible citations were retrieved and screened in full text for eligibility. Full 
text articles were evaluated for eligibility by a single reviewer, after a training period to ensure 
consistency between all reviewers. For all papers reviewed in full-text we recorded reasons for 
exclusion. 
Data Extraction and Data Management  
The evidence map includes a structured set of elements on the population, the intervention 
(or predictors), examined outcomes, and study design features (PICOD). The evidence map is 
restricted to primary studies, systematic reviews, and clinical practice guidelines. 
• For populations, we recorded information on participants age (mean age and whether the 
study, or an analyzed subgroup, focused on participants ≥60 years, ≥65 years, and/or ≥75 
years), special populations (e.g., Medicare, Veterans Administration databases), sex, and 
race/ethnicity. We captured information on setting (e.g., inpatient, ED, outpatient), 
how/why opioids were used (e.g., appropriate by prescription, misuse, illicit), and 
features of people’s pain, as relevant, including time course (acute, subacute, chronic) 
and cause (e.g., surgery, cancer, neuropathic). 
• Pertaining to Guiding Question 2, we captured predictors (and risk factors) listed in the 
Guiding Question, including patient demographics, social conditions, setting or 
environmental factors, pain conditions or comorbidities, cognitive or physical function, 
frailty or geriatric syndromes, history of pain, history of opioid use or misuse, history of 
nonopioid substance use disorders, medication factors (e.g., dose) and polypharmacy. We 
also captured physician characteristics (e.g., primary vs. specialty care), clinical team 
characteristics, and health system characteristics. Finally, we captured other predictors of 
potential interest. 
• Pertaining to Guiding Question 3, we captured interventions listed in the Guiding 
Question, including screening tools and questionnaires, prediction tools or models, 
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clinical support tools, quality improvement initiatives or implementation strategies, and 
models of care. We included opioid and nonopioid medications for pain management, 
pharmacologic treatments for opioid misuse or OUD (i.e., medication assisted 
treatments), and non-pharmacologic interventions for opioid misuse or OUD (e.g., 
cognitive behavioral therapy). Finally, we captured other interventions of potential 
interest. 
• Also pertaining to Guiding Question 3, we extracted information on the intent of the 
interventions, including appropriately reducing opioid use, reducing opioid risks (related 
to harms, misuse, and OUD), identifying opioid misuse and OUD, treatment of opioid 
misuse or OUD, to help providers in some other way to management opioid use, and 
other intents of potential interest. 
• We extracted all eligible specific outcome categories, including pain, opioid use, opioid 
prescriptions, “direct” opioid harms (e.g., misuse, OUD, long-term use), “indirect” opioid 
harms (e.g., falls, cognitive decline, cardiovascular events), physical functioning, 
emotional functioning (including quality of life), and health service and care utilization. 
Finally, we captured other outcomes of potential interest. 
• We extracted a range of features related to study design, including the basic study design 
(e.g., randomized controlled trial, case series), the directionality (prospective vs. 
retrospective), and the temporality (cross-sectional vs. longitudinal). We also captured 
the study’s country and setting (e.g., ED), the sample size, enrollment years, and follow-
up duration (as relevant).  
 
From each eligible article we extracted bibliographic information (first author, journal, year 
of publication) and study name (as applicable). All data was extracted in a predefined electronic 
form. 
Assessment of Methodological Risk of Bias of Individual Studies  
Technical Briefs do not assess strength of evidence; therefore studies were not assessed for 
methodological risk of bias. 
Data Synthesis  
We summarized Key Informant input and use it to inform the design of the Conceptual 
Framework, in terms of the data items to be extracted; to identify important evidence gaps; and 
to prioritize gaps into research needs.  
To synthesize the evidence base, we first categorized studies as pertaining to either predictor 
analyses or to identifiable interventions. An individual article could contain both predictor 
analyses and intervention analyses. 
Predictor Studies 
Predictor studies are those that describe an association between a predictor and an outcome. 
The predictors could be characteristics of participants, providers, settings, or regions, such as, 
respectively, race/ethnicity, provider specialty, clinic type, or poverty level in a given county. 
For our first-pass inclusion of studies in this category, we did not consider the type of analysis 
done (e.g., descriptive/narrative only, other qualitative, subgroup data, comparisons of 
subgroups, regression analyses). 
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To focus on those studies of greatest potential value to inform either clinical decisionmaking 
or research into future potential tools or instruments, we focused on those studies that reported 
multivariable analyses of outcomes of interest within clearly specified cohorts of older adults. 
From these studies, we extracted data from the reported multivariable analyses, including 
outcome, predictor and comparator, (adjusted) relative effect size and associated data, and notes 
as necessary.  
When articles reported separate multivariable analyses for different outcomes, these were 
each extracted separately and in full. When articles reported related or overlapping multivariable 
analyses of the same outcome (e.g., separate analyses in different subgroups or at different time 
points), we selected one of the analyses to extract but noted that other analyses were reported. 
We used our judgment to determine, on a case-by-case basis, which analysis to extract, but erred 
on the side of including the most complete analysis (e.g., of the total group instead of a 
subgroup) and/or analyses that provided stronger associations (see next paragraph). Our logic for 
including the strongest associations was that these studies are providing preliminary assessments 
of which predictors may accurately predict the outcome in a future instrument to be created and 
validated. We believe that instrument developers will likely be most interested in, and will 
further test, all predictors that have been found to be strongly associated with a given outcome. 
Within these studies with multivariable analyses, we assigned each reported outcome into a 
predictor category relevant to the Conceptual Framework. The effect size estimates from these 
multivariable analyses were each categorized according to the direction of the association and by 
following schema: 
• Strong, statistically significant association between (categorical) predictor and higher 
risk of outcome: relative effect size ≥2 (or ≤0.5) 
• Weak, statistically significant association between (categorical) predictor and higher 
risk of outcome: relative effect size between 0.5 and 2.0 
• Statistically significant association between continuous predictor and risk of outcome. 
Because we could not estimate a standardized effect size, we did not classify these 
associations as strong or weak. 
• No statistically significant association between predictor and outcome (regardless of 
relative effect size magnitude) 
Intervention Studies 
We sought those studies that evaluated an identifiable intervention in studies that met 
eligibility criteria and pertained to older adults. The interventions could be directed at patients, 
providers, clinics (or other healthcare organizations), or society (e.g., implemented 






Appendix C. Key Informant Discussion 
Overview 
Here we provide an overview of our discussions with Key Informants that helped to shape 
the Conceptual Framework and to evaluate the evidence base. 
When discussing factors that might potentially be drivers behind increases in opioid use and 
opioid-related hospitalizations or ED visits, the definition of “older” was a key theme. A 
considerable degree of uncertainty existed about who should be considered an “older” adult. The 
lack of clarity presents as a barrier to advancing research and knowledge for geriatric patients, 
and may serve as a facilitator that encourages more opioid prescribing among older adults by 
allowing providers to ignore the distinctions between younger and older patients. Additionally, 
few Key Informants felt there was sufficient clarity about how multimorbidity, polypharmacy, 
frailty, cognitive and physical impairment, and other characteristics common among older adults 
should be considered when providers are 1) initially prescribing opioids, 2) continuing opioids, 
and 3) de-prescribing or de-escalating opioids. The opportunity to speak with other physicians 
and healthcare professionals to create an appropriate individualized pain treatment plan could 
help providers to overcome this uncertainty. However, the absence of insurer reimbursement or 
other financial incentives serves as a major barrier to the formation of interdisciplinary pain 
treatment teams and treatment plan use. Key Informants pointed out that opioids are a path of 
much less resistance in comparison, and that providers are forced to make prescribing decisions 
based on the resources available to them. Aside from or due to interactions with the multitude of 
provider factors, patient characteristics were also discussed as potential drivers of increased 
opioid use and related harms among older adults. Cancer, history of substance use across the life 
course, and attitudes toward legal and illegal drug use were all identified as potentially important 
patient-level risk factors among older adults. 
On the topic of interventions for reducing the risk of potentially inappropriate prescribing of 
opioids among older adults, Key Informants underscored the severe lack of research and 
resulting knowledge gap about the comparative effectiveness and safety of opioid versus 
nonopioid (drug and non-drug) interventions. Knowledge was identified as a pre-requisite for 
development of any interventions since reducing opioid use will likely require increasing use of 
nonopioid therapies to address patients’ pain. Adaptations to nonopioid treatments are likely to 
also be necessary for older adults (e.g., physical therapy due to prevalent mobility limitations), 
but such treatments could reduce opioid use, especially if incorporated into a multimodal stepped 
care pain therapy approach. There was a fair amount of enthusiasm among Key Informants for 
multimodal stepped care pain therapy, but resource constraints were identified as a major barrier 
to widespread implementation and continued use among older adults. Finally, Key Informants 
highlighted the need to create interdisciplinary pain treatment teams as an intervention, and to 
develop tools and algorithms for providers to apply to their older patients to help with screening 
and risk stratification for clinical management. Patient characteristics like frailty, cognitive 
impairment, dementia, disability, and multimorbidity were noted as characteristics that should be 
explicitly address during the development phase of any interventions (e.g., screening tools). 
The Key Informants were specifically asked about risk factors for opioid misuse, abuse, and 
OUD in older adults; many felt that the strongest risk factor was likely the lack of provider 
monitoring. Some Key Informants conceptualized the lack of monitoring as inappropriate 
management of patients on opioids, which they felt was part of a broader issue around absence of 
adequate healthcare professional training in pain management and interventions to stimulate 
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greater uptake of such training. The lack of screening tools specifically designed for or studied in 
older adults was thought to be a major determinant of misuse, abuse, and OUD. Provider 
perceptions that older adults are not at significant risk was hypothesized both as a reason for the 
lack of screening tools in older adults and the reason that opioid misuse, abuse, and OUD may be 
increasing in this population. Key Informants stated that even when providers believe there is 
indeed a significant risk, health systems, organizations, and clinical practice settings often do not 
share their belief or feel that the population at risk is not sufficiently large to merit a focus (i.e., 
to merit older adult-specific screening tools). Finally, risk factors for opioid misuse, abuse, and 
OUD in older adults were perceived as empirically unsupported by the data. The absence of data 
was itself perceived as a risk factor because such information is necessary to develop tools and 
interventions. This is especially true given that older adults who misuse opioids are hypothesized 
to differ in their demographic, clinical, and other characteristics from 1) older adults with pain 
who do not misuse opioids or develop OUD, and 2) younger adults misusing opioids or who 
have OUD. Opioid contracts were mentioned by Key Informants, but appear not to be widely 
used for older adults. 
When specifically asked about interventions to reduce opioid misuse, abuse, and OUD in 
older adults, Key Informants were enthusiastic about Screening, Brief Intervention, and Referral 
to Treatment (SBIRT) and deprescribing protocols. Deprescribing protocols specifically for 
opioids or focused on pain in older adults do not yet exist per Key Informants, but many felt that 
they could be effective if they included an appropriate transition to treatments that prevent 
relapse when the patient is addicted to opioids. There was also enthusiasm for the ORT, which 
has gained traction among providers due to its brevity and ease of use. While the absence of 
screening tools was a major theme during discussions of risk factors for opioid misuse, abuse, 
and OUD in older adults, there was discordance between Key Informants about how to address 
that issue. Some Key Informants strongly believed that screening tools developed in younger 
populations could be readily applied to older adults. Others believed that research would be 
necessary to adapt, validate, and confirm the effectiveness of those tools, especially if OUD 
prevention was a focus of them. Other Key Informants believed that it would be best to develop 
new screening tools for older adults that would explicitly take into account older adults’ unique 
demographic and clinical characteristics. Regardless of how tools might ultimately be developed, 
Key Informants agreed that the feasibility of implementing any tools or interventions is a major 
concern given health systems’ perceived unwillingness to deploy them, allocate sufficient time to 
providers to apply tools, or train staff. 
Many Key Informants believed that co-prescribing of medications with related therapeutic 
effects, such as benzodiazepines or non-benzodiazepine hypnotics, was the strongest risk factor 
for opioid-related hospitalizations or ED visits among older adults. Related to co-prescribing, 
providers unknowingly duplicating another provider’s opioid prescription for an older patient 
(e.g., due to lack of communication) was identified as a major problem and risk factor for opioid-
related harm. Providers’ inability to accurately assess an older adult’s likelihood of benefit from 
an opioid relative to their likelihood of harm was considered another particularly strong risk. 
Other risk factors that emerged through Key Informant discussions included polypharmacy, 
multimorbidity, isolation (e.g., living at home alone), location of residence (e.g., at home versus 
in a long-term care facility, in a certain state or region), psychiatric conditions (including 
depression and suicidal ideation), and caregiver support (e.g., the availability of family members 
to assist with medication management and activities of daily living).  
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Few interventions were specifically identified to reduce the risk of opioid-related 
hospitalizations and ED visits among older adults. Key Informants identified the lack of a 
detailed understanding about why hospitalizations and ED visits related to opioids were 
increasing over time as a major barrier to developing interventions. No Key Informant was 
confident in a given explanation or believed the mechanism for the observed time trends was 
obvious. Interventions involving the training of healthcare professionals and organizing 
providers into multidisciplinary teams was a repeated focus. 
Throughout all discussions, Key Informants identified several areas in which research is 
urgent and would be particularly impactful: 
• Establishing clear age thresholds and distinguishing how risk factors for opioid-
related harms vary both within and between age groups 
• Distinguishing between age and birth cohort effects as explanations for the increases 
in opioid-related hospitalizations and ED visits over time 
• Comparative effectiveness of opioid versus nonopioid interventions with an explicit 
focus on frailty, multimorbidity, and other characteristics unique to older adults 
• How to clearly define provider responsibilities for prescribing, continuing, and 
deprescribing opioids when multiple providers care for a single older patient 
• Medication and recreational cannabis or marijuana use as both a risk factor for 
opioid-related harms and a potential intervention to reduce them 
• Validation of existing screening tools for opioid misuse or opioid in older adults 
• Developing separate screening tools for identifying opioid misuse versus opioid-
related harms that occur under appropriate use circumstances or use as prescribed by 
a provider 
• Tramadol use in older adults and how tramadol should fit into a pain management 
strategy 
• How opioids are currently used in older adults with cancer and how pain 




Table C-1. Systems framework for factors driving opioid use among older adults 
Relevant 
Components Factor: Actor Factor: Behavior Factor: Influences 
Patient; Provider; 
Setting  
Provider Categorization of patients as 
“older” based on different 




on the threshold selected 
by one provider versus 
another 
Disagreement between policies and programs 
(e.g., Older Americans Act versus Medicare 
health insurance program eligibility) on who 
should be defined as “older” 
 
Clinical guidelines referring to different groups 
as “older” 
 
Researchers defining different groups as 
“older” (e.g., age ≥50 versus ≥60 versus ≥65) 
Patient  Patient Use of many legal 
prescription drugs and 
illegal recreational drugs 
across the life course in 
certain age cohorts 
Historical and cultural access and acceptance 
of legal and illegal drug use among present 
older adult cohort (i.e., “baby boomer” 
cohort) increases acceptability of taking 
opioids 
Patient; Provider Provider Practice trends toward and 
greater acceptability of 
using short-acting opioids, 
lower doses, and opioid 
products without 
acetaminophen rather 
than long-acting opioids in 
older adults with chronic 
pain 
Provider perception that age (younger vs. 
older) does not seem to impact use of 
opioids in chronic pain patients, though 
providers aim to use more nonopioid 
treatments in older adults  
Social and societal expectation to use more 
nonopioid modalities  
Provider, Pain Provider Appropriate use of opioids 
to manage pain (i.e., good 
pain management care) 
Legitimate patient pain requiring opioid 
management 
Provider; Setting Provider Inappropriate prescribing 
and over-prescribing of 
opioids 
Faster and easier to prescribe an opioid than 
not prescribing a drug or recommending a 
non-pharmacologic therapy 
 
Lack of insurer reimbursement for 
interdisciplinary communication between 
providers and development of an opioid-
sparing treatment plan 





Lack of insurer reimbursement for topical 
NSAIDs and other nonopioid therapies 
 
Health system leadership pressure to prescribe 
opioids and other treatments reimbursed by 
insurer 
Patient; Provider Provider Prescribing high-dose or 
more opioids to an older 
adult because they have 
cancer without a thorough 
assessment of the exact 
source or type of pain 
Patient: cancer 
 
Provider perception that cancer pain is a 
special pain type for which typical pain 
management and opioid prescribing 
principles do not apply 
 
Provider perception that cancer is broadly a 
proxy for limited life expectancy (perceived 
prognosis drives prescribing) 
 
Provider conceptualization of cancer as either 
an acute or chronic condition 
 
Provider not assessing source of “cancer 
pain”—surgical, trauma, chronic, 
musculoskeletal, neuropathic, etc. 
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Table C-2. Systems framework for interventions that exist or could exist to reduce the risk of 
potentially inappropriate prescribing for older adults 




Behavior Factor: Influences 





















Lack of empirical evidence to support 
the use of many nonopioid treatments 
(either versus no treatment or 
opioids) despite the fact that patients 
seek them out 
 



















Provider: need to know how to work 
with older adults and how to adapt 
intervention (e.g., stretching, 
flexibility, or strengthening exercises) 
so that patients can engage despite 
frailty, cognitive impairment, disability, 
and other characteristics 
 
Patient: Frailty, dementia, and other 
characteristics, thus interventions 
need to be adapted; equity factors 
(some population more likely to have 




Health system commitment to providing 
services (e.g., via an Integrative 
Health Center) despite no or poor 
reimbursement 




















Local resources impeding widespread 
and consistent implementation even 
when empirical evidence is generated 
to support the use of multimodal 
stepped care pain therapy 
 








Behavior Factor: Influences 













Lack of perceived need for team-based 
care relative to other acute and 
chronic clinical conditions. 
 
Provider or personnel preparation 
 
Failure by providers to use or integrate 
the resources and skills of other 
disciplines like counseling, 
rehabilitation, and mental health 
 
Improved coordination of mental health 
with respect to chronic pain, and lack 
of clarity about who is responsible for 
coordination  
 
Improved training in other disciplines 
(e.g., counseling, rehabilitation and 
mental health), and increased 
capacity for training 
 
Patient: depression 


















Resources impeding implementation, 
including difficulties obtaining 
financial support to organize 
neurosurgeons, physical therapists, 
pain specialists, geriatricians and 
others into a team to identify the 
source(s) of pain and develop a 
personalized treatment plan  
 
Interdisciplinary pain programs and 
clinics (originally created for complex 
patient cases) closing over time 
(since the 1990’s), especially in rural 
areas 














a patient’s care 
team 
Lack of consistency in training and 
quality control for many disciplines 
offering nonopioid services, such as 
massage therapy and acupuncture 
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Behavior Factor: Influences 




















Existence of algorithms adapted to older 
population, specifically taking into 
account prevalent contraindications to 
nonopioid drugs (e.g., declining renal 
function and the use of either NSAIDs 
or gabapentin) 
 
Existing clinical guidance is not easily 










for older adults 
Provider; 
Setting 




that uses a 
given 
individual’s 
clinical data as 
an input and 







Lack of empirically documented risk 
factors for opioid misuse in an older 
population, especially “early life” 
factors like smoking, childhood 
trauma, and family history of alcohol 
or other substance use 
 
Incomplete understanding of whether 
tools must be developed separately 
for older adults with versus without a 
history of substance use in order for 
the tools to have good performance 
Table C-3. Systems framework for strongest predictors for opioid misuse, abuse, and opioid use 
disorder in older adults 
Relevant 
Components Factor: Actor Factor: Behavior Factor: Influences 
Provider Providers, 
patient 
Inappropriate management of people 
on opioids (and continuation of 
opioids) 
Provider: Futility influenced by lack of 
training in pain management; lack of 
familiarity with Food and Drug 
Administration-approved treatments 
for opioid use disorder; clinician 
engagement 
Patient: stoicism; lower tolerance 
among older patients for same doses 
of opioids in younger patients 
Provider Providers 
(Prescribers) 
Prescribing opioids long-term for 
musculoskeletal conditions causing 
chronic pain 
Unclear/Not specified 
Patient Patient Addiction to alcohol and concurrent 
use of alcohol with opioids 
Interaction or interplay between birth 










Lack of care coordination with other 
providers of patient (e.g., 
communicate what is being 
prescribed in one setting to 
provider in another setting), and 
therapeutic duplication of another 
provider’s opioid prescription due 
to ignorance of the other 
prescription 
Patient: multiple conditions leading to 
care by multiple providers; ability to 
receive care in multiple systems paid 
for by multiple insurers (e.g., single 
patient receiving care from the 
Veterans Health Administration [VHA] 
and a non-VHA provider who bill 
services to Medicare) 
Provider/Setting: Lack of clarity about 
what person or entity is responsible 
for coordinating multiple providers  
Provider Provider Non-use of opioid contracts Patient: Age >75 
Provider: Greater concern about 
children or adult caregivers diverting 
opioids from the older patient and 
using them 
Provider Provider Lack of patient referral to behavior 
health providers who are able to 
spend more time investigating and 
assessing for possible opioid 
misuse 
Patient: Age >75  
Provider: Greater concern about 
children or adult caregivers diverting 




Provider Lack of using screening tool(s) Availability (lack) of a tool specific to 
older adults to predict individual 
patients’ risk of opioid misuse or OUD 
Availability of prescription drug 
monitoring plans and urine toxicology 
(screens) 
Belief that a lot of data already exists on 
how to screen, regardless of age 
Belief that existing screening tools in 
younger populations are too lengthy 
and unable to be adopted in routine 
clinical practice 
Provider Provider Lack of screening to detect opioid 
misuse and OUD  
Provider: Biases of the practitioners; 
prevalent beliefs that older adults do 
not or are unlikely to misuse opioids 
or develop OUD 






Table C-4. Systems framework for interventions that exist or could exist to reduce opioid-related 





















Provider Act in a guideline-
concordant manner by 
detoxing patients on 
long-term opioids while 
also transitioning them 
to a treatment to 
prevent relapse and 
overdose 
Provider: Training in the use of 
medications for OUD and how 
to appropriately manage opioid 
withdrawal 
 
Guidance: by SAMHSA  
Provider; 
Guidance 
Provider Use of active 
deprescribing protocols, 
and where relevant, 
offering patient 
enrollment in formal 
deprescribing programs 
for opioids or other co-
prescribed drugs (e.g., 
benzodiazepines or 
non-benzodiazepine 
hypnotics) that could 




Provider: Understanding that 
writing a simple schedule of 
reduced doses is not sufficient 
for appropriate deprescribing 
 
Guidance: Clinic protocol, other 
 
Patient: presence of opioids and 




Provider Use of deprescribing 
protocols for those with 
an index event, such as 
a recent fall that 
resulted in an ED visit, 
and in settings not 
traditionally related to 
pain (e.g., a geriatric 
falls clinic) 
Provider: Understanding that 
writing a simple schedule of 
reduced doses is not sufficient 
for appropriate deprescribing 
 
Guidance: Clinic protocol, other 
 




Provider Collaborating with primary 
care provider and 
physical therapy to 
ensure that treatments 
are substituted when an 
opioid is deprescribed   
Ability to collaborate with primary 
care provider or physical 
therapy 
 
Patient’s ability to tolerate 
acetaminophen 
 





Patient comorbidities that may 
serve as a contraindication, 





















Use of screening tools to 
identify or predict the 
risk of opioid-related 
harms (e.g., falls) under 
appropriate opioid use 
circumstances 
Provider: Capability to use tool 
 
Guidance: Brevity of tool 
 
Setting: Many health systems 
faced with the challenge of 
maintaining many screening 
tools in the electronic medical 
record, thus prefer not to 
implement screening tools that 
do not apply to the whole 
health system  
Provider; 
Guidance 
Provider Use screening tool for 
misuse of opioids and 
OUD, such as the 
Opioid Risk Tool (ORT) 
designed for primary 
care settings 
Provider: Perceived opioid 
misuse (e.g., multiple 
prescribers, using medication 
for the wrong purpose) 
 
Guidance: (barrier) tools can be 
very lengthy and difficult to 
implement in practice; the 
ORT, while simple and 
validated, has not been tested 
in older adults 
Provider; 
Patient  
Provider Use clinical algorithm to 
screen patients for 
eligibility to have 
deprescribing protocols 
applied 
Patient: Presence of concomitant 


























Patient: Chronic pain condition 
requiring pain treatment not 
contraindicated by 
comorbidities or conditions; 
likelihood of adherence if 
patient is required to visit a 
practitioner (e.g., a massage 
therapist) multiple times per 
week 
  
Pain type: If pharmacologic or 
non-pharmacologic treatment 
addresses that specific pain 










Provider Providers Deliver SBIRT to older 
adults with OUD or who 
are at high risk of OUD 
Provider: availability of a brief 
intervention like individual or 
group therapy 
 














Provider Provider Using PDMPs to monitor 
opioid use in older 
adults 
Provider access to PDMPs 
 
Ability of PDMP to integrate with 
electronic medical record 
systems used by providers to 
display information 
 
Ability of PDMP to facilitate 
communication between 
providers 
Abbreviations: CDC = centers for disease control and prevention, ED = emergency department, ORT = opioid risk tool, OUD = 
opioid use disorder, PDMP = prescription drug monitoring program, SBIRT = screening, brief intervention, and referral to 




Table C-5. Systems framework for strongest predictors of opioid related hospitalizations or 
emergency department visits 
Relevant Components Factor: Actor Factor: Behavior Factor: Influences 
Patient Patient Taking multiple medications 
(engaging in polypharmacy) 
that interact, produce similar 
effects, or lead to confusion 






Patient Patient Suicide (intentionally 
overdosing on opioids) 
Isolation, depression, suicidal 
ideation, psychiatric 
conditions, lack of family 
support, and general social-
behavioral risk 
Patient; Provider Provider Potentially inappropriate 
prescribing of opioids 
among older adults with 
depression and suicidal 
ideation 
Provider difficulty recognizing 
depression in older adults; 
Lack of coordinated care 
between primary care and 
mental health providers 
Patient; Provider Provider Prescribing high doses of 
opioids 
Presence of poorly controlled 
chronic obstructive 
pulmonary disease (COPD) 
or severe liver disease 
 
Caregiver knowledge about 
adverse effect monitoring 
Patient; Setting Caregiver Helping manage (monitor and 
administer) medication in 
older adults (especially 
those with cognitive 
impairment or dementia) 
Not specified; implied that 
caregiver support could help 
older adults avoid 
unintentional opioid 
overdoses 
Provider; Patient Provider (multiple; 
across different 
conditions) 
Poor communication among 
providers for same patient 
resulting in multiple opioid 
prescriptions or 
prescriptions for 
medications that interact 
with opioids  
Patient: multiple chronic 
comorbidities 
 
Electronic medical record and 
administrative billing 
systems disconnected and 
not sharing information (e.g., 
dual enrollment in Medicare 
and Veterans Health 
Administration)  
Provider Provider Not treating older adults’ pain 
properly, especially when 
pain is chronic (specific 
behaviors not made explicit) 
 
Lack of training programs in 
pain management, and 
subsequent lack of providers 
trained to properly treat pain  
 
Possible implication that 
medical schools and other 
health professional schools 
not offering sufficient training 




Relevant Components Factor: Actor Factor: Behavior Factor: Influences 
Provider Provider Failure to conduct a more 
thorough (or any) risk-
benefit assessment of 
prescribing opioids, 
continuing opioids, or 
adjusting dose (to keep as 
low as possible) in an older 
patient at each clinical visit 
(with goal of keeping the 
patient on the lowest dose 
necessary) 
Not explicitly specified; 
implication was time 
pressures and potential lack 
of knowledge among 
providers 
 
Providers asking older adult 
how much of an opioid they 
are taking per day or other 
unit of time, and asking 
about any adverse events to 
opioid 
Setting; Patient  Patient Individuals waiting until they 
are in a pain crisis to use 
the ED, and using the ED 
more frequently for pain 
care 
Patient: Rural (vs. urban) 
residence, 
community resources,  
Medicaid expanded (vs. not 
expanded) states 
Provider Provider Prescribing inappropriate or 
less effective nonopioid 
drugs to manage pain, 
ultimately resulting in more 
opioid use later 
Resistance from insurance 
companies, especially 
toward pain medicine 
specialists attempting to 
avoid using opioids (e.g., by 
using pregabalin) 
 
Insurance coverage for 
nonopioid pain management 
(i.e., opioids cheaper and 
easier) 
Provider Provider  Inappropriate prescribing and 
management of opioids for 
older persons 
Lack of geriatrics training; 
inequitable distribution of 
geriatrics providers by 
geographic region 
Setting Nursing homes and 
other long-term care 
providers; health 
systems 
Providing more post-acute 
care and long-term care at 
patients’ homes rather than 
in nursing homes, skilled 
nursing facilities, or other 
long-term care settings with 
staff that have potentially 
more training in pain 
management and geriatrics 
Workforce, workforce training, 
family caregiving 
 
Patient: Care setting 
preferences 




Table C-6. Systems framework interventions that exist or could exist to reduce opioid-related 
hospitalizations or emergency department visits 
Intervention Relevant 
components 
Factor: Actor Factor: Behavior Factor: Influences 
1: Train providers in 
pain medicine 
Provider; Guidance Provider Providing sufficient training in 
pain medicine or related 
principles, including how to 
prescribe nonopioid therapies 
and deprescribe opioids. 
System issues, structural issues 
 
Medical, Nursing, Dental, and Health 
Professional Schools and Training 
Program curricula 
2: Train caregivers Patient; Provider Provider Teach caregivers (e.g., family 
members, home health aides) 
about how to monitor for 
opioid adverse events and 
how to intervene if an 
overdose is occurring (e.g., 
by using naloxone) 
Patient: Cognitive impairment or dementia 
requiring medication management 
 
Lack of coverage for home care services 
 
Lack of training for family members or 
home health aides 












for older patients 
Provider; Guidance Provider Initiate opioids at a geriatric 
dose rather than the 
recommended adult non-
geriatric dose (e.g., at a half 
or even a quarter of the non-
geriatric dose) and titrate up 
slowly to ensure that the 
lowest necessary dose is 
used and the probability of 
adverse effects is minimized 
Provider awareness of clinical 




Appendix D. Evidence Map and Other Findings 
Evidence Map 
The literature search yielded 6244 citations, of which 4153 were screened in duplicate. At 
this stage of screening, the Abstrackr program predicted that the remaining unscreened abstracts 
would be highly unlikely to be relevant. Consistent with this, the last approximately 200 citations 
that were screened yielded no potentially relevant abstracts. Figure D-1 summarizes the literature 
flow. 
Citation screening yielded 536 abstracts of potential interest across Guiding Questions. There 
were 449 articles retrieved in full text and entered into the evidence map. Of these, 258 articles 
were rejected as not being relevant to Guiding Questions 2 or 3. The primary reasons for 
rejection included that the study did not report analyses for populations ≥60 years of age (or ≥50 
years), articles did not report on analyses specific to older adults (e.g., they only compared 
findings in older vs. younger adults, not among older adults), the study did not evaluate opioids, 
or the study evaluated only opioid effectiveness for pain control. Among these studies, we found 
74 studies that focused on adults ≥50 years (but not ≥60 years) or had a mean age between 50 
and 60 years. A further 133 were rejected for not being a study of an intervention or a 
multivariable analysis of the association between risk factors and outcomes of interest. Thus, 57 
studies, in 58 articles, are included in the report. 
PROSPERO 
Our search of the PROSPERO database yielded 310 citations. After screening, we found 24 
of potential interest, of which 18 were rejected upon inspection of the full records in 
PROSPERO. Most were rejected because the records did not indicate a focus or an interest in the 
subgroup of older adults; six records were rejected because the reviews focus on effect and/or 






Figure D-1. Literature flow 
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Table D-1. Planned systematic reviews found in PROSPERO 
PROSPERO ID Topic Condition Age, Years Intervention Outcomes Study Designs Search 
Year 
Stage 
CRD42018089907 RF for 
prolonged Tx 





Any 2018 Completed, 
published 











Opioid use Instrument 
development 
2018 Ongoing 
CRD42018092943 Screening for 
opioid harms 
Pain ≥65 (None) Cognitive Any 2019 Ongoing 
CRD42019110462 Treatment of 
OUD 












19+ (None) OUD etc. 
(prevalence) 
Any 2018 Ongoing 
CRD42017057904 Pain 
assessment 
Dementia Any Pain assessment 
techniques 
Pain, Tx, QoL, 
etc. 




with pain Tx 
Pain ≥65 (None) Pain, Fxn, QoL, 
Experiences 
QR 2019 Ongoing 
Abbreviations: Fxn = function, ID = identification number, OUD = opioid use disorder, QoL = quality of life, QR = qualitative research, RF = risk factors, Tx = treatment(s). 

















NCT02090972 Completed No Results 
Available 
None, per se Opioid use Bone density 
measures 
≥60 1000 Case 
Control 
Feb 2015 







≥65 16 RCT Nov 2013 




Table D-3a. Studies with multivariable analyses of associations: Outcome data 
Rows* Author Year PMID Outcome Category Outcome 
1-3 Al Dabbagh 2016 26707940 Long-term use Earlier discontinuation of opioid prescriptions 
4 Alam 2012 22412106 Long-term use Long-term opioid Use 
5-21 Brescia 2019 31447051 Long-term use New persistent long term use 
22-42 Cancienne 2018 28887020 Long-term use Prolonged postoperative opioid use after total knee arthroplasty 
43-48 Carey 2018 29800019 Overdose Opioid overdose 
49 Carter 2019 30863796 Death Death (vs. routine ED discharge) 
50-60 Carter 2019 30863796 Opioid misuse Opioid misuse 
61-78 Choi 2017 28699829 Opioid misuse Opioid use disorder 
79-86 Choi 2019 30585135 Hospitalization Any ED visit 
87-95 Cochran 2017 28489491 Opioid misuse Count of symptoms of prescription opioid misuse (via the POMI Prescription 
Opioid Misuse Index) 
96-122 Curtis 2017 28635179 Long-term use Long-term opioid use (>90 days) 
123-140 Daoust 2018 28767563 Long-term use Opioid use 1 year after injury 
141-145 Dasinger 2019 30879796 Hospitalization Post-discharge readmission within 30 days 
146-158 Gold 2016 27564407 Opioid misuse High-Risk Obtainment of Prescription Opioids 
159-168 Grigoras 2018 29159797 Death Opioid mortality 
169-172 Grigoras 2018 29159797 Death Synthetic opioid mortality 
173-176 Grigoras 2018 29159797 Death Natural and semi-synthetic opioid mortality 
177-179 Grigoras 2018 29159797 Death Heroin mortality 
180-182 Grigoras 2018 29159797 Death Methadone mortality 
183-207 Hadlandsmyth 2018 28927564 Long-term use Opioid Use at 12 Months 
208-220 Hamina 2017 28092324 Long-term use Long-term opioid use 
221 Hoffman 2017 28531306 Harm/mental health Depression 
222 Hoffman 2017 28531306 Harm/mental health Alcohol abuse 
223 Hoffman 2017 28531306 Harm/mental health Other substance abuse 
224 Hoffman 2017 28531306 Harm/mental health Other substance overdose 
225 Hoffman 2017 28531306 Harm/mental health Other substance dependence 
226 Hoffman 2017 28531306 Long-term use Opioid dependence 
227 Hoffman 2017 28531306 Opioid misuse Opioid abuse 
228 Hoffman 2017 28531306 Overdose Opioid overdose 
229-246 Inacio 2016 27130165 Long-term use New chronic opioid use 
247-256 Jain 2018 29561298 Long-term use Long-term opioid use 
257-258 Jeffery 2018 28967517 Long-term use Long-term opioid use 
259-262 Jena 2014 24553363 Hospitalization admission to hospital 
263-278 Jena 2014 24553363 Multiple prescribers prescribing of opioids by multiple providers 
279-293 Karttunen 2019 30370943 Long-term use Prolonged opioid use 
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Rows* Author Year PMID Outcome Category Outcome 
294-295 Kuo 2016 26522794 Hospitalization ER visit 
296-297 Kuo 2016 26522794 Hospitalization Hospitalization 
298-317 Lalic 2018 29451672 Long-term use Opioid persistence 
318-328 Lindestrand 2015 25952252 Long-term use Persistent opioid use (6 mo after hip fracture) 
329-335 Lo-Ciganic 2019 30901048 Overdose Opioid overdose 
336-339 Loeb 2020 31584849 Long-term use New chronic opioid use 
340-356 McDermott 2019 30396321 Long-term use Continuous Opioid Use at 6 Months 
357-395 Musich 2019 30401575 Long-term use Chronic opioid use> 90 days 
396-442 Namba 2018 29753617 Long-term use Number of Prescriptions days 271-360 post-op 
443-470 Nelson 2020 31445908 Long-term use Persistent opioid use 
471-482 Park 2010 20664342 Opioid misuse Opioid misuse 
483-531 Rao 2018 29891412 Long-term use Opioid use days 271-360 postoperative 
532-573 Santosa 2020 31349994 Long-term use New persistent opioid use 
574-575 Schepis 2019 30328160 Harm/mental health Suicidal ideation 
576-610 Shah 2019 31026356 Long-term use Prolonged Opioid Prescribing 
611-637 Suda 2017 28408172 Multiple prescribers Opioid overlap (multiple prescribers) 
638-645 Taipale 2019 30325873 Harm/physical Hip fracture 
646 Vozoris 2016 27418553 Death COPD or pneumonia-related mortality 
647 Vozoris 2016 27418553 Death All-cause mortality 
648 Vozoris 2016 27418553 Harm/physical Outpatient respiratory exacerbations 
649 Vozoris 2016 27418553 Hospitalization Emergency room visits for COPD or pneumonia 
650 Vozoris 2016 27418553 Hospitalization Hospitalisations for COPD or pneumonia 
651 Vozoris 2016 27418553 Hospitalization ICU admissions during hospitalisations for COPD or pneumonia 
652 Zeng 2019 30860559 Death All-cause mortality 
653-661 Zoorob 2018 29537112 Death Drug overdose fatality (very high overdose vs low overdose at county-level) 
* Row numbers are included to help the reader align the various sections of the table. In this first section, duplicate (identical) rows are condensed and the ranges of relevant rows 




Table D-3b. Studies with multivariable analyses of associations: Factor data and estimates 
Row Author Year Factor Category Risk Factor Estimate (95% CI) P 
1 Al Dabbagh 2016 Age Age ≥70 1.9 (1.5–2.3) < 0.001 
2 Al Dabbagh 2016 Gender Female 1.2 (1.0–1.4) 0.1 
3 Al Dabbagh 2016 Cause of pain Fracture type: Open 0.6 (0.4–1.0) 0.06 
4 Alam 2012 Opioid use Age 1.44 (1.39-1.50) 
5 Brescia 2019 Comorbidity Gastrointestinal complication 1.49 (1.05-2.12) 0.026 
6 Brescia 2019 Cause of pain Open lung resection  1.32 (1.07-1.63) 0.008 
7 Brescia 2019 Opioid use Periop opioid Rx pre-surgery 1.98 (1.74-2.24) <0.001 
8 Brescia 2019 Opioid amount Total perioperative opioid dose, per OME 1.00 (1.00-1.00) <0.001 
9 Brescia 2019 Comorbidity Length of hospital stay, d 1.03 (1.02-1.04) <0.001 
10 Brescia 2019 Age Age, y 0.99 (0.98-1.00) 0.018 
11 Brescia 2019 Gender Female 1.14 (1.04-1.25) 0.007 
12 Brescia 2019 Race/ethnicity Black 1.50 (1.29-1.75) <0.001 
13 Brescia 2019 Income Dual Medicare and Medicaid eligibility 1.40 (1.25-1.57) <0.001 
14 Brescia 2019 Comorbidity Disability (Medicare qualification status) 1.46 (1.23-1.73) <0.001 
15 Brescia 2019 Comorbidity Charlson Comorbidity Index 3,4 1.14 (1.02-1.26) 0.018 
16 Brescia 2019 Tobacco Tobacco use, current or past 1.10 (1.01-1.20) 0.021 
17 Brescia 2019 Mental health Schizophrenia 0.69 (0.52-0.91) 0.010 
18 Brescia 2019 Substance misuse Drug and substance use disorder 1.31 (1.05-1.63) 0.017 
19 Brescia 2019 Cause of pain Arthritis 1.13 (1.04-1.23) 0.006 
20 Brescia 2019 Cause of pain Back pain 1.27 (1.16-1.38) <0.001 
21 Brescia 2019 Cause of pain Other pain disorder 1.10 (1.02-1.19) 0.019 
22 Cancienne 2018 Opioid use Overall (any?) narcotic prescription filled preoperatively 5.47 (5.31-5.64) <0.0001 
23 Cancienne 2018 Opioid amount Filled one narcotic prescription filled preoperatively 2.78 (2.68-2.90) <0.0001 
24 Cancienne 2018 Opioid amount Filled two narcotic prescriptions filled preoperatively 5.93 (5.62-6.26) <0.0001 
25 Cancienne 2018 Opioid amount Filled three narcotic prescriptions filled preoperatively 15.05 (14.00-16.17) <0.0001 
26 Cancienne 2018 Opioid amount Filled four or more narcotic prescriptions filled preoperatively 20.34 (18.69-22.14) <0.0001 
27 Cancienne 2018 Opioid use Tramadol preoperative prescription filled 1.02 (0.98-1.06) 0.394 
28 Cancienne 2018 Nonpain tx Anxiolytics preoperative prescription filled 1.52 (1.46-1.58) <0.0001 
29 Cancienne 2018 Nonopioid pain tx Muscle relaxants preoperative prescription filled 1.64 (1.55-1.74) <0.0001 
30 Cancienne 2018 Methadone Methadone preoperative prescription filled 3.68 (2.90-4.68) <0.0001 
31 Cancienne 2018 Tobacco Tobacco use preoperatively 1.44 (1.39-1.51) <0.0001 
32 Cancienne 2018 Substance misuse Alcohol abuse preoperatively 1.19 (1.10-1.29) <0.0001 
33 Cancienne 2018 Substance misuse Marijuana use/abuse preoperatively 1.47 (1.15-1.89) 0.002 
34 Cancienne 2018 Substance misuse Cocaine use/abuse preoperatively 1.24 (0.85-1.79) 0.263 
35 Cancienne 2018 Substance misuse Amphetamine use/abuse preoperatively 1.14 (0.72-1.82) 0.578 
36 Cancienne 2018 Gender Male 1.03 (1.00-1.07) 0.053 
37 Cancienne 2018 Comorbidity Obesity (BMI 30-39.9) 1.08 (1.04-1.12) <0.0001 
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38 Cancienne 2018 Comorbidity Morbid obesity (BMI >=40) 1.35 (1.31-1.40) <0.0001 
39 Cancienne 2018 Mental health Depression 1.32 (1.28-1.36) <0.0001 
40 Cancienne 2018 Cause of pain Back pain/lumbago 1.38 (1.34-1.42) <0.0001 
41 Cancienne 2018 Cause of pain Migraine headaches 1.22 (1.16-1.29) <0.0001 
42 Cancienne 2018 Cause of pain Fibromyalgia 1.17 (1.13-1.21) <0.0001 
43 Carey 2018 Opioid misuse >210 days of opioid supplied in 180 days 3.49 (3.22-3.77) 
44 Carey 2018 # Prescribers or 
pharmacists 
Any overlapping opioid claim 3.17 (2.96–3.38) 
45 Carey 2018 # Prescribers or 
pharmacists 
≥5 prescribers 4.15 (3.78–4.52) 
46 Carey 2018 # Prescribers or 
pharmacists 
≥5 pharmacies 5.46 (4.75–6.16) 
47 Carey 2018 # Prescribers or 
pharmacists 
Any out-of-state prescriber 2.34 (2.07–2.61) 
48 Carey 2018 # Prescribers or 
pharmacists 
Any out-of-state pharmacy 1.77 (1.52–2.02) 
49 Carter 2019 Opioid misuse Opioid misuse 0.85 (0.72, 0.99) 
50 Carter 2019 Age Age 65-74 6.75 (6.63, 7.27) 
51 Carter 2019 Age Age 75–84 2.16 (1.99, 2.34) 
52 Carter 2019 Gender Female 1.12 (1.07, 1.16) 
53 Carter 2019 Comorbidity No. of chronic conditions 1.27 (1.26, 1.28) 
54 Carter 2019 Substance misuse Alcohol-related visit 2.88 (2.70, 3.07) 
55 Carter 2019 Cause of pain Injury-related visit 2.89 (2.77, 3.02) 
56 Carter 2019 Insurance Medicaid 1.56 (1.41, 1.73) 
57 Carter 2019 Insurance Non-Medicaid/Medicare 0.84 (0.79, 0.89) 
58 Carter 2019 Income Income: Lowest quartine 1.26 (1.20, 1.31) 
59 Carter 2019 Income Income: Highest quartine 0.78 (0.74, 0.82) 
60 Carter 2019 Residence Rural residence 0.99 (0.94, 1.04) 
61 Choi 2017 Substance misuse Marijuana use disorder, past year 2.95 (1.11–7.79) 
62 Choi 2017 Age Age, per year (implied) 0.96 (0.94–0.99) 
63 Choi 2017 Gender Male 0.96 (0.58–1.58) 
64 Choi 2017 Race/ethnicity Non-Hispanic Black 1.15 (0.62–2.12) 
65 Choi 2017 Race/ethnicity Hispanic 1.92 (1.08–3.39) 
66 Choi 2017 Race/ethnicity American Indian 2.30 (0.69–7.65) 
67 Choi 2017 Social Married/cohabiting 0.93 (0.60–1.44) 
68 Choi 2017 Education College degree 0.80 (0.41–1.56) 
69 Choi 2017 Employment Employed full-/part-time 0.58 (0.37–0.89) 
70 Choi 2017 Comorbidity Chronic conditions, n 1.12 (0.92–1.36) 
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71 Choi 2017 Cause of pain Injury, past year 1.51 (0.96–2.38) 
72 Choi 2017 Pain Pain interference: Little/moderate 3.94 (1.73–8.95) 
73 Choi 2017 Pain Pain interference: Severe 9.68 (3.90–24.08) 
74 Choi 2017 Mental health Major depressive disorder, past year 0.96 (0.55–1.66) 
75 Choi 2017 Mental health Anxiety disorder, past year 2.71 (1.56–4.72) 
76 Choi 2017 Mental health PTSD, past year 1.34 (0.69–2.62) 
77 Choi 2017 Substance misuse Alcohol use disorder, past year 2.95 (1.67–5.21) 
78 Choi 2017 Tobacco Nicotine use disorder, past year 1.70 (1.03–2.82) 
79 Choi 2019 Opioid use Opioid use, not misuse 2.25 (2.05–2.47) 
80 Choi 2019 Opioid misuse Opioid misuse 1.99 (1.55–2.56) 
81 Choi 2019 Opioid use Opioid use, not misuse 2.87 (2.48–3.32) 
82 Choi 2019 Opioid misuse Opioid misuse 2.57 (1.88–3.51) 
83 Choi 2019 Opioid use Opioid use, not misuse 1.13 (1.04–1.23) 
84 Choi 2019 Opioid misuse Opioid misuse 1.16 (0.98–1.38) 
85 Choi 2019 Opioid use Opioid use, not misuse 1.32 (1.15–1.50) 
86 Choi 2019 Opioid misuse Opioid misuse 1.05 (0.77–1.42) 
87 Cochran 2017 Opioid misuse Illicit drug use  2.4 (1.46–3.95) 0.001 
88 Cochran 2017 Substance misuse Hazardous drinking 0.91 (0.49–1.69) 0.76 
89 Cochran 2017 Mental health Depression 1.2 (0.80–1.80) 0.37 
90 Cochran 2017 Mental health PTSD 0.86 (0.46–1.61) 0.65 
91 Cochran 2017 Comorbidity General health 1.6 (0.63–4.07) 0.33 
92 Cochran 2017 Pain Pain 1.30 (0.55–3.05) 0.55 
93 Cochran 2017 Gender Female 0.48 (0.13–1.77) 0.27 
94 Cochran 2017 Education Less than high school 0.3 (0.03–2.92) 0.31 
95 Cochran 2017 Residence Rural pharmacy 0.23 (0.04–1.27) 0.09 
96 Curtis 2017 Age Age, 5-year increments 0.83 (0.82–0.83) 
97 Curtis 2017 Gender Male 0.86 (0.84–0.88) 
98 Curtis 2017 Race/ethnicity White Race 0.85 (0.82–0.88) 
99 Curtis 2017 Race/ethnicity Other Race 0.63 (0.59–0.66) 
100 Curtis 2017 Comorbidity Acute myocardial infarction 0.94 (0.90–0.98) 
101 Curtis 2017 Comorbidity Coronary heart disease 1.11 (1.08–1.14) 
102 Curtis 2017 Comorbidity Peripheral vascular disorder 1.18 (1.14–1.22) 
103 Curtis 2017 Comorbidity Cerebrovascular disease 0.89 (0.86–0.93) 
104 Curtis 2017 Comorbidity Chronic pulmonary disease 1.18 (1.15–1.21) 
105 Curtis 2017 Comorbidity Other rheumatic disease (aside from RA) 1.07 (1.03–1.12) 
106 Curtis 2017 Comorbidity Peptic ulcer disease 1.35 (1.25–1.46) 
107 Curtis 2017 Comorbidity Hemiplegia or paraplegia 0.70 (0.61–0.81) 
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108 Curtis 2017 Comorbidity Renal disease 1.29 (1.25–1.33) 
109 Curtis 2017 Comorbidity Moderate or severe liver disease 1.22 (1.00–1.50) 
110 Curtis 2017 Cause of pain Metastatic solid tumor 1.85 (1.65–2.06) 
111 Curtis 2017 Cause of pain Back pain 2.96 (2.89–3.03) 
112 Curtis 2017 Cause of pain Soft tissue rheumatism including fibromyalgia 1.75 (1.71–1.79) 
113 Curtis 2017 Mental health Anxiety 1.46 (1.42–1.51) 
114 Curtis 2017 Mental health Depression 1.66 (1.61–1.71) 
115 Curtis 2017 Nonpain tx Biologic disease- modifying antirheumatic drug 1.32 (1.29–1.35) 
116 Curtis 2017 Nonopioid pain tx 1–2 fills and less than a 90-day supply of NSAID 1.30 (1.26–1.34) 
117 Curtis 2017 Nonopioid pain tx 3 or more fills or more than a 90-day supply of NSAID 1.47 (1.44–1.51) 
118 Curtis 2017 Healthcare 
utilization 
Any hospitalization 2.31 (2.25–2.38) 
119 Curtis 2017 Healthcare 
utilization 
Any claim for durable medical equipment 1.66 (1.63–1.70) 
120 Curtis 2017 Income Median household income Quartile 1 1.46 (1.41–1.51) 
121 Curtis 2017 Income Median household income Quartile 2 1.33 (1.29–1.37) 
122 Curtis 2017 Income Median household income Quartile 3 1.20 (1.17–1.24) 
123 Daoust 2018 Gender Female 1.27 (1.16–1.38) 
124 Daoust 2018 Cause of pain Motor vehicle accident 0.87 (0.75–1.00) 
125 Daoust 2018 Cause of pain Weapon or blunt object 0.98 (0.73–1.31) 
126 Daoust 2018 Cause of pain 2 injuries 1.01 (0.92–1.10) 
127 Daoust 2018 Cause of pain >=3 injuries 0.95 (0.85–1.07) 
128 Daoust 2018 Cause of pain Head injury 0.97 (0.84–1.11) 
129 Daoust 2018 Cause of pain Face injury 1.08 (0.95–1.24) 
130 Daoust 2018 Cause of pain Thorax injury 1.15 (1.03–1.28) 
131 Daoust 2018 Cause of pain Spine injury 1.62 (1.46–1.80) 
132 Daoust 2018 Cause of pain Lower extremity 1.32 (1.13–1.53) 
133 Daoust 2018 Cause of pain Major trauma (ISS >15) 0.81 (0.69–0.95) 
134 Daoust 2018 Substance misuse History of alcoholism 1.28 (0.94–1.74) 
135 Daoust 2018 Mental health History of depression 1.32 (1.13–1.53) 
136 Daoust 2018 Mental health History of anxiety 1.12 (0.99–1.27) 
137 Daoust 2018 Healthcare 
utilization 
Surgery during hospitalization 0.99 (0.91–1.07) 
138 Daoust 2018 Opioid amount 1 opioid prescription in prior 12 months 2.26 (2.00–2.56) 
139 Daoust 2018 Opioid amount >=2 opioid prescriptions in prior 12 mo 11.4 (10.5–12.5) 
140 Daoust 2018 Opioid use Opioid prescriptions w/in 3 mo of trauma 3.05 (2.83–3.29) 
141 Dasinger 2019 Opioid use Preop opioids infrequent 1.17 (1.04-1.31) 
142 Dasinger 2019 Opioid use Preop opioids not daily 1.28 (1.08-1.52) 
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143 Dasinger 2019 Opioid use Preop opioids  daily 1.49 (1.27-1.74) 
144 Dasinger 2019 Opioid use Opioids "on hand" at (first) admission 1.15 (1.00-1.31)  
<0.05 implied 
145 Dasinger 2019 Opioid use Opioid Rx filled at (first) discharge 1.13 (1.04-1.23) 
146 Gold 2016 Opioid misuse Lifetime recreational use of prescription opioids 3.0 (2.4–3.4) 
147 Gold 2016 Age Age 65-69 2.4 (1.7–2.9) 
148 Gold 2016 Age Age 70-74 1.6 (0.9–2.4) 
149 Gold 2016 Age Age 75-79 2.2 (1.5–2.9) 
150 Gold 2016 Age Age 80-84 2.9 (2.2–3.3) 
151 Gold 2016 Age Age >=85 2.8 (2.0–3.3) 
152 Gold 2016 Gender Female 1.6 (1.2–2.0) 
153 Gold 2016 Education Some college 1.9 (1.4–2.4) 
154 Gold 2016 Education College degree 2.1 (1.5–2.6) 
155 Gold 2016 Social Social connectedness (Lubben Social Network Scale-6; higher 
more connected) 
2.0 (1.8–2.3) 
156 Gold 2016 Quality of life Mental and physical health (SF-12 ) 1.3 (0.6–2.3) 
157 Gold 2016 Opioid misuse Lifetime illicit drug use 1.8 (1.6–2.1) 
158 Gold 2016 Tobacco Cigarette use in past year 1.5 (0.9–2.4) 
159 Grigoras 2018 Income Under poverty line, % in county 0.28 <0.001 
160 Grigoras 2018 Opioid prescription Prescription rate in county 0.28 <0.001 
161 Grigoras 2018 Race/ethnicity White, % in county 0.16 <0.001 
162 Grigoras 2018 Opioid prescription Physicians, opioid-prescribing, Medicare-enrolled, per county 
population 
-0.07 0.01 
163 Grigoras 2018 Specialty Emergency medicine prescription rate 0.21 <0.001 
164 Grigoras 2018 Specialty Family medicine prescription rate 0.11 0.008 
165 Grigoras 2018 Specialty Internal medicine prescription rate 0.10 0.018 
166 Grigoras 2018 Specialty Physician assistant prescription rate 0.08 0.021 
167 Grigoras 2018 Opioid prescription Super-prescriber prescription rate 0.14 <0.001 
168 Grigoras 2018 Opioid prescription Non-super-prescriber prescription rate 0.07 <0.001 
169 Grigoras 2018 Income Under poverty line, % in county 0.53 <0.001 
170 Grigoras 2018 Opioid prescription Prescription rate in county 0.32 0.02 
171 Grigoras 2018 Race/ethnicity White, % in county 0.41 <0.001 
172 Grigoras 2018 Opioid prescription Physicians, opioid-prescribing, medicare-enrolled, per county 
population 
-0.32 <0.001 
173 Grigoras 2018 Income Under poverty line, % in county 0.37 <0.001 
174 Grigoras 2018 Opioid prescription Prescription rate in county 0.26 0.05 
175 Grigoras 2018 Race/ethnicity White, % in county 0.21 0.001 
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176 Grigoras 2018 Opioid prescription Physicians, opioid-prescribing, medicare-enrolled, per county 
population 
-0.22 <0.001 
177 Grigoras 2018 Income Under poverty line, % in county 0.42 <0.001 
178 Grigoras 2018 Opioid prescription Prescription rate in county 0.49 0.03 
179 Grigoras 2018 Race/ethnicity White, % in county 0.37 <0.001 
180 Grigoras 2018 Income Under poverty line, % in county 0.33 <0.001 
181 Grigoras 2018 Opioid prescription Prescription rate in county 0.44 0.05 
182 Grigoras 2018 Race/ethnicity White, % in county 0.26 0.007 
183 Hadlandsmyth 2018 Gender Female 0.53 (0.21-1.35) 
184 Hadlandsmyth 2018 Age Age >70 0.935 
185 Hadlandsmyth 2018 Race/ethnicity African American 0.70 (0.38-1.27) 
186 Hadlandsmyth 2018 Race/ethnicity Other race 2.16 (0.91-5.15) 
187 Hadlandsmyth 2018 Comorbidity BMI: Underweight 5.11 (0.52-50.63) 
188 Hadlandsmyth 2018 Comorbidity BMI: Overweight/obese 1.03 (0.42-2.54) 
189 Hadlandsmyth 2018 Cause of pain Pre-TKA chronic pain 1.25 (0.84-1.86) 
190 Hadlandsmyth 2018 Comorbidity Charlson Comorbidity index: 2-3 0.69 (0.43-1.14) 
191 Hadlandsmyth 2018 Comorbidity Charlson Comorbidity index: 4-5 0.82 (0.46-1.48) 
192 Hadlandsmyth 2018 Comorbidity Charlson Comorbidity index: >5 1.26 (0.63-2.48) 
193 Hadlandsmyth 2018 Opioid use Pre-TKA opioid use 7.81 (4.07-15.00) 
194 Hadlandsmyth 2018 Mental health Psychiatric diagnosis 1.04 (0.63-1.71) 
195 Hadlandsmyth 2018 Substance misuse Substance use 1.74 (1.01-2.99) 
196 Hadlandsmyth 2018 Nonopioid pain tx Muscle relaxant use, prior not active 0.67 (0.17-2.69) 
197 Hadlandsmyth 2018 Nonopioid pain tx Muscle relaxant use, active 1.94 (1.28-2.94) 
198 Hadlandsmyth 2018 Benzo Benzo use, prior not active 1.11 (0.26-4.71) 
199 Hadlandsmyth 2018 Benzo Benzo use, active 1.10 (0.69-1.75) 
200 Hadlandsmyth 2018 Nonpain tx Non-benzo hypnotic use, prior not active 0.62 (0.09-4.42) 
201 Hadlandsmyth 2018 Nonpain tx Non-benzo hypnotic use, active 0.83 (0.44-1.58) 
202 Hadlandsmyth 2018 Nonpain tx Antidepressant use, prior not active 0.40 (0.06-2.78) 
203 Hadlandsmyth 2018 Nonpain tx Antidepressant use, active 0.93 (0.56-1.54) 
204 Hadlandsmyth 2018 Nonpain tx Antiepileptic use, prior not active 0.45 (0.06-3.37) 
205 Hadlandsmyth 2018 Nonpain tx Antiepileptic use, active 1.38 (0.90-2.12) 
206 Hadlandsmyth 2018 Healthcare 
utilization 
Duration of hospital stay, per day 1.00 (0.99-1.01) 
207 Hadlandsmyth 2018 Cause of pain Unilateral knee replacement 0.19 (0.05-0.76) 
208 Hamina 2017 Comorbidity Alzheimer disease 1.07 (1.02-1.12) 
209 Hamina 2017 Gender Female 1.32 (1.24-1.40) 
210 Hamina 2017 Age Age ≥80 1.20 (1.14-1.27) 
211 Hamina 2017 Income Medium SES 1.01 (0.96-1.07) 
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212 Hamina 2017 Income Low SES 1.27 (1.16-1.40) 
213 Hamina 2017 Comorbidity Asthma/COPD 1.06 (0.98-1.14) 
214 Hamina 2017 Comorbidity CVD 1.15 (1.09-1.21) 
215 Hamina 2017 Comorbidity DM 1.08 (1.01-1.16) 
216 Hamina 2017 Cause of pain Hx of hip fracture 1.12 (1.01-1.25) 
217 Hamina 2017 Cause of pain Osteoporosis 1.31 (1.23-1.39) 
218 Hamina 2017 Cause of pain Rheumatoid arthritis 1.35 (1.23-1.49) 
219 Hamina 2017 Substance misuse History of substance abuse 1.26 (1.07-1.48) 
220 Hamina 2017 Benzo History of long‐term benzodiazepine use 1.62 (1.54-1.71) 
221 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 1.53 (1.29-1.82) 
222 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 1.38 (0.90-2.11) 
223 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 1.81 (0.92-3.58) 
224 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 1.82 (0.92-3.6) 
225 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 1.73 (1.21-2.49) 
226 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 2.85 (1.54-5.47) 
227 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 3.97 (0.87-28.9) 
228 Hoffman 2017 Opioid duration Opioid treatment ≥90 days 5.12 (1.63-19.62) 
229 Inacio 2016 Gender Female 1.40 (1.00 to 1.96) 
230 Inacio 2016 Cause of pain Back pain 3.90 (2.85 to 5.33) 
231 Inacio 2016 Mental health Depression 1.70 (1.20 to 2.41) 
232 Inacio 2016 Substance misuse Alcohol abuse 2.16 (0.75 to 6.22) 
233 Inacio 2016 Mental health Psychoses 1.39 (0.65 to 2.96) 
234 Inacio 2016 Mental health Anxiety 1.00 (0.66 to 1.50) 
235 Inacio 2016 Comorbidity Migraine 5.11 (1.08 to 24.18) 
236 Inacio 2016 Comorbidity Liver mild disease 4.33 (1.08 to 17.35) 
237 Inacio 2016 Comorbidity Weight loss 2.60 (1.06 to 6.39) 
238 Inacio 2016 Comorbidity Dementia 2.19 (1.04 to 4.61) 
239 Inacio 2016 Comorbidity Gastric acid disease 1.62 (1.16 to 2.25) 
240 Inacio 2016 Comorbidity Hyperlipidaemia 1.38 (1.00 to 1.91) 0.048 
241 Inacio 2016 Comorbidity Diabetes with complications 1.86 (0.97 to 3.57) 0.063 
242 Inacio 2016 Comorbidity Others <1.6 NS 
243 Inacio 2016 Benzo hypnotics and sedatives (prior use) 1.56 (1.13 to 2.16) 
244 Inacio 2016 Nonopioid pain tx antineuropathic pain (prior use) 3.11 (2.05 to 4.72) 
245 Inacio 2016 Nonopioid pain tx muscle relaxants (prior use) 1.95 (0.39 to 9.74) 
246 Inacio 2016 Nonpain tx corticosteroids 1.17 (0.79 to 1.74) 
247 Jain 2018 Opioid use Preoperative chronic opioid therapy 8.08 7.40–8.80 <0.001 
248 Jain 2018 Mental health Anxiety 1.23 1.14–1.34 <0.001 
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249 Jain 2018 Mental health Depression 1.28 1.19–1.39 <0.001 
250 Jain 2018 Cause of pain Inflammatory arthritis 1.35 1.27–1.45 <0.001 
251 Jain 2018 Tobacco Tobacco use disorder 1.48 1.34–1.63 <0.001 
252 Jain 2018 Substance misuse Drug abuse/dependence 1.98 1.64–2.4 
253 Jain 2018 Race/ethnicity African-American 1.24 1.11–1.4 <0.001 
254 Jain 2018 Gender Female 1.09 1.03–1.16 0.005 
255 Jain 2018 Insurance Medicare advantage 1.73 1.57–1.9 <0.001 
256 Jain 2018 Age Age >80 0.45 0.42–0.49 <0.001 
257 Jeffery 2018 Opioid stewardship Nonconcordant 1.30 (1.18–1.42) 
258 Jeffery 2018 Opioid stewardship Nonconcordant 4.42 (4.18–4.66) 
259 Jena 2014 # Prescribers or 
pharmacists 
1 opioid prescriber 1.64 (1.59 to 1.69) 
260 Jena 2014 # Prescribers or 
pharmacists 
2 opioid prescribers 1.97 (1.92 to 2.02) 
261 Jena 2014 # Prescribers or 
pharmacists 
3 opioid prescribers 2.33 (2.25 to 2.41) 
262 Jena 2014 # Prescribers or 
pharmacists 
>=4 opioid prescribers 3.24 (3.14 to 3.33) 
263 Jena 2014 Age Age: 65-74 1.55 (1.53 to 1.57) 
264 Jena 2014 Age Age: 75-84 1.32 (1.31 to 1.34) 
265 Jena 2014 Race/ethnicity Race: Non-Hispanic black 1.20 (1.18 to 1.22) 
266 Jena 2014 Gender Female 0.98 (0.97 to 0.99) 
267 Jena 2014 Residence Rural 0.81 (0.68 to 0.97) 
268 Jena 2014 Income Median household income in zipcode 1.03 (1.03 to 1.04) 
269 Jena 2014 Income Low-income subsidy only 0.88 (0.87 to 0.90) 
270 Jena 2014 Income Medicare-Medicaid dual eligible 0.91 (0.90 to 0.91) 
271 Jena 2014 Nonpain tx Anti-neoplastic agents 1.17 (1.15 to 1.92) 
272 Jena 2014 Nonpain tx Stimulants 1.04 (1.01 to 1.07) 
273 Jena 2014 Nonpain tx Psychotherapeutic/neurological agents 0.87 (0.86 to 0.89) 
274 Jena 2014 Nonpain tx Central nervous system drugs 1.10 (1.09 to 1.10) 
275 Jena 2014 Nonpain tx Neuromuscular agents 1.28 (1.27 to 1.29) 
276 Jena 2014 Nonopioid pain tx Non-narcotic analgesic 1.26 (1.25 to 1.27) 
277 Jena 2014 Insurance Medicare Advantage 1.07 (1.06 to 1.08) 
278 Jena 2014 Opioid stewardship State prescription drug monitoring program 1.01 (0.99 to 1.02) 
279 Karttunen 2019 Comorbidity Alzheimer disease 0.63 (0.60‐0.66) 
280 Karttunen 2019 Age Age ≥ 80 0.92 (0.87‐0.97) 
281 Karttunen 2019 Income Socioeconomic position: Medium 1.06 (1.00‐1.12) 
282 Karttunen 2019 Income Socioeconomic position: Low 1.27 (1.15‐1.41) 
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283 Karttunen 2019 Comorbidity Cardiovascular disease 1.27 (1.20‐1.34) 
284 Karttunen 2019 Comorbidity Diabetes 1.17 (1.08‐1.26) 
285 Karttunen 2019 Comorbidity Asthma/COPD 1.28 (1.18‐1.38) 
286 Karttunen 2019 Cause of pain Rheumatoid arthritis 1.39 (1.25‐1.54) 
287 Karttunen 2019 Comorbidity History of hip fracture 1.60 (1.38‐1.85) 
288 Karttunen 2019 Comorbidity Osteoporosis 1.13 (1.02‐1.26) 
289 Karttunen 2019 Mental health Depression or bipolar disorder 1.13 (1.02‐1.26 
290 Karttunen 2019 Mental health Schizophrenia 0.78 (0.64‐0.95) 
291 Karttunen 2019 Substance misuse History of substance abuse 1.32 (1.16‐1.52) 
292 Karttunen 2019 Cause of pain Active cancer 1.78 (1.62‐1.96) 
293 Karttunen 2019 Benzo History of long‐term benzodiazepine use 2.24 (2.11‐2.37) 
294 Kuo 2016 Opioid type  Schedule II opioid use >=90 d 1.74 (1.62-1.86) 
295 Kuo 2016 Opioid type Schedule III opioid use >=90 d 1.46 (1.38-1.54) 
296 Kuo 2016 Opioid type Schedule II opioid use >=90 d 1.78 (1.66-1.90) 
297 Kuo 2016 Opioid type Schedule III opioid use >=90 d 1.47 (1.40-1.54) 
298 Lalic 2018 Gender Male 0.71 (0.63-0.81) 
299 Lalic 2018 Income Govt subsidy 1.54 (1.37-1.74) 
300 Lalic 2018 Opioid type Strong opioid 1.51 (1.32-1.73) 
301 Lalic 2018 Opioid type Transdermal opioid 4.24 (3.85-4.68) 
302 Lalic 2018 Opioid amount MEq 250-499 1.68 (1.54-1.85) 
303 Lalic 2018 Opioid amount MEq 500-749 1.77 (1.28-2.45) 
304 Lalic 2018 Opioid amount MEq ≥750 2.20 (1.84-2.63) 
305 Lalic 2018 Comorbidity 1-2 comorbidities 1.69 (0.84-3.84) 
306 Lalic 2018 Comorbidity 3-4 comorbidities 2.00 (1.01-3.94) 
307 Lalic 2018 Comorbidity >=5 comorbidities 1.69 (0.86-3.33) 
308 Lalic 2018 Mental health Depression 1.53 (1.43-1.64) 
309 Lalic 2018 Mental health Psychotic illness 2.60 (2.29-2.95) 
310 Lalic 2018 Substance misuse Alcohol dependence 0.66 (0.20-2.14) 
311 Lalic 2018 Comorbidity Migraine 0.59 (0.31-1.12) 
312 Lalic 2018 Tobacco Nicotine dependence 1.80 (1.44-2.24) 
313 Lalic 2018 Benzo Benzodiazapines (prior use) 1.27 (1.18-1.37) 
314 Lalic 2018 Nonopioid pain tx Paracetamol (prior use) 2.15 (2.01-2.31) 
315 Lalic 2018 Nonopioid pain tx NSAIDs (prior use) 1.17 (1.10-1.25) 
316 Lalic 2018 Nonopioid pain tx Pregabalin (prior use) 1.55 (1.40-1.72) 
317 Lalic 2018 Nonpain tx Stimulants (prior use) 0.94 (0.28-3.19) 
318 Lindestrand 2015 Gender Male NS 
319 Lindestrand 2015 Age Age >=82 NS 
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320 Lindestrand 2015 Social Home dwelling NS 
321 Lindestrand 2015 Healthcare 
utilization 
Admitted to geriatric ward postoperatively 1.69 (0.96–2.94) 0.07 
322 Lindestrand 2015 Cause of pain Pertrochanteric fracture NS 
323 Lindestrand 2015 Comorbidity ASA score >2, NS 
324 Lindestrand 2015 Cause of pain Osteoporosis, 2.38 (1.16–4.76) <0.05 
325 Lindestrand 2015 Cause of pain Cancer diagnosis, NS 
326 Lindestrand 2015 Cause of pain Active cancer 3.13 (0.85–11.11) 0.09 
327 Lindestrand 2015 Opioid use Opioid usage before admission 5.88 (3.23–11.11) 
328 Lindestrand 2015 Opioid stewardship Tapering plan 0.56 (0.32–0.96) <0.05 
329 Lo-Ciganic 2019 Opioid amount Total MME 1.0 
330 Lo-Ciganic 2019 Substance misuse Hx SUD/AUD 0.9 
331 Lo-Ciganic 2019 Opioid amount Average daily MME 0.82 
332 Lo-Ciganic 2019 Age Age (Medicare) 0.69 
333 Lo-Ciganic 2019 Comorbidity Disability status 0.61 
334 Lo-Ciganic 2019 Opioid amount No. opioid fills 0.6 
335 Lo-Ciganic 2019 Miscellaneous Others <40% 
336 Loeb 2020 Cause of pain Cancer risk category (prostate), distant mets (eg) 9.66 (2.08-50.0) 0.003 
337 Loeb 2020 Comorbidity Charlson Comorbidity Index 3+ 3.38 (1.30-7.27) 0.004 
338 Loeb 2020 Social Unmarried 1.39 (1.05-1.84) 0.02 
339 Loeb 2020 Education Education, high 0.74 (0.52-1.06) 0.10 
340 McDermott 2019 Age Age 70-74 0.76 (0.39-1.51) 
341 McDermott 2019 Age Age >=75 0.48 (0.23-0.98) 
342 McDermott 2019 Gender Female 0.47 (0.24-0.91) 
343 McDermott 2019 Race/ethnicity Non-(White, non-Hispanic) 1.26 (0.61-2.61) 
344 McDermott 2019 Social Non-married 2.22 (1.19-4.14) 
345 McDermott 2019 Residence Nonmetropolitan 0.91 (0.41-1.96) 
346 McDermott 2019 Cause of pain Tumor stages, treatments, types, etc. NS 
347 McDermott 2019 Comorbidity Comorbidity index 1 1.85 (0.94-3.63) 
348 McDermott 2019 Comorbidity Comorbidity index >=2 1.14 (0.56-2.34) 
349 McDermott 2019 Income Median income level, lowest quartile 0.90 (0.37-2.22) 
350 McDermott 2019 Opioid use Prior opioid use 3.56 (1.95-6.50) 
351 McDermott 2019 Tobacco History of tobacco use 3.84 (1.44-10.24) 
352 McDermott 2019 Substance misuse History of alcohol/substance abuse 0.37 (0.12-1.12) 
353 McDermott 2019 Opioid type First opioid prescribed: Codeine 0.32 (0.08-1.21) 
354 McDermott 2019 Opioid type First opioid prescribed: Oxycodone 0.26 (0.10-0.67) 
355 McDermott 2019 Opioid amount Initial high-dose opioid use 2.82 (1.41-5.65) 
356 McDermott 2019 Opioid type Initial long-acting opioid use 1.83 (0.87-3.85) 
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357 Musich 2019 Gender Female 1.19 <0.0001 
358 Musich 2019 Age Age 70-74 0.9 0.0003 
359 Musich 2019 Age Age 75-79 0.88 0.0002 
360 Musich 2019 Age Age 80-84 0.94 0.1 
361 Musich 2019 Age Age ≥85 1.19 <0.0001 
362 Musich 2019 omitted PCP per 100,000 1 0.07 
363 Musich 2019 Race/ethnicity Minority low 1.06 0.22 
364 Musich 2019 Race/ethnicity Minority medium 1.04 0.39 
365 Musich 2019 Income Income low 1.49 <0.0001 
366 Musich 2019 Income Income medium 1.27 <0.0001 
367 Musich 2019 Residence Urban 0.9 0.0001 
368 Musich 2019 omitted Midwest 1.13 <0.0001 
369 Musich 2019 omitted Northeast 0.84 <0.0001 
370 Musich 2019 omitted West 1.22 <0.0001 
371 Musich 2019 Insurance Plan type: medium coverage 1.26 <0.0001 
372 Musich 2019 Insurance Plan type: other (<medium) 1.05 0.11 
373 Musich 2019 Comorbidity Pre-period HCC Score 0.50 to <1.20 (Hierarchical Condition 
Category) 
1.58 <0.0001 
374 Musich 2019 Comorbidity Pre-period HCC Score 1.20 to <2.80 2.49 <0.0001 
375 Musich 2019 Comorbidity Pre-period HCC Score ≥2.8 4.34 <0.0001 
376 Musich 2019 Opioid type Index opioid category = 1: Long-acting 26.24 <0.0001 
377 Musich 2019 Opioid type Index opioid category = 6: Tramadol 3.6 <0.0001 
378 Musich 2019 Cause of pain 1st opioid >30 days after chronic back pain 2.17 <0.0001 
379 Musich 2019 Cause of pain 1st opioid within 30 days after new back pain 1.78 <0.0001 
380 Musich 2019 Cause of pain 1st opioid within 30 days after TKA 1.02 0.8 
381 Musich 2019 Cause of pain 1st opioid within 30 days after trauma 0.63 <0.0001 
382 Musich 2019 Nonopioid pain tx Muscle relaxant use 2.83 <0.0001 
383 Musich 2019 Nonpain tx Antipsychotic use 1.43 <0.0001 
384 Musich 2019 Nonopioid pain tx NSAID use 1.62 <0.0001 
385 Musich 2019 Nonpain tx Sleep medication use 1.79 <0.0001 
386 Musich 2019 Nonopioid pain tx Physical therapy use 1.43 <0.0001 
387 Musich 2019 Benzo Benzodiazepine in post only (new) 2.21 <0.0001 
388 Musich 2019 Benzo Benzodiazepine use in pre and post 1.26 <0.0001 
389 Musich 2019 Benzo Benzodiazepine use in pre only 0.75 <0.0001 
390 Musich 2019 Mental health Depression in post only (new) 1.77 <0.0001 
391 Musich 2019 Mental health Depression in pre and post 1.38 <0.0001 
392 Musich 2019 Mental health Depression in pre only 1.18 0.0006 
393 Musich 2019 Mental health Anxiety in post only (new) 1.36 <0.0001 
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394 Musich 2019 Mental health Anxiety in pre and post 1.26 <0.0001 
395 Musich 2019 Mental health Anxiety in pre only 1.15 0.001 
396 Namba 2018 Opioid amount Preoperative number of opioid prescriptions 1.09 (1.09-1.09) <0.001 
397 Namba 2018 Nonopioid pain tx Preoperative NSAID use 1.04 (1.01-1.08) 0.011 
398 Namba 2018 Gender Female 1.03 (1.00-1.07) 0.092 
399 Namba 2018 Age Age (per 10-y increment) (3/4 >=61) 0.91 (0.89-0.93) <0.001 
400 Namba 2018 Race/ethnicity Asian 0.65 (0.59-0.72) <0.001 
401 Namba 2018 Race/ethnicity Black 1.08 (1.02-1.14) 0.009 
402 Namba 2018 Race/ethnicity Hispanic 1.02 (0.98-1.07) 0.343 
403 Namba 2018 Comorbidity BMI (per 5 point increment) 1.02 (1.01-1.03) 0.007 
404 Namba 2018 Mental health Anxiety 1.09 (1.05-1.14) <0.001 
405 Namba 2018 Mental health Bipolar 0.88 (0.77-1.00) 0.05 
406 Namba 2018 Mental health Depression 1.17 (1.12-1.23) <0.001 
407 Namba 2018 Opioid duration Opioid dependency 0.55 (0.49-0.62) <0.001 
408 Namba 2018 Mental health PTSD 1.44 (1.22-1.69) <0.001 
409 Namba 2018 Substance misuse Substance abuse 1.28 (1.21-1.35) <0.001 
410 Namba 2018 Comorbidity Diabetes 1.07 (1.04-1.11) <0.001 
411 Namba 2018 Comorbidity AIDS 0.37 (0.26-0.53) <0.001 
412 Namba 2018 Comorbidity Deficiency anemia 1.06 (1.00-1.12) 0.044 
413 Namba 2018 Comorbidity Rheumatoid arthritis 1.25 (1.15-1.36) <0.001 
414 Namba 2018 Comorbidity Chronic blood loss anemia 0.89 (0.78-1.01) 0.083 
415 Namba 2018 Comorbidity Congestive heart failure 1.2 (1.09-1.33) <0.001 
416 Namba 2018 Comorbidity Chronic lung disease 1.06 (1.00-1.11) 0.033 
417 Namba 2018 Comorbidity Coagulopthy 1.19 (1.05-1.35) 0.008 
418 Namba 2018 Comorbidity Hypertension 1.09 (1.04-1.14) 0.001 
419 Namba 2018 Comorbidity Hypothyroidism 0.99 (0.94-1.05) 0.858 
420 Namba 2018 Comorbidity Liver disease 1.17 (1.04-1.3) 0.007 
421 Namba 2018 Comorbidity Fluid and electrolyte disorders 1.04 (0.96-1.12) 0.31 
422 Namba 2018 Comorbidity Other neurological disorders 1.19 (1.10-1.29) <0.001 
423 Namba 2018 Comorbidity Paralysis 0.86 (0.69-1.06) 0.152 
424 Namba 2018 Comorbidity Peripheral vascular disease 1.12 (1.03-1.22) 0.008 
425 Namba 2018 Comorbidity Pulmonary circulation disorder 0.96 (0.78-1.17) 0.667 
426 Namba 2018 Comorbidity Renal failure 1.05 (0.98-1.12) 0.166 
427 Namba 2018 Comorbidity Peptic ulcer disease bleeding 1.17 (0.69-2.00) 0.552 
428 Namba 2018 Comorbidity Valvular disease 1.06 (0.95-1.18) 0.313 
429 Namba 2018 Comorbidity Weight loss 1.01 (0.80-1.28) 0.91 
430 Namba 2018 Cause of pain Arthritis 1.07 (0.96-1.18) 0.21 
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431 Namba 2018 Cause of pain Back pain 1.35 (1.29-1.41) <0.001 
432 Namba 2018 Cause of pain Carpal tunel 0.75 (0.65-0.87) <0.001 
433 Namba 2018 Cause of pain Costochondritis and intracostal muscle injury 0.93 (0.60-1.44) 0.754 
434 Namba 2018 Comorbidity Dementia 0.72 (0.62-0.85) <0.001 
435 Namba 2018 Cause of pain Fibromyalgia 1.15 (1.06-1.25) 0.001 
436 Namba 2018 Cause of pain Fractures and contusions 0.96 (0.85-1.08) 0.475 
437 Namba 2018 Cause of pain Joint pain 0.94 (0.90-0.98) 0.003 
438 Namba 2018 Cause of pain Limb-extremity pain 1.01 (0.89-1.15) 0.84 
439 Namba 2018 Cause of pain Neck pain 1.11 (1.03-1.19) 0.007 
440 Namba 2018 Cause of pain Osteoarthritis 1.06 (0.97-1.16) 0.17 
441 Namba 2018 Cause of pain Other musculoskeletal pain 1.14 (0.95-1.36) 0.157 
442 Namba 2018 Cause of pain Nonspecific chronic pain 1.08 (1.04-1.13) <0.001 
443 Nelson 2020 Age Age 66-70 1.55 (1.16-2.06)  
0.004 (overall age) 
444 Nelson 2020 Age Age 71-75 1.09 (0.81-1.46)  
0.004 (overall age) 
445 Nelson 2020 Age Age 76-80 1.25 (0.93-1.69)  
0.004 (overall age) 
446 Nelson 2020 Gender Female 1.02 (0.84-1.23) 0.837 
447 Nelson 2020 Race/ethnicity Hispanic 1.33 (0.90-1.97)  
0.235 (overall race) 
448 Nelson 2020 Race/ethnicity Non-Hispanic Black 1.00 (0.67-1.51)  
0.235 (overall race) 
449 Nelson 2020 Race/ethnicity Non-Hispanic Other 0.79 (0.54-1.15)  
0.235 (overall race) 
450 Nelson 2020 Residence Metropolitan 1.02 (0.81-1.29)  
0.15 (overall residence) 
451 Nelson 2020 Residence Urban 1.45 (0.97-2.18) 
0.15 (overall residence) 
452 Nelson 2020 Residence Less urban 0.80 (0.56-1.15) 
0.15 (overall residence) 
453 Nelson 2020 Residence Rural/unknown  0.93 (0.53-1.62)  
0.15 (overall residence) 
454 Nelson 2020 Social Not married 0.99 (0.82-1.21) 0.457 
455 Nelson 2020 omitted HS educ in zip code, no 5.66-10.5% 1.09 (0.83-1.42)  
<0.001 (overall) 
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457 Nelson 2020 omitted HS educ in zip code, no >=19.35% 1.86 (1.32-2.61)  
<0.001 (overall) 
458 Nelson 2020 Income Below poverty line in zip code 5.24-10.03% 1.15 (0.88-1.50)  
0.647 (overall) 
459 Nelson 2020 Income Below poverty line in zip code 10.03-18.19% 1.11 (0.82-1.51)  
0.647 (overall) 
460 Nelson 2020 Income Below poverty line in zip code >=18.19% 1.00 (0.70-1.43)  
0.647 (overall) 
461 Nelson 2020 Cause of pain Lung cancer stage, various 0.667 (overall) 
462 Nelson 2020 Cause of pain Lung surgery type, various 0.341 (overall) 
463 Nelson 2020 Cause of pain Thoroscopic surgery 0.75 (0.62-0.90) 0.003 
464 Nelson 2020 Nonpain tx Adjuvant radiation 1.36 (1.06-1.74)  
0.037 (overall) 
465 Nelson 2020 Nonpain tx Neoadjuvant radiation 1.47 (0.70-3.09)  
0.037 (overall) 
466 Nelson 2020 Nonpain tx Adjuvant chemotherapy 1.87 (1.49-2.33)  
<0.001 (overall) 
467 Nelson 2020 Nonpain tx Neoadjuvant chemotherapy 0.87 (0.48-1.56)  
<0.001 (overall) 
468 Nelson 2020 Cause of pain Lung cancer grade, various 0.213 (overall) 
469 Nelson 2020 Comorbidity Charlson comorbidity 1 1.34 (1.10-1.64)  
0.010 (overall) 
470 Nelson 2020 Comorbidity Charlson comorbidity 2+ 1.27 (1.00-1.60)  
0.010 (overall) 
471 Park 2010 Age Age (>=65) -0.157 0.201 
472 Park 2010 Gender Male 3.102 0.086 
473 Park 2010 Race/ethnicity Minority 0.102 0.929 
474 Park 2010 Cause of pain Cancer 0.512 0.774 
475 Park 2010 Pain Pain severity (Brief Pain Inventory (BPI)) 0.226 0.043 
476 Park 2010 Pain Duration of pain (6 mo or longer) 2.956 0.391 
477 Park 2010 Activities of Daily 
Living 
Older American Resources and Services Activities of Daily 
Living (OARS ADL) 
-0.498 0.007 
478 Park 2010 Substance misuse CAGE 1.187 0.024 
479 Park 2010 Mental health Center for Epidemiologic Studies Depression Scale-10 (CESD-
10) 
0.366 0.024 
480 Park 2010 Mental health Existential Well-Being Subscale of the Spiritual Well-Being 
Scale (EWB) 
-0.024 0.697 
481 Park 2010 Social Lubben Social Network Scale (LSNS) -0.073 0.585 
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482 Park 2010 Social ENRICH Social Support Instrument (ESSI) -0.268 0.072 
483 Rao 2018 Gender Female 1.10 (1.03-1.17) 0.006 
484 Rao 2018 Race/ethnicity African American 0.88 (0.78-1.00) 0.043 
485 Rao 2018 Race/ethnicity Asian 1.17 (0.95-1.43) 0.133 
486 Rao 2018 Race/ethnicity Hispanic 1.02 (0.92-1.12) 0.757 
487 Rao 2018 Race/ethnicity Other race 1.60 (1.29-1.98) <0.001 
488 Rao 2018 Comorbidity BMI 30-34.9 1.01 (0.93-1.09) 0.830 
489 Rao 2018 Comorbidity BMI ≥35 0.96 (0.88-1.06) 0.409 
490 Rao 2018 Comorbidity ASA class ≥3 1.15 (1.06-1.23) <0.001 
491 Rao 2018 Opioid amount Preoperative opioid Rx: 1-4 Rx 2.15 (1.85-2.51) <0.001 
492 Rao 2018 Opioid amount Preoperative opioid Rx: >=5 Rx 9.83 (8.53-11.32) <0.001 
493 Rao 2018 Comorbidity Chronic blood loss anemia 0.78 (0.60-1.02) 0.068 
494 Rao 2018 Comorbidity Chronic pulmonary disease 1.04 (0.96-1.13) 0.296 
495 Rao 2018 Comorbidity Coagulopathy 1.24 (1.00-1.53) 0.054 
496 Rao 2018 Comorbidity Congestive heart failure 1.08 (0.93-1.25) 0.335 
497 Rao 2018 Comorbidity Deficiency anemia 1.07 (0.97-1.19) 0.154 
498 Rao 2018 Comorbidity Diabetes 0.96 (0.87-1.06) 0.443 
499 Rao 2018 Comorbidity Fluid and electrolyte disorders 1.03 (0.92-1.17) 0.571 
500 Rao 2018 Comorbidity Hypertension 1.05 (0.97-1.15) 0.230 
501 Rao 2018 Comorbidity Hypothyroidism 1.00 (0.90-1.10) 0.977 
502 Rao 2018 Comorbidity Liver disease 1.01 (0.86-1.20) 0.867 
503 Rao 2018 Comorbidity Neurodegenerative disorders 1.17 (1.04-1.31) 0.010 
504 Rao 2018 Comorbidity Paralysis 0.71 (0.47-1.08) 0.107 
505 Rao 2018 Comorbidity Peripheral vascular disease 0.92 (0.82-1.02) 0.096 
506 Rao 2018 Comorbidity Renal failure 0.97 (0.88-1.06) 0.482 
507 Rao 2018 Comorbidity Rheumatoid arthritis/collagen vascular disease 1.03 (0.90-1.17) 0.680 
508 Rao 2018 Comorbidity Valvular disease 1.00 (0.86-1.16) 0.965 
509 Rao 2018 Comorbidity Weight loss 0.92 (0.75-1.14) 0.461 
510 Rao 2018 Mental health Anxiety 1.11 (1.03-1.20) 0.005 
511 Rao 2018 Mental health Bipolar disorder 0.88 (0.72-1.06) 0.182 
512 Rao 2018 Mental health Dementia and psychosis 1.03 (0.94-1.13) 0.498 
513 Rao 2018 Mental health Depression 1.08 (1.00-1.17) 0.042 
514 Rao 2018 Opioid duration Opioid dependence 1.23 (1.05-1.43) 0.010 
515 Rao 2018 Mental health Post-traumatic stress disorder 1.25 (0.96-1.63) 0.099 
516 Rao 2018 Substance misuse Substance abuse 1.17 (1.07-1.28) <0.001 
517 Rao 2018 Cause of pain Arthritis 0.92 (0.83-1.01) 0.084 
518 Rao 2018 Cause of pain Chronic back pain, h/o 1.21 (1.12-1.29) <0.001 
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519 Rao 2018 Cause of pain Carpal tunnel 1.06 (0.85-1.32) 0.630 
520 Rao 2018 Cause of pain Fibromyalgia 1.20 (1.04-1.38) 0.013 
521 Rao 2018 Cause of pain Fractures and contusions with chronic pain, h/o 0.86 (0.75-0.99) 0.040 
522 Rao 2018 Cause of pain Limb extremity pain, chronic, h/o 0.70 (0.58-0.85) <0.001 
523 Rao 2018 Cause of pain Neck pain, chronic, h/o 0.99 (0.89-1.11) 0.856 
524 Rao 2018 Cause of pain Osteoarthritis 0.98 (0.88-1.08) 0.651 
525 Rao 2018 Cause of pain Other musculoskeletal pain, chronic, h/o 1.07 (0.86-1.34) 0.523 
526 Rao 2018 Cause of pain Abdominal pain/hernia, chronic, h/o 0.92 (0.79-1.08) 0.328 
527 Rao 2018 Cause of pain General chronic pain 1.38 (1.28-1.50) <0.001 
528 Rao 2018 Cause of pain Kidney/gall stones pain, h/o 1.18 (0.91-1.53) 0.202 
529 Rao 2018 Cause of pain Migraines 1.08 (0.92-1.26) 0.329 
530 Rao 2018 Cause of pain Neurologic pain, chronic 0.91 (0.83-1.01) 0.068 
531 Rao 2018 Cause of pain Tension headache, chronic, h/o 1.15 (0.92-1.45) 0.219 
532 Santosa 2020 Opioid amount High-risk prescribing: Opioid overlap 5.15 (4.03 6.59) <0.001 
533 Santosa 2020 Benzo High-risk prescribing: Benzodiazepine overlap 4.83 (4.08 5.71) <0.001 
534 Santosa 2020 Opioid type High-risk prescribing: Use of long-acting opioids 2.87 (2.18 3.76) <0.001 
535 Santosa 2020 Opioid amount High-risk prescribing: Opioid doses ≥100 MME 1.22 (1.09 1.36) <0.001 
536 Santosa 2020 Cause of pain Major surgery 1.24 (1.17 1.31) <0.001 
537 Santosa 2020 Opioid prescription Filled a prescription for opioids within 30 days before surgery 1.67 (1.58 1.77) <0.001 
538 Santosa 2020 Opioid amount Total prescription filled between the month before surgery and 2 
weeks after discharge >=75th percentile (300 OMEs) 
1.44 (1.37 1.52) <0.001 
539 Santosa 2020 Benzo Filled benzos, sedatives, hypnotics, anxiolytic prescriptions 
within 30 days before surgery 
1.24 (1.14 1.35) <0.001 
540 Santosa 2020 Comorbidity Filled Anticoagulant Prescriptions within 30 days before surgery 1.03 (0.77 1.39) 0.822 
541 Santosa 2020 Age Age 70-74 0.94 (0.88 1.00) 0.068 
542 Santosa 2020 Age Age 75-79 1.02 (0.95 1.10) 0.513 
543 Santosa 2020 Age Age 80-84 1.04 (0.96 1.13) 0.330 
544 Santosa 2020 Age Age ≥85 1.09 (0.99 1.21) 0.085 
545 Santosa 2020 Gender Female 1.02 (0.97 1.07) 0.413 
546 Santosa 2020 Race/ethnicity Black 1.23 (1.12 1.36) <0.001 
547 Santosa 2020 Race/ethnicity Hispanic 1.07 (0.91 1.25) 0.401 
548 Santosa 2020 Race/ethnicity Race, Other 0.64 (0.54 0.75) <0.001 
549 Santosa 2020 Residence Metropolitan counties 1.02 (0.96 1.08) 0.549 
550 Santosa 2020 omitted East south central 1.27 (1.15 1.40) <0.001 
551 Santosa 2020 omitted Middle Atlantic 0.85 (0.77 0.93) 0.001 
552 Santosa 2020 omitted Mountain 1.11 (1.00 1.24) 0.061 
553 Santosa 2020 omitted New England 0.85 (0.74 0.97) 0.016 
554 Santosa 2020 omitted Pacific 0.95 (0.87 1.04) 0.292 
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555 Santosa 2020 omitted South Atlantic 1.01 (0.93 1.10) 0.821 
556 Santosa 2020 omitted West north central 1.01 (0.92 1.12) 0.812 
557 Santosa 2020 omitted West south central 1.17 (1.07 1.28) 0.001 
558 Santosa 2020 Income Medicaid eligible 1.45 (1.35 1.55) <0.001 
559 Santosa 2020 Comorbidity Charlson comorbidity index 1, 2 1.18 (1.11 1.27) <0.001 
560 Santosa 2020 Comorbidity Charlson comorbidity index CCI 3, 4 1.41 (1.31 1.52) <0.001 
561 Santosa 2020 Comorbidity Charlson comorbidity index ≥5 1.71 (1.58 1.84) <0.001 
562 Santosa 2020 Tobacco History of tobacco use 1.03 (0.97 1.09) 0.381 
563 Santosa 2020 Mental health Adjustment disorder 0.99 (0.82 1.18) 0.877 
564 Santosa 2020 Mental health Anxiety disorder 1.07 (1.00 1.15) 0.058 
565 Santosa 2020 Mental health Mood disorder 1.16 (1.09 1.24) <0.001 
566 Santosa 2020 Mental health Suicide or self-harm history 1.60 (1.05 2.44) 0.029 
567 Santosa 2020 Mental health Disruptive disorder 0.80 (0.56 1.13) 0.207 
568 Santosa 2020 Mental health Personality disorder 1.32 (0.90 1.93) 0.157 
569 Santosa 2020 Mental health Psychosis 0.97 (0.83 1.13) 0.689 
570 Santosa 2020 Substance misuse Alcohol or substance abuse disorders 1.38 (1.20 1.59) <0.001 
571 Santosa 2020 Cause of pain Arthritis pain 1.01 (0.95 1.07) 0.810 
572 Santosa 2020 Cause of pain Back pain 1.16 (1.07 1.27) 0.001 
573 Santosa 2020 Cause of pain Neck pain 0.92 (0.80 1.04) 0.181 
574 Schepis 2019 Opioid use Past‐year Opioid use, without misuse 1.00 (0.73‐1.37) 
575 Schepis 2019 Opioid misuse Past‐year Opioid misuse 1.84 (1.07‐3.19) 
576 Shah 2019 Comorbidity Years since cancer diagnosis 1.09 (1.08-1.10) 
577 Shah 2019 Age Age 75-84 0.96 (0.91-1.01) 
578 Shah 2019 Age Age >=85 0.83 (0.78-0.89) 
579 Shah 2019 Gender Female 1.40 (1.31-1.50) 
580 Shah 2019 Race/ethnicity Black 1.01 (0.93-1.10) 
581 Shah 2019 Race/ethnicity Hispanic 0.78 (0.73-0.83) 
582 Shah 2019 Race/ethnicity Other race 0.61 (0.52-0.73) 
583 Shah 2019 Residence Urban 1.10 (1.04-1.16) 
584 Shah 2019 Residence Rural 1.05 (0.90-1.23) 
585 Shah 2019 Cause of pain Breast cancer 1.06 (0.96-1.16) 
586 Shah 2019 Cause of pain Lung cancer 1.21 (1.06-1.37) 
587 Shah 2019 Cause of pain Colorectal cancer 0.99 (0.90-1.09) 
588 Shah 2019 Opioid use Opioid naïve 0.11 (0.10-0.11) 
589 Shah 2019 Income Medicaid eligible 1.57 (1.49-1.66) 
590 Shah 2019 Comorbidity Charlson Comorbidity Score ≥1 1.29 (1.23-1.36) 
591 Shah 2019 Mental health Depression 1.32 (1.23-1.41) 
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592 Shah 2019 Substance misuse Alcohol abuse 1.27 (0.95-1.69) 
593 Shah 2019 Substance misuse Drug abuse 2.51 (1.96-3.22) 
594 Shah 2019 Comorbidity Years since cancer diagnosis 1.33 (1.32-1.35) 
595 Shah 2019 Age Age 75-84 1.03 (0.94-1.13) 
596 Shah 2019 Age Age >=85 0.97 (0.86-1.10) 
597 Shah 2019 Gender Female 1.50 (1.32-1.72) 
598 Shah 2019 Race/ethnicity Black 1.00 (0.86-1.18) 
599 Shah 2019 Race/ethnicity Hispanic 0.86 (0.76-0.97) 
600 Shah 2019 Race/ethnicity Other race 0.68 (0.50-0.91) 
601 Shah 2019 Residence Urban 1.21 (1.10-1.33) 
602 Shah 2019 Residence Rural 1.20 (0.92-1.57) 
603 Shah 2019 Cause of pain Breast cancer 1.00 (0.84-1.19) 
604 Shah 2019 Cause of pain Lung cancer 1.09 (0.83-1.43) 
605 Shah 2019 Cause of pain Colorectal cancer 0.99 (0.83-1.18) 
606 Shah 2019 Income Medicaid eligible 1.62 (1.46-1.81) 
607 Shah 2019 Comorbidity Charlson Comorbidity Score ≥1 1.53 (1.40-1.67) 
608 Shah 2019 Mental health Depression 1.35 (1.16-1.58) 
609 Shah 2019 Substance misuse Alcohol abuse 1.25 (0.63-2.50) 
610 Shah 2019 Substance misuse Drug abuse 1.76 (0.81-3.82) 
611 Suda 2017 Gender Female 1.08 0.384 
612 Suda 2017 Age Age 71-75 0.85 0.095 
613 Suda 2017 Age Age 76-80 0.63 <0.0001 
614 Suda 2017 Age Age 81-85 0.59 <0.0001 
615 Suda 2017 Age Age 86-90 0.47 <0.0001 
616 Suda 2017 Age Age >91 0.42 0.001 
617 Suda 2017 Race/ethnicity African American 0.76 0.053 
618 Suda 2017 Race/ethnicity Non-Hispanic 1.19 0.431 
619 Suda 2017 Insurance No copay 2.95 <0.0001 
620 Suda 2017 Insurance Some copay 1.94 <0.0001 
621 Suda 2017 Residence 5-20 miles 1.12 0.235 
622 Suda 2017 Residence 21-40 miles 1.29 0.007 
623 Suda 2017 Residence 41-60 miles 1.37 0.004 
624 Suda 2017 Residence >60 miles 0.96 0.777 
625 Suda 2017 Income Median household income, per $10,000 0.87 0.001 
626 Suda 2017 Income Percent below poverty level, per % 0.99 0.038 
627 Suda 2017 Residence Rural 1.30 0.001 
628 Suda 2017 Comorbidity Hierarchical Condition Category (HCC) risk score, per point 1.10 <0.0001 
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629 Suda 2017 Tobacco Smoking 1.13 0.104 
630 Suda 2017 Mental health Suicide or self injury 0.87 0.830 
631 Suda 2017 Mental health Sleep disorder 2.00 <0.0001 
632 Suda 2017 Mental health Psychiatric diagnosis 2.30 <0.0001 
633 Suda 2017 Substance misuse Substance abuse 1.88 <0.0001 
634 Suda 2017 Substance misuse Alcohol abuse 1.02 0.854 
635 Suda 2017 Healthcare 
utilization 
Primary care (Medicare), per day (implied) 1.04 <0.0001 
636 Suda 2017 Healthcare 
utilization 
Specialty care (Medicare), per day (implied) 1.01 <0.0001 
637 Suda 2017 Healthcare 
utilization 
Length of stay (Medicare), per day (implied) 1.01 0.009 
638 Taipale 2019 Opioid use Opioid user 1.96 (1.27-3.02) 
639 Taipale 2019 Opioid duration 1-60 d opioid use 2.37 (1.04-5.41) 
640 Taipale 2019 Opioid duration 61-180 d opioid use 1.79 (0.82-3.89) 
641 Taipale 2019 Opioid duration 181-365 d opioid use 1.43 (0.61-3.37) 
642 Taipale 2019 Opioid duration >365 d opioid use 2.59 (0.92-7.28) 
643 Taipale 2019 Opioid type Weak opioid 1.75 (0.91-3.35) 
644 Taipale 2019 Opioid type Buprenorphine 2.10 (1.41-3.13) 
645 Taipale 2019 Opioid type Strong opioid 2.89 (1.32-6.32) 
646 Vozoris 2016 Opioid use New opioid use 2.16 (1.61–2.88) 
647 Vozoris 2016 Opioid use New opioid use 1.76 (1.57–1.98) 
648 Vozoris 2016 Opioid use New opioid use 0.88 (0.83–0.94) 
649 Vozoris 2016 Opioid use New opioid use 1.14 (1.00–1.29) 
650 Vozoris 2016 Opioid use New opioid use 1.08 (0.97–1.21) 
651 Vozoris 2016 Opioid use New opioid use 0.99 (0.74–1.33) 
652 Zeng 2019 Opioid type Tramadol 2.00 (1.33, 3.01) 
653 Zoorob 2018 Benzo Benzodiazepine, % 1.356 <0.05 
654 Zoorob 2018 Opioid use Opioid % 1.124 <0.01 
655 Zoorob 2018 Benzo Benzod, %, * opioid, % (interaction) 1.077 <0.01 
656 Zoorob 2018 Income Income 1.001 >0.10 
657 Zoorob 2018 Income Poverty, % 1.128 <0.01 
658 Zoorob 2018 Race/ethnicity Hispanic, % 0.960 <0.01 
659 Zoorob 2018 Race/ethnicity Black, % 0.908 <0.01 
660 Zoorob 2018 Residence Rural 0.763 <0.01 




Table D-3c. Studies with multivariable analyses of associations: Other information 
Row Author Year Metric Comparator Note 
1 Al Dabbagh 2016 HR <70 Outcome is a "good" outcome 
2 Al Dabbagh 2016 HR Male ditto 
3 Al Dabbagh 2016 HR Closed ditto 
4 Alam 2012 OR no prescription  
5 Brescia 2019 OR No  
6 Brescia 2019 OR Other CT surgery  
7 Brescia 2019 OR Post-surgery Rx  
8 Brescia 2019 OR (continuous)  
9 Brescia 2019 OR (continuous)  
10 Brescia 2019 OR (continuous)  
11 Brescia 2019 OR Male  
12 Brescia 2019 OR White  
13 Brescia 2019 OR No  
14 Brescia 2019 OR Old age  
15 Brescia 2019 OR 0-2 Similar, stronger for higher scores 
16 Brescia 2019 OR No  
17 Brescia 2019 OR No  
18 Brescia 2019 OR No  
19 Brescia 2019 OR No  
20 Brescia 2019 OR No  
21 Brescia 2019 OR No  
22 Cancienne 2018 OR Unclear  
23 Cancienne 2018 OR Unclear  
24 Cancienne 2018 OR Unclear  
25 Cancienne 2018 OR Unclear  
26 Cancienne 2018 OR Unclear  
27 Cancienne 2018 OR No  
28 Cancienne 2018 OR No  
29 Cancienne 2018 OR No  
30 Cancienne 2018 OR No  
31 Cancienne 2018 OR No  
32 Cancienne 2018 OR No  
33 Cancienne 2018 OR No  
34 Cancienne 2018 OR No  
35 Cancienne 2018 OR No  
36 Cancienne 2018 OR Female  
37 Cancienne 2018 OR No  
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38 Cancienne 2018 OR No  
39 Cancienne 2018 OR No  
40 Cancienne 2018 OR No  
41 Cancienne 2018 OR No  
42 Cancienne 2018 OR No  
43 Carey 2018 RR No possible misuse  
44 Carey 2018 RR No possible misuse  
45 Carey 2018 RR No possible misuse  
46 Carey 2018 RR No possible misuse  
47 Carey 2018 RR No possible misuse  
48 Carey 2018 RR No possible misuse  
49 Carter 2019 OR No  
50 Carter 2019 OR >=85  
51 Carter 2019 OR >=85  
52 Carter 2019 OR Male  
53 Carter 2019 OR (continuous)  
54 Carter 2019 OR No  
55 Carter 2019 OR No  
56 Carter 2019 OR Medicare  
57 Carter 2019 OR Medicare  
58 Carter 2019 OR Middle quartiles  
59 Carter 2019 OR Middle quartiles  
60 Carter 2019 OR No  
61 Choi 2017 OR No  
62 Choi 2017 OR (continuous)  
63 Choi 2017 OR Female  
64 Choi 2017 OR Non-Hispanic White  
65 Choi 2017 OR Non-Hispanic White  
66 Choi 2017 OR Non-Hispanic White  
67 Choi 2017 OR No  
68 Choi 2017 OR No  
69 Choi 2017 OR No  
70 Choi 2017 OR (continuous)  
71 Choi 2017 OR No  
72 Choi 2017 OR None  
73 Choi 2017 OR None  
74 Choi 2017 OR No  
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75 Choi 2017 OR No  
76 Choi 2017 OR No  
77 Choi 2017 OR No  
78 Choi 2017 OR No  
79 Choi 2019 OR No use  
80 Choi 2019 OR No use  
81 Choi 2019 OR No use  
82 Choi 2019 OR No use  
83 Choi 2019 Incident rate ratio No use  
84 Choi 2019 Incident rate ratio No use  
85 Choi 2019 Incident rate ratio No use  
86 Choi 2019 Incident rate ratio No use  
87 Cochran 2017 Incidence rate ratio (continuous) 0-10 behaviors based on the Drug Abuse Screening Test-
10 (DAST-10) 
88 Cochran 2017 Incidence rate ratio (continuous) 0 to 12 scores based on Alcohol Use Disorders 
Identification Test-C (AUDIT-C) 
89 Cochran 2017 Incidence rate ratio (continuous) 0 to 6 based on Patient Health Question-2 (PHQ-2) 
90 Cochran 2017 Incidence rate ratio (continuous) 0 to 4 based on the Primary Care-Posttraumatic Stress 
Disorder assessment 
91 Cochran 2017 Incidence rate ratio (continuous) Subscale from Short-Form Survey 12 (SF-12) 
92 Cochran 2017 Incidence rate ratio (continuous) Subscale from Short-Form Survey 12 (SF-12) 
93 Cochran 2017 Incidence rate ratio Male  
94 Cochran 2017 Incidence rate ratio High school education 
or more 
 
95 Cochran 2017 Incidence rate ratio Urban pharmacy  
96 Curtis 2017 OR .  
97 Curtis 2017 OR Female  
98 Curtis 2017 OR African American  
99 Curtis 2017 OR African American  
100 Curtis 2017 OR No  
101 Curtis 2017 OR No  
102 Curtis 2017 OR No  
103 Curtis 2017 OR No  
104 Curtis 2017 OR No  
105 Curtis 2017 OR No  
106 Curtis 2017 OR No  
107 Curtis 2017 OR No  
108 Curtis 2017 OR No  
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109 Curtis 2017 OR No  
110 Curtis 2017 OR No  
111 Curtis 2017 OR No  
112 Curtis 2017 OR No  
113 Curtis 2017 OR No  
114 Curtis 2017 OR No  
115 Curtis 2017 OR No  
116 Curtis 2017 OR No fill of NSAID  
117 Curtis 2017 OR No fill of NSAID  
118 Curtis 2017 OR No  
119 Curtis 2017 OR No  
120 Curtis 2017 OR Quartile 4 (highest)  
121 Curtis 2017 OR Quartile 4 (highest)  
122 Curtis 2017 OR Quartile 4 (highest)  
123 Daoust 2018 OR Male  
124 Daoust 2018 OR Fall  
125 Daoust 2018 OR Fall  
126 Daoust 2018 OR 1 injury  
127 Daoust 2018 OR 1 injury  
128 Daoust 2018 OR No  
129 Daoust 2018 OR No  
130 Daoust 2018 OR No  
131 Daoust 2018 OR No  
132 Daoust 2018 OR No  
133 Daoust 2018 OR No  
134 Daoust 2018 OR No  
135 Daoust 2018 OR No  
136 Daoust 2018 OR No  
137 Daoust 2018 OR No  
138 Daoust 2018 OR 0 prescriptions  
139 Daoust 2018 OR 0 prescriptions  
140 Daoust 2018 OR No  
141 Dasinger 2019 OR No opioids  
142 Dasinger 2019 OR No opioids  
143 Dasinger 2019 OR No opioids  
144 Dasinger 2019 OR No  
145 Dasinger 2019 OR No  
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146 Gold 2016 RRR No Multiple prescribers, fake Rx, stole, from friend or relative 
(free or bought), from drug dealer or internet, "some other 
way" 
147 Gold 2016 RRR 60-64 ditto 
148 Gold 2016 RRR 60-64 ditto 
149 Gold 2016 RRR 60-64 ditto 
150 Gold 2016 RRR 60-64 ditto 
151 Gold 2016 RRR 60-64 ditto 
152 Gold 2016 RRR Male ditto 
153 Gold 2016 RRR No college ditto 
154 Gold 2016 RRR No college ditto 
155 Gold 2016 RRR (continuous) ditto 
156 Gold 2016 RRR (continuous) ditto 
157 Gold 2016 RRR No ditto 
158 Gold 2016 RRR No ditto 
159 Grigoras 2018 Coefficient (continuous)  
160 Grigoras 2018 Coefficient (continuous)  
161 Grigoras 2018 Coefficient (continuous)  
162 Grigoras 2018 Coefficient (continuous)  
163 Grigoras 2018 Coefficient (continuous)  
164 Grigoras 2018 Coefficient (continuous)  
165 Grigoras 2018 Coefficient (continuous)  
166 Grigoras 2018 Coefficient (continuous)  
167 Grigoras 2018 Coefficient (continuous) Top 25% 
168 Grigoras 2018 Coefficient (continuous)  
169 Grigoras 2018 Coefficient (continuous)  
170 Grigoras 2018 Coefficient (continuous)  
171 Grigoras 2018 Coefficient (continuous)  
172 Grigoras 2018 Coefficient (continuous)  
173 Grigoras 2018 Coefficient (continuous)  
174 Grigoras 2018 Coefficient (continuous)  
175 Grigoras 2018 Coefficient (continuous)  
176 Grigoras 2018 Coefficient (continuous)  
177 Grigoras 2018 Coefficient (continuous)  
178 Grigoras 2018 Coefficient (continuous)  
179 Grigoras 2018 Coefficient (continuous)  
180 Grigoras 2018 Coefficient (continuous)  
181 Grigoras 2018 Coefficient (continuous)  
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182 Grigoras 2018 Coefficient (continuous)  
183 Hadlandsmyth 2018 RR Male No Long-Term Opioids Before TKA  
(model for + long term use generally has smaller 
associations) 
184 Hadlandsmyth 2018 RR (est) 60-70 ditto 
185 Hadlandsmyth 2018 RR Caucasian ditto 
186 Hadlandsmyth 2018 RR Caucasian ditto 
187 Hadlandsmyth 2018 RR Normal weight ditto 
188 Hadlandsmyth 2018 RR Normal weight ditto 
189 Hadlandsmyth 2018 RR No ditto 
190 Hadlandsmyth 2018 RR 0-1 ditto 
191 Hadlandsmyth 2018 RR 0-1 ditto 
192 Hadlandsmyth 2018 RR 0-1 ditto 
193 Hadlandsmyth 2018 RR No ditto 
194 Hadlandsmyth 2018 RR No ditto 
195 Hadlandsmyth 2018 RR No ditto 
196 Hadlandsmyth 2018 RR None ditto 
197 Hadlandsmyth 2018 RR None ditto 
198 Hadlandsmyth 2018 RR None ditto 
199 Hadlandsmyth 2018 RR None ditto 
200 Hadlandsmyth 2018 RR None ditto 
201 Hadlandsmyth 2018 RR None ditto 
202 Hadlandsmyth 2018 RR None ditto 
203 Hadlandsmyth 2018 RR None ditto 
204 Hadlandsmyth 2018 RR None ditto 
205 Hadlandsmyth 2018 RR None ditto 
206 Hadlandsmyth 2018 RR (continuous) ditto 
207 Hadlandsmyth 2018 RR Bilateral ditto 
208 Hamina 2017 OR No  
209 Hamina 2017 OR Male  
210 Hamina 2017 OR <80  
211 Hamina 2017 OR High  
212 Hamina 2017 OR High  
213 Hamina 2017 OR No  
214 Hamina 2017 OR No  
215 Hamina 2017 OR No  
216 Hamina 2017 OR No  
217 Hamina 2017 OR No  
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218 Hamina 2017 OR No  
219 Hamina 2017 OR No  
220 Hamina 2017 OR No  
221 Hoffman 2017 HR <90 days  
222 Hoffman 2017 HR <90 days  
223 Hoffman 2017 HR <90 days  
224 Hoffman 2017 HR <90 days  
225 Hoffman 2017 HR <90 days  
226 Hoffman 2017 HR <90 days  
227 Hoffman 2017 HR <90 days  
228 Hoffman 2017 HR <90 days  
229 Inacio 2016 OR Male  
230 Inacio 2016 OR No  
231 Inacio 2016 OR No  
232 Inacio 2016 OR No  
233 Inacio 2016 OR No  
234 Inacio 2016 OR No  
235 Inacio 2016 OR No  
236 Inacio 2016 OR No  
237 Inacio 2016 OR No  
238 Inacio 2016 OR No  
239 Inacio 2016 OR No  
240 Inacio 2016 OR No  
241 Inacio 2016 OR No  
242 Inacio 2016 OR No  
243 Inacio 2016 OR No  
244 Inacio 2016 OR No  
245 Inacio 2016 OR No  
246 Inacio 2016 OR No  
247 Jain 2018 OR No  
248 Jain 2018 OR No  
249 Jain 2018 OR No  
250 Jain 2018 OR No  
251 Jain 2018 OR No  
252 Jain 2018 OR No  
253 Jain 2018 OR No  
254 Jain 2018 OR No  
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Row Author Year Metric Comparator Note 
255 Jain 2018 OR No  
256 Jain 2018 OR <=80  
257 Jeffery 2018 RR Guideline concordant 
(≤3 d & ≤50 MME/d & 
not long acting) 
ED setting 
258 Jeffery 2018 RR Guideline concordant 
(≤3 d & ≤50 MME/d & 
not long acting) 
Non-ED setting 
259 Jena 2014 OR 0 providers (implied)  
260 Jena 2014 OR 0 providers (implied)  
261 Jena 2014 OR 0 providers (implied)  
262 Jena 2014 OR 0 providers (implied)  
263 Jena 2014 OR ≥85  
264 Jena 2014 OR ≥85  
265 Jena 2014 OR Non-Hispanic white Other races smaller associations 
266 Jena 2014 OR Male  
267 Jena 2014 OR Metropolitan area  
268 Jena 2014 OR (continuous)  
269 Jena 2014 OR Non-eligible for subsidy  
270 Jena 2014 OR Non-eligible for subsidy  
271 Jena 2014 OR No  
272 Jena 2014 OR No  
273 Jena 2014 OR No  
274 Jena 2014 OR No  
275 Jena 2014 OR No  
276 Jena 2014 OR No  
277 Jena 2014 OR No  
278 Jena 2014 OR No  
279 Karttunen 2019 OR No  
280 Karttunen 2019 OR <80 Separate analyses for AD and no AD 
281 Karttunen 2019 OR High ditto 
282 Karttunen 2019 OR High ditto 
283 Karttunen 2019 OR No ditto 
284 Karttunen 2019 OR No ditto 
285 Karttunen 2019 OR No ditto 
286 Karttunen 2019 OR No ditto 
287 Karttunen 2019 OR No ditto 
288 Karttunen 2019 OR No ditto 
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289 Karttunen 2019 OR No ditto 
290 Karttunen 2019 OR No ditto 
291 Karttunen 2019 OR No ditto 
292 Karttunen 2019 OR No ditto 
293 Karttunen 2019 OR No ditto 
294 Kuo 2016 OR No  
295 Kuo 2016 OR No  
296 Kuo 2016 OR No  
297 Kuo 2016 OR No  
298 Lalic 2018 OR Female 2 models (65-84 yo; 85-99 yo); Stronger association 
chosen here 
299 Lalic 2018 OR No ditto 
300 Lalic 2018 OR Weak opioid ditto 
301 Lalic 2018 OR Oral opioid ditto 
302 Lalic 2018 OR MEq <250 ditto 
303 Lalic 2018 OR MEq <250 ditto 
304 Lalic 2018 OR MEq <250 ditto 
305 Lalic 2018 OR 0 comorbidities ditto 
306 Lalic 2018 OR 0 comorbidities ditto 
307 Lalic 2018 OR 0 comorbidities ditto 
308 Lalic 2018 OR No ditto 
309 Lalic 2018 OR No ditto 
310 Lalic 2018 OR No ditto 
311 Lalic 2018 OR No ditto 
312 Lalic 2018 OR No ditto 
313 Lalic 2018 OR No ditto 
314 Lalic 2018 OR No ditto 
315 Lalic 2018 OR No ditto 
316 Lalic 2018 OR No ditto 
317 Lalic 2018 OR No ditto 
318 Lindestrand 2015 OR Female Also 3 mo analysis 
319 Lindestrand 2015 OR <82 ditto 
320 Lindestrand 2015 OR No ditto 
321 Lindestrand 2015 OR No ditto 
322 Lindestrand 2015 OR No ditto 
323 Lindestrand 2015 OR 0-1 ditto 
324 Lindestrand 2015 OR No ditto 
325 Lindestrand 2015 OR No ditto 
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326 Lindestrand 2015 OR No ditto 
327 Lindestrand 2015 OR No ditto 
328 Lindestrand 2015 OR No 3 mo (6 mo smaller, NS effect) 
329 Lo-Ciganic 2019 importance  Importance is a measure of each variable’s cumulative 
contribution toward reducing square error, or 
heterogeneity within the subset, after the data set is 
sequentially split according to that variable. Thus, 
importance reflects a variable’s significance in prediction. 
330 Lo-Ciganic 2019 importance  ditto 
331 Lo-Ciganic 2019 importance  ditto 
332 Lo-Ciganic 2019 importance  ditto 
333 Lo-Ciganic 2019 importance  ditto 
334 Lo-Ciganic 2019 importance  ditto 
335 Lo-Ciganic 2019 importance  ditto 
336 Loeb 2020 OR Very low risk Also (but lower) for lower categories: Low-Regional mets 
337 Loeb 2020 OR CCI 0 Similar for CCI 1, 2 
338 Loeb 2020 OR Married  
339 Loeb 2020 OR Low Similar for intermediate education 
340 McDermott 2019 OR 66-69 Also 3 mo analysis 
341 McDermott 2019 OR 66-69 ditto 
342 McDermott 2019 OR Male ditto 
343 McDermott 2019 OR White, non-Hispanic ditto 
344 McDermott 2019 OR Married ditto 
345 McDermott 2019 OR Metropolitan ditto 
346 McDermott 2019 OR (various) ditto 
347 McDermott 2019 OR 0 ditto 
348 McDermott 2019 OR 0 ditto 
349 McDermott 2019 OR Others ditto 
350 McDermott 2019 OR No ditto 
351 McDermott 2019 OR No ditto 
352 McDermott 2019 OR No ditto 
353 McDermott 2019 OR Hydrocodone ditto 
354 McDermott 2019 OR Hydrocodone ditto 
355 McDermott 2019 OR No ditto 
356 McDermott 2019 OR No ditto 
357 Musich 2019 OR Male  
358 Musich 2019 OR 65-69  
359 Musich 2019 OR 65-69  
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360 Musich 2019 OR 65-69  
361 Musich 2019 OR 65-69  
362 Musich 2019 OR (continuous)  
363 Musich 2019 OR Minority high  
364 Musich 2019 OR Minority high  
365 Musich 2019 OR Income high  
366 Musich 2019 OR Income high  
367 Musich 2019 OR Other (non-urban)  
368 Musich 2019 OR South  
369 Musich 2019 OR South  
370 Musich 2019 OR South  
371 Musich 2019 OR High coverage  
372 Musich 2019 OR High coverage  
373 Musich 2019 OR HCC <0.5  
374 Musich 2019 OR HCC <0.5  
375 Musich 2019 OR HCC <0.5  
376 Musich 2019 OR No long-acting  
377 Musich 2019 OR No tramadol  
378 Musich 2019 OR No chronic back pain  
379 Musich 2019 OR No new back pain  
380 Musich 2019 OR No TKA  
381 Musich 2019 OR No Trauma  
382 Musich 2019 OR No  
383 Musich 2019 OR No  
384 Musich 2019 OR No  
385 Musich 2019 OR No  
386 Musich 2019 OR No  
387 Musich 2019 OR No benzo  
388 Musich 2019 OR No benzo  
389 Musich 2019 OR No benzo  
390 Musich 2019 OR No depression  
391 Musich 2019 OR No depression  
392 Musich 2019 OR No depression  
393 Musich 2019 OR No anxiety  
394 Musich 2019 OR No anxiety  
395 Musich 2019 OR No anxiety  
396 Namba 2018 OR (continuous) Also data for earlier time periods 
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397 Namba 2018 OR No ditto 
398 Namba 2018 OR Male ditto 
399 Namba 2018 OR (continuous) ditto 
400 Namba 2018 OR White ditto 
401 Namba 2018 OR White ditto 
402 Namba 2018 OR White ditto 
403 Namba 2018 OR (continuous) ditto 
404 Namba 2018 OR No ditto 
405 Namba 2018 OR No ditto 
406 Namba 2018 OR No ditto 
407 Namba 2018 OR No ditto 
408 Namba 2018 OR No ditto 
409 Namba 2018 OR No ditto 
410 Namba 2018 OR No ditto 
411 Namba 2018 OR No ditto 
412 Namba 2018 OR No ditto 
413 Namba 2018 OR No ditto 
414 Namba 2018 OR No ditto 
415 Namba 2018 OR No ditto 
416 Namba 2018 OR No ditto 
417 Namba 2018 OR No ditto 
418 Namba 2018 OR No ditto 
419 Namba 2018 OR No ditto 
420 Namba 2018 OR No ditto 
421 Namba 2018 OR No ditto 
422 Namba 2018 OR No ditto 
423 Namba 2018 OR No ditto 
424 Namba 2018 OR No ditto 
425 Namba 2018 OR No ditto 
426 Namba 2018 OR No ditto 
427 Namba 2018 OR No ditto 
428 Namba 2018 OR No ditto 
429 Namba 2018 OR No ditto 
430 Namba 2018 OR No ditto 
431 Namba 2018 OR No ditto 
432 Namba 2018 OR No ditto 
433 Namba 2018 OR No ditto 
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434 Namba 2018 OR No ditto 
435 Namba 2018 OR No ditto 
436 Namba 2018 OR No ditto 
437 Namba 2018 OR No ditto 
438 Namba 2018 OR No ditto 
439 Namba 2018 OR No ditto 
440 Namba 2018 OR No ditto 
441 Namba 2018 OR No ditto 
442 Namba 2018 OR No ditto 
443 Nelson 2020 OR >80  
444 Nelson 2020 OR >80  
445 Nelson 2020 OR >80  
446 Nelson 2020 OR Male  
447 Nelson 2020 OR Non-Hispanic white  
448 Nelson 2020 OR Non-Hispanic white  
449 Nelson 2020 OR Non-Hispanic white  
450 Nelson 2020 OR Big metropolitan  
451 Nelson 2020 OR Big metropolitan  
452 Nelson 2020 OR Big metropolitan  
453 Nelson 2020 OR Big metropolitan  
454 Nelson 2020 OR Married  
455 Nelson 2020 OR <5.66%  
456 Nelson 2020 OR <5.66%  
457 Nelson 2020 OR <5.66%  
458 Nelson 2020 OR <5.24%  
459 Nelson 2020 OR <5.24%  
460 Nelson 2020 OR <5.24%  
461 Nelson 2020 OR Stage I  
462 Nelson 2020 OR Lobectomy  
463 Nelson 2020 OR Open surgery  
464 Nelson 2020 OR No RT  
465 Nelson 2020 OR No RT  
466 Nelson 2020 OR No chemotheapy  
467 Nelson 2020 OR No chemotheapy  
468 Nelson 2020 OR Well differentiated  
469 Nelson 2020 OR 0  
470 Nelson 2020 OR 0  
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471 Park 2010 B (linear association, not 
beta) 
(continuous)  
472 Park 2010 B Female  
473 Park 2010 B No  
474 Park 2010 B No  
475 Park 2010 B (continuous)  
476 Park 2010 B No  
477 Park 2010 B (continuous)  
478 Park 2010 B (continuous)  
479 Park 2010 B (continuous)  
480 Park 2010 B (continuous)  
481 Park 2010 B (continuous)  
482 Park 2010 B (continuous)  
483 Rao 2018 IRR Male Also analyses for prior 3 quarters, separately 
484 Rao 2018 IRR White ditto 
485 Rao 2018 IRR White ditto 
486 Rao 2018 IRR White ditto 
487 Rao 2018 IRR White ditto 
488 Rao 2018 IRR <30 ditto 
489 Rao 2018 IRR <30 ditto 
490 Rao 2018 IRR 1-2 ditto 
491 Rao 2018 IRR 0 Rx ditto 
492 Rao 2018 IRR 0 Rx ditto 
493 Rao 2018 IRR No ditto 
494 Rao 2018 IRR No ditto 
495 Rao 2018 IRR No ditto 
496 Rao 2018 IRR No ditto 
497 Rao 2018 IRR No ditto 
498 Rao 2018 IRR No ditto 
499 Rao 2018 IRR No ditto 
500 Rao 2018 IRR No ditto 
501 Rao 2018 IRR No ditto 
502 Rao 2018 IRR No ditto 
503 Rao 2018 IRR No ditto 
504 Rao 2018 IRR No ditto 
505 Rao 2018 IRR No ditto 
506 Rao 2018 IRR No ditto 
507 Rao 2018 IRR No ditto 
D-39 
 
Row Author Year Metric Comparator Note 
508 Rao 2018 IRR No ditto 
509 Rao 2018 IRR No ditto 
510 Rao 2018 IRR No ditto 
511 Rao 2018 IRR No ditto 
512 Rao 2018 IRR No ditto 
513 Rao 2018 IRR No ditto 
514 Rao 2018 IRR No ditto 
515 Rao 2018 IRR No ditto 
516 Rao 2018 IRR No ditto 
517 Rao 2018 IRR No ditto 
518 Rao 2018 IRR No ditto 
519 Rao 2018 IRR No ditto 
520 Rao 2018 IRR No ditto 
521 Rao 2018 IRR No ditto 
522 Rao 2018 IRR No ditto 
523 Rao 2018 IRR No ditto 
524 Rao 2018 IRR No ditto 
525 Rao 2018 IRR No ditto 
526 Rao 2018 IRR No ditto 
527 Rao 2018 IRR No ditto 
528 Rao 2018 IRR No ditto 
529 Rao 2018 IRR No ditto 
530 Rao 2018 IRR No ditto 
531 Rao 2018 IRR No ditto 
532 Santosa 2020 OR No  
533 Santosa 2020 OR No  
534 Santosa 2020 OR No  
535 Santosa 2020 OR No  
536 Santosa 2020 OR Minor surgery  
537 Santosa 2020 OR Rx only filled within 14 
days after surgical 
discharge 
 
538 Santosa 2020 OR OMEs < 75th percentile  
539 Santosa 2020 OR No refill  
540 Santosa 2020 OR No refill  
541 Santosa 2020 OR Age 65-69  
542 Santosa 2020 OR Age 65-69  
543 Santosa 2020 OR Age 65-69  
D-40 
 
Row Author Year Metric Comparator Note 
544 Santosa 2020 OR Age 65-69  
545 Santosa 2020 OR Male  
546 Santosa 2020 OR White  
547 Santosa 2020 OR White  
548 Santosa 2020 OR White  
549 Santosa 2020 OR Nonmetropolitan  
550 Santosa 2020 OR East north central  
551 Santosa 2020 OR East north central  
552 Santosa 2020 OR East north central  
553 Santosa 2020 OR East north central  
554 Santosa 2020 OR East north central  
555 Santosa 2020 OR East north central  
556 Santosa 2020 OR East north central  
557 Santosa 2020 OR East north central  
558 Santosa 2020 OR No  
559 Santosa 2020 OR CCI 0  
560 Santosa 2020 OR CCI 0  
561 Santosa 2020 OR CCI 0  
562 Santosa 2020 OR No  
563 Santosa 2020 OR No  
564 Santosa 2020 OR No  
565 Santosa 2020 OR No  
566 Santosa 2020 OR No  
567 Santosa 2020 OR No  
568 Santosa 2020 OR No  
569 Santosa 2020 OR No  
570 Santosa 2020 OR No  
571 Santosa 2020 OR No  
572 Santosa 2020 OR No  
573 Santosa 2020 OR No  
574 Schepis 2019 OR No past-year use  
575 Schepis 2019 OR No  
576 Shah 2019 OR (continuous) All 
577 Shah 2019 OR 65-74 All 
578 Shah 2019 OR 65-74 All 
579 Shah 2019 OR Male All 
580 Shah 2019 OR White All 
D-41 
 
Row Author Year Metric Comparator Note 
581 Shah 2019 OR White All 
582 Shah 2019 OR White All 
583 Shah 2019 OR Metropolitan All 
584 Shah 2019 OR Metropolitan All 
585 Shah 2019 OR Prostate cancer All 
586 Shah 2019 OR Prostate cancer All 
587 Shah 2019 OR Prostate cancer All 
588 Shah 2019 OR No All 
589 Shah 2019 OR No All 
590 Shah 2019 OR No All 
591 Shah 2019 OR No All 
592 Shah 2019 OR No All 
593 Shah 2019 OR No All 
594 Shah 2019 OR (continuous) Opioid naïve 
595 Shah 2019 OR 65-74 Opioid naïve 
596 Shah 2019 OR 65-74 Opioid naïve 
597 Shah 2019 OR Male Opioid naïve 
598 Shah 2019 OR White Opioid naïve 
599 Shah 2019 OR White Opioid naïve 
600 Shah 2019 OR White Opioid naïve 
601 Shah 2019 OR Metropolitan Opioid naïve 
602 Shah 2019 OR Metropolitan Opioid naïve 
603 Shah 2019 OR Prostate cancer Opioid naïve 
604 Shah 2019 OR Prostate cancer Opioid naïve 
605 Shah 2019 OR Prostate cancer Opioid naïve 
606 Shah 2019 OR No Opioid naïve 
607 Shah 2019 OR No Opioid naïve 
608 Shah 2019 OR No Opioid naïve 
609 Shah 2019 OR No Opioid naïve 
610 Shah 2019 OR No Opioid naïve 
611 Suda 2017 OR Male  
612 Suda 2017 OR 66-70  
613 Suda 2017 OR 66-70  
614 Suda 2017 OR 66-70  
615 Suda 2017 OR 66-70  
616 Suda 2017 OR 66-70  
617 Suda 2017 OR White  
D-42 
 
Row Author Year Metric Comparator Note 
618 Suda 2017 OR Hispanic  
619 Suda 2017 OR Full copay  
620 Suda 2017 OR Full copay  
621 Suda 2017 OR >5 miles  
622 Suda 2017 OR >5 miles  
623 Suda 2017 OR >5 miles  
624 Suda 2017 OR >5 miles  
625 Suda 2017 OR (continuous) inconsistent across variables 
626 Suda 2017 OR (continuous) Poorly defined, inconsistent across variables 
627 Suda 2017 OR Urban  
628 Suda 2017 OR (continuous) HCC=risk-adjustment model originally designed to 
estimate future health care costs for patients. 
629 Suda 2017 OR No  
630 Suda 2017 OR No  
631 Suda 2017 OR No  
632 Suda 2017 OR No  
633 Suda 2017 OR No  
634 Suda 2017 OR No  
635 Suda 2017 OR (continuous)  
636 Suda 2017 OR (continuous)  
637 Suda 2017 OR (continuous)  
638 Taipale 2019 HR Non-user  
639 Taipale 2019 HR 0 days (implied)  
640 Taipale 2019 HR 0 days (implied)  
641 Taipale 2019 HR 0 days (implied)  
642 Taipale 2019 HR 0 days (implied)  
643 Taipale 2019 HR No opioid (implied)  
644 Taipale 2019 HR No opioid (implied)  
645 Taipale 2019 HR No opioid (implied)  
646 Vozoris 2016 HR No use  
647 Vozoris 2016 HR No use  
648 Vozoris 2016 HR No use  
649 Vozoris 2016 HR No use  
650 Vozoris 2016 HR No use  
651 Vozoris 2016 HR No use  
652 Zeng 2019 HR Other analgesic 1 of multiple comparisons 




Row Author Year Metric Comparator Note 
654 Zoorob 2018 OR (continuous) ditto 
655 Zoorob 2018 OR (continuous) ditto 
656 Zoorob 2018 OR (continuous) ditto 
657 Zoorob 2018 OR (continuous) ditto 
658 Zoorob 2018 OR (continuous) ditto 
659 Zoorob 2018 OR (continuous) ditto 
660 Zoorob 2018 OR Non-rural ditto 
661 Zoorob 2018 OR (continuous) ditto 
 
Abbreviations: AD = Alzheimer disease, ADL = activities of daily living, AIDS = acquired immunodeficiency syndrome, ASA =  American Society of Anesthesiology 
(grade), AUD = alcohol use disorder, B = beta coefficient, BMI = body mass index, CAGE = alcohol use disorder prediction tool, COPD = chronic obstructive pulmonary 
disease, ED = emergency department, ER = emergency room, HR = hazard ratio, Hx = history of, ICU = intensive care unit, IRR = incidence rate ratio, MEq = morphine 
equivalents, MME = mean morphine equivalents, NS = nonsignificant, NSAID = nonsteroidal anti-inflammatory drug, OR = odds ratio, PTSD = posttraumatic stress disorder, 
QoL = quality of life, RR = risk ratio, RRR = relative risk ratio, Rx = prescription, SES = socioeconomic status, SUD = substance use disorder, TKA = total knee arthroplasty, 




Table D-4. Intervention Studies 
Author PMID GQ 3 Intervention GQ 3 Intent/Goal of Intervention 
Beaudoin 27426210 Screening Question / Questionnaire (e.g. that identify possible 
misuse by having older adults answer a series of questions) 
Intervention helps providers identify opioid misuse or opioid use 
disorder in older adults 
Chang 31187888 Motivational interviewing training Manage prescription opioid abuse among older adults 
Chen 31314748 Opioid safety initiative Reduce opioid prescriptions while maintaining pain control 
Cheng 31234786 Prediction Tool / Model Intervention helps providers identify opioid misuse or opioid use 
disorder in older adults 
Darchuk 20735746 Non-Pharmacologic Treatments (e.g. Cognitive Behavioral 
Therapy and Related Interventions) for Pain Control) 
Discontinuation of all opioid and simple analgesics taken for 
relief of chronic pain 





Bundle of educational modalities Decrease opioid discharge pack use in patients treated and 
released from the ED 
Henderson 26056833 Prediction Tool / Model Intervention helps providers identify opioid misuse or opioid use 
disorder in older adults 
Moyo 28498498, 
31372990 
Prescription drug monitoring program Reduce opioid prescriptions (state-wide) 
Park 21143370 Prediction Tool / Model Intervention helps providers identify opioid misuse or opioid use 
disorder in older adults 
Pasquale 2017 
29199396 
Provision of patient information; Educational materials Reduce pain- and opioid-related outcomes 
Rose 2016 26431852 Patient education pamphlet Safe opioid storage, opioid weaning, and opioid disposal; and 
post-operative opioid cessation 
Schaffer 29581162 Introduction of tamper resistant formulation Intervention helps providers reduce the risk of adverse events 
Tiet 30947051 Screening Question / Questionnaire (e.g. that identify possible 
misuse by having older adults answer a series of questions) 
Intervention helps providers identify opioid misuse or opioid use 
disorder in older adults 
Vicentini 31810456 Access to nonopioid Free acetaminophen prescription 
Yarbrough 28101955 Quality Improvement Initiatives / Implementation Strategies to 
Promoted Evidence-based Care 
Intervention helps providers reduce the risk of adverse events 




Table D-5. Baseline data for included studies 
Author PMID Mean 
Age 






Opioid Use Type 
Al Dabbagh 
26707940 









No 56 NR Appropriate prescription opioid use 
Alam 
22412106 
76 All of study 
population 
. Not an 
analyzed 
cohort 






. Unclear No 59 80 Misuse, prescription opioid, but not 















64.5 NR Several 
Carey 
29800019 


























No 58.6 NR Several 
Chang 2019 
31187888 
NR Unclear Unclear Unclear No NR NR Misuse, prescription opioid, but not 


















No 66 NR Misuse, prescription opioid, recreational (e.g, 











No 53 75 Several 
Choi 
30585135 









No NR NR Several 
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Author PMID Mean 
Age 






Opioid Use Type 
Cochran 
28489491 










No 66.7 NR Misuse, prescription opioid, but not 














Medicare 76 84 Several 
Daoust 
28767563 










No 69.2 NR Misuse, prescription opioid, but not 












No 50 76 Appropriate prescription opioid use 
Draper 
25247846 
81.9 All of study 
population 
Unclear Unclear No 63.3 NR Several 
Gold 
27564407 












No 58.1 87.3 Misuse, prescription opioid, recreational (e.g, 






































Veterans NR NR Appropriate prescription opioid use 
Hamina 
28092324 









No NR NR Appropriate prescription opioid use 
Henderson 
26056833 












No 58 100 Several 
Hoffman 
28531306 
67 Unclear Unclear Unclear No 47.2 NR Appropriate prescription opioid use 
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Author PMID Mean 
Age 






Opioid Use Type 
Inacio 
27130165 









No 51.3 NR Appropriate prescription opioid use 
Jain 
29561298 
65.6 Unclear Unclear Unclear No 58.5 75.1 Appropriate prescription opioid use 
Jeffery 
28967517 











Medicare 63.3 81.1 Appropriate prescription opioid use 
Karttunen 
30370943 









No 70 NR Appropriate prescription opioid use 
Kuo 
26522794 












Medicare 67.2 81.8 Appropriate prescription opioid use 
Lalic 
29451672 











No NR NR Appropriate prescription opioid use 
Lindestrand 
25952252 









No 72 NR Several 
Lo-Ciganic 
30901048 









Medicare 63 82 Misuse, prescription opioid, but not 
recreational (e.g., taking more than prescribed) 
McDermott 
30396321 

























Medicare 62 78.3 Appropriate prescription opioid use 
Namba 
29753617 











No 62.9 65.9 Several 
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Author PMID Mean 
Age 






Opioid Use Type 
Park 
20664342 










No 31.3 51.5 Misuse, prescription opioid, but not 
recreational (e.g., taking more than prescribed) 
Park 
21143370 










No 29.3 50.7 Misuse, prescription opioid, but not 
recreational (e.g., taking more than prescribed) 
Pasquale 
29199396 






















No 48.1 80.5 Appropriate prescription opioid use 
Rose 
26431852 









No 58 NR Appropriate prescription opioid use 
Schaffer 
29581162 











No NR NR Misuse, prescription opioid, but not 
recreational (e.g., taking more than prescribed) 
Schepis 
30328160 










No NR NR Misuse, prescription opioid, recreational (e.g, 















Medicare 56 74 Misuse, prescription opioid, but not 
recreational (e.g., taking more than prescribed) 
Suda 
28408172 










Veterans 22.3 NR Appropriate prescription opioid use 
Taipale 
30325873 











No 66.7 NR Appropriate prescription opioid use 
Tiet 2019 
30947051 









Veterans 5 54.7 Opioid use disorder 
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Author PMID Mean 
Age 



















No 79.3 NR Appropriate prescription opioid use 
Vozoris 
27418553 












Appropriate prescription opioid use 
Yarbrough 
28101955 









Medicare NR NR Unclear/Undefined/Other 
Zeng 
30860559 









No 63 NR Appropriate prescription opioid use 
Zoorob 
29537112 










Medicare NR NR Appropriate prescription opioid use 




Table D-6. Study design data of included studies 
Author 
PMID 

















































































Retrospective Longitudinal Canada Outpatient / 
community 
/ clinics 












































USA Several or 
Transitions 
of Care 




























































USA Unclear / 
Undefined 



























Norway Outpatient / 
community 
/ clinics 





































































































Retrospective Longitudinal Canada Outpatient / 
community 
/ clinics 






























Prospective Longitudinal USA Outpatient / 
community 
/ clinics 











Australia Several or 
Transitions 
of Care 






































































Retrospective Longitudinal USA Several or 
Transitions 
of Care 









Prospective Longitudinal Finland Several or 
Transitions 
of Care 


















































































Retrospective Longitudinal Australia Inpatient / 
hospital 

























































Retrospective Longitudinal USA Several or 
Transitions 
of Care 
































































































Retrospective Longitudinal USA Several or 
Transitions 
of Care 
























Prospective Longitudinal Australia Unclear/Un
defined 


































































Retrospective Longitudinal US Outpatient / 
community 
/ clinics 





























Retrospective Longitudinal USA Several or 
Transitions 
of Care 









































Prospective Longitudinal US Outpatient / 
community 
/ clinics 




























Prospective Longitudinal US Outpatient / 
community 
/ clinics 





























Prospective Longitudinal US Several or 
Transitions 
of Care 






























Prospective Longitudinal USA Unclear/Un
defined 













































Prospective Longitudinal Canada Inpatient / 
hospital 



























Prospective Longitudinal Australia Outpatient / 
community 
/ clinics 















US Outpatient / 
community 
/ clinics 

















Retrospective Longitudinal US Unclear/Un
defined 

























US Outpatient / 
community 
/ clinics 















Finland Outpatient / 
community 
/ clinics 













Prospective Longitudinal US Outpatient / 
community 
/ clinics 















Prospective Longitudinal Italy Outpatient / 
community 
/ clinics 


































Canada Several or 
Transitions 
of Care 




















































Retrospective Longitudinal UK Outpatient / 
community 
/ clinics 



























































Appendix E. Rejected Articles 
Table E-1. Rejected studies: Did not meet principal eligibility criteria 
Author PMID Rejection Reason Mean age 
Sumner 26383533 Age <50 (mean or median) and no subgroup >=60 
 
Banerjee 27552496 Age <50 (mean or median) and no subgroup >=60 49.7 
Banerjee 31145217 Age <50 (mean or median) and no subgroup >=60 NR 
Bates 27770163 Age <50 (mean or median) and no subgroup >=60 49.9 
Becker 18222051 Age <50 (mean or median) and no subgroup >=60 
 
Bedard 29958754 Age <50 (mean or median) and no subgroup >=60 NR 
Bedard 29452972 Age <50 (mean or median) and no subgroup >=60 NR 
Bohnert 26807540 Age <50 (mean or median) and no subgroup >=60 
 
Choi 31071494 Age <50 (mean or median) and no subgroup >=60 
 
Cicero 21831562 Age <50 (mean or median) and no subgroup >=60 25-34 
Curtis 16704515 Age <50 (mean or median) and no subgroup >=60 38 
Darke 19489991 Age <50 (mean or median) and no subgroup >=60 29.3 
Deyo 23459134 Age <50 (mean or median) and no subgroup >=60 48.6 
Dursteler-MacFarland 21592331 Age <50 (mean or median) and no subgroup >=60 38 
Edelman 27186715 Age <50 (mean or median) and no subgroup >=60 48 
Gilbert 20309384 Age <50 (mean or median) and no subgroup >=60 48.7 
Gotthardt 26747613 Age <50 (mean or median) and no subgroup >=60 44 
Johnson 17682079 Age <50 (mean or median) and no subgroup >=60 39.3 
Kaasalainen 103802641 Age <50 (mean or median) and no subgroup >=60 45 
Mancino 20465373 Age <50 (mean or median) and no subgroup >=60 48.2 
McHugh 2016-41984-001 Age <50 (mean or median) and no subgroup >=60 28.4 
Merlo 26971079 Age <50 (mean or median) and no subgroup >=60 43 
Ogle 22925507 Age <50 (mean or median) and no subgroup >=60 41.8 
Oliva 26675643 Age <50 (mean or median) and no subgroup >=60 48.7 
Pope 27353833 Age <50 (mean or median) and no subgroup >=60 49 
Santora 17935930 Age <50 (mean or median) and no subgroup >=60 42 
Scherrer 2016-08181-001 Age <50 (mean or median) and no subgroup >=60 49 
Shi 21951787 Age <50 (mean or median) and no subgroup >=60 49 
Song 29200349 Age <50 (mean or median) and no subgroup >=60 47.6 
Summers 129418933 Age <50 (mean or median) and no subgroup >=60 46 
Trafton 16562404 Age <50 (mean or median) and no subgroup >=60 49 
Tye 28187073 Age <50 (mean or median) and no subgroup >=60 49 
White 19789432 Age <50 (mean or median) and no subgroup >=60 
 
Wichmann 22505303 Age <50 (mean or median) and no subgroup >=60 34.2 
Ahn 26360141 Age <50 (mean or median) and no subgroup >=60 NR 
Wu 17000351 Age 50-59.9 (mean or median) and no subgroup >=60 53 
Alemi 30283729 Age 50-59.9 (mean or median) and no subgroup >=60 59.45 
Annaheim 28835980 Age 50-59.9 (mean or median) and no subgroup >=60 58.8 
E-2 
 
Author PMID Rejection Reason Mean age 
Armaghani 25417827 Age 50-59.9 (mean or median) and no subgroup >=60 57 
Back 19542794 Age 50-59.9 (mean or median) and no subgroup >=60 51.6 
Barnett 31144281 Age 50-59.9 (mean or median) and no subgroup >=60 58.4 
Barry 21354703 Age 50-59.9 (mean or median) and no subgroup >=60 52 
Barry 30176548 Age 50-59.9 (mean or median) and no subgroup >=60 52 
Bell 26684868 Age 50-59.9 (mean or median) and no subgroup >=60 
 
Brown 22320029 Age 50-59.9 (mean or median) and no subgroup >=60 NR 
Campbell 29410132 Age 50-59.9 (mean or median) and no subgroup >=60 51.8 
Campbell 20724688 Age 50-59.9 (mean or median) and no subgroup >=60 
 
Carroll 22729963 Age 50-59.9 (mean or median) and no subgroup >=60 58 
Carroll 2016-04174-019 Age 50-59.9 (mean or median) and no subgroup >=60 58.1 
Chang 25159493 Age 50-59.9 (mean or median) and no subgroup >=60 59.1 
Choung 19367263 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Compton 18508231 Age 50-59.9 (mean or median) and no subgroup >=60 53 
Conner 2010-02907-004 Age 50-59.9 (mean or median) and no subgroup >=60 NR, but in 50s 
de Sola 29248566 Age 50-59.9 (mean or median) and no subgroup >=60 50.5 
Demidenko 28807135 Age 50-59.9 (mean or median) and no subgroup >=60 55 
Dobscha 23269280 Age 50-59.9 (mean or median) and no subgroup >=60 56.8 
Duensing 20429822 Age 50-59.9 (mean or median) and no subgroup >=60 53 
Edelman 30615036 Age 50-59.9 (mean or median) and no subgroup >=60 55 
Engel 25202832 Age 50-59.9 (mean or median) and no subgroup >=60 56.8 
Fareed 19461397 Age 50-59.9 (mean or median) and no subgroup >=60 55.6 
Fareed 104694982 Age 50-59.9 (mean or median) and no subgroup >=60 52 
Frank 25716075 Age 50-59.9 (mean or median) and no subgroup >=60 58.5 
Gaither 30122319 Age 50-59.9 (mean or median) and no subgroup >=60 51 
Garcia 28807366 Age 50-59.9 (mean or median) and no subgroup >=60 57 
Gressler 29189516 Age 50-59.9 (mean or median) and no subgroup >=60 57.3 
Hansen 26899477 Age 50-59.9 (mean or median) and no subgroup >=60 51.6 
Hartel 16838244 Age 50-59.9 (mean or median) and no subgroup >=60 NR 
Hausmann 23273103 Age 50-59.9 (mean or median) and no subgroup >=60 57 
Hser 15669446 Age 50-59.9 (mean or median) and no subgroup >=60 58.4 
Hser 11343531 Age 50-59.9 (mean or median) and no subgroup >=60 57.4 
Ives 16595013 Age 50-59.9 (mean or median) and no subgroup >=60 52 
Kim 27869630 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Lane 29044798 Age 50-59.9 (mean or median) and no subgroup >=60 56.3 
Larney 25575652 Age 50-59.9 (mean or median) and no subgroup >=60 55 
Liebschutz 28715535 Age 50-59.9 (mean or median) and no subgroup >=60 54.7 
Lintzeris 26498741 Age 50-59.9 (mean or median) and no subgroup >=60 55 
Loftus 20693876 Age 50-59.9 (mean or median) and no subgroup >=60 51.5 
Lofwall 15857727 Age 50-59.9 (mean or median) and no subgroup >=60 53.9 
Mahowald 15641058 Age 50-59.9 (mean or median) and no subgroup >=60 59 
Manhapra 26429726 Age 50-59.9 (mean or median) and no subgroup >=60 52.73 
E-3 
 
Author PMID Rejection Reason Mean age 
Marienfeld 25781867 Age 50-59.9 (mean or median) and no subgroup >=60 55.4 
McPherson 29905648 Age 50-59.9 (mean or median) and no subgroup >=60 54.6 
Morasco 18291290 Age 50-59.9 (mean or median) and no subgroup >=60 59.8 
Morasco 21562923 Age 50-59.9 (mean or median) and no subgroup >=60 54.2 
Naliboff 21111684 Age 50-59.9 (mean or median) and no subgroup >=60 52.6 
Nielsen 28067693 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Ompad 2016-44052-004 Age 50-59.9 (mean or median) and no subgroup >=60 55.8 
Outlaw 2012-07962-004 Age 50-59.9 (mean or median) and no subgroup >=60 58.5 
Painter 29095057 Age 50-59.9 (mean or median) and no subgroup >=60 53.8 
Peters 29122425 Age 50-59.9 (mean or median) and no subgroup >=60 57 
Radmard 30049329 Age 50-59.9 (mean or median) and no subgroup >=60 58.75 
Reid 11929502 Age 50-59.9 (mean or median) and no subgroup >=60 54 
Rodgers 22410178 Age 50-59.9 (mean or median) and no subgroup >=60 54 
Rojas 29915947 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Roland 30589633 Age 50-59.9 (mean or median) and no subgroup >=60 56.1 
Rosen 15331811 Age 50-59.9 (mean or median) and no subgroup >=60 NR (but in the 50s) 
Rosen 18515693 Age 50-59.9 (mean or median) and no subgroup >=60 53 
Rosenthal 30199478 Age 50-59.9 (mean or median) and no subgroup >=60 51 
Ruggles 27475945 Age 50-59.9 (mean or median) and no subgroup >=60 50 
Scherrer 26755784 Age 50-59.9 (mean or median) and no subgroup >=60 55.4 
Sekhon 23746149 Age 50-59.9 (mean or median) and no subgroup >=60 58 
Sharan 29244102 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Taber 27983881 Age 50-59.9 (mean or median) and no subgroup >=60 55.9 
Torres 21451118 Age 50-59.9 (mean or median) and no subgroup >=60 55 
Vargas-Schaffer 28340165 Age 50-59.9 (mean or median) and no subgroup >=60 57 
Wilder 26566771 Age 50-59.9 (mean or median) and no subgroup >=60 (two clinics reported 
separately) 55.2, 46.2 
Williams 25265035 Age 50-59.9 (mean or median) and no subgroup >=60 59.4 
Wilsey 19594846 Age 50-59.9 (mean or median) and no subgroup >=60 57.5 
Zywiel 22048093 Age 50-59.9 (mean or median) and no subgroup >=60 56 
Vakharia 30547120 Age NR (mean or median) and no subgroup >=60 NR 
Vakharia 30918797 Age NR (mean or median) and no subgroup >=60 NR 
Williams 29735614 Age NR (mean or median) and no subgroup >=60 NR 
West 26660909 Age NR (mean or median) and no subgroup >=60   
Seppala 29402646 Age NR (mean or median) and no subgroup >=60 
 
Vallerand 106574301 Age NR (mean or median) and no subgroup >=60 
 
Scherrer 28033519 Age NR (mean or median) and no subgroup >=60 
 
Adogwa 30292669 Age NR (mean or median) and no subgroup >=60 
 
Boylan 29681163 Age NR (mean or median) and no subgroup >=60 NR 
Bradford 29610897 Age NR (mean or median) and no subgroup >=60 
 
Chindalore 15943961 Age NR (mean or median) and no subgroup >=60 
 




Author PMID Rejection Reason Mean age 
Gaither 27610580 Age NR (mean or median) and no subgroup >=60 
 
Hadland 30657529 Age NR (mean or median) and no subgroup >=60 
 
Hamilton 19418342 Age NR (mean or median) and no subgroup >=60 NR 
Hernandez 30099175 Age NR (mean or median) and no subgroup >=60 
 
Hoggatt 2017-14649-001 Age NR (mean or median) and no subgroup >=60 
 
Huhn 30384321 Age NR (mean or median) and no subgroup >=60 NR 
Hyer 19928594 Age NR (mean or median) and no subgroup >=60 
 
Im 2015-27785-022 Age NR (mean or median) and no subgroup >=60 NR 
Lin 30646077 Age NR (mean or median) and no subgroup >=60 NR 
Lin 18075408 Age NR (mean or median) and no subgroup >=60 
 
Lin 26129993 Age NR (mean or median) and no subgroup >=60 NR 
Maust 30554562 Age NR (mean or median) and no subgroup >=60 
 
Maxwell 2011-11276-005 Age NR (mean or median) and no subgroup >=60 NR 
Moriya 30395428 Age NR (mean or median) and no subgroup >=60 NR 
Mosher 28340259 Age NR (mean or median) and no subgroup >=60 NR 
Mowbray 26093503 Age NR (mean or median) and no subgroup >=60 NR 
Oliva 22115887 Age NR (mean or median) and no subgroup >=60 NR 
Palamar 30553910 Age NR (mean or median) and no subgroup >=60 NR 
Parsons 2014-25113-001 Age NR (mean or median) and no subgroup >=60 
 
Patel 28983558 Age NR (mean or median) and no subgroup >=60 NR 
Pierce 29573622 Age NR (mean or median) and no subgroup >=60 NR 
Powell 29408153 Age NR (mean or median) and no subgroup >=60 
 
Sayuk 29327358 Age NR (mean or median) and no subgroup >=60 NR 
Shiner 28481727 Age NR (mean or median) and no subgroup >=60 
 
Vasilenko 28938183 Age NR (mean or median) and no subgroup >=60 
 
Wall 29220668 Age NR (mean or median) and no subgroup >=60 
 
Wei 30747958 Age NR (mean or median) and no subgroup >=60 NR 
Krebs 2018-12570-001 Comparison of opioid vs non-opioid only (no high-risk 
subgroups identified or effect modification analyses) 
 
Basak 31210142 Comparison of opioid vs non-opioid only (no high-risk 
subgroups identified or effect modification analyses) 
 
Rose 30471102 Comparison with younger only (not *among* older adults) NR 
Roy 28831278 Comparison with younger only (not *among* older adults)  
Abrams 21609851 Comparison with younger only (not *among* older adults) NR 
Badrakalimuthu 104314645 Comparison with younger only (not *among* older adults)  
Bedard 29292342 Comparison with younger only (not *among* older adults) NR 
Bedard 28917616 Comparison with younger only (not *among* older adults) NR 
Bohnert 21467284 Comparison with younger only (not *among* older adults) NR 
Bohnert 28301070 Comparison with younger only (not *among* older adults) NR 
Boscarino 20712819 Comparison with younger only (not *among* older adults) NR 
Carew 30317161 Comparison with younger only (not *among* older adults)  
Chan 30855717 Comparison with younger only (not *among* older adults) NR 
E-5 
 
Author PMID Rejection Reason Mean age 
Cryar 29705679 Comparison with younger only (not *among* older adults)  
Firoz 15353395 Comparison with younger only (not *among* older adults)  
Gagliese 10969291 Comparison with younger only (not *among* older adults)  
Huang 29161066 Comparison with younger only (not *among* older adults) NR 
Orhurhu 31077526 Comparison with younger only (not *among* older adults)  
Papaleontiou 20533971 Comparison with younger only (not *among* older adults)  
Pillans 28253466 Comparison with younger only (not *among* older adults)  
Rudd 26720857 Comparison with younger only (not *among* older adults)  
Saha 27337416 Comparison with younger only (not *among* older adults)  
Vanderlip 25277462 Comparison with younger only (not *among* older adults)  
Westermeyer 2016-41355-009 Comparison with younger only (not *among* older adults)  
Zautcke 11781905 Comparison with younger only (not *among* older adults) NR 
Al Achkar 29347984 Comparison with younger only (not *among* older adults) NR 
Bartels 2018-23449-011 Comparison with younger only (not *among* older adults) NR 
Bartels 29627407 Comparison with younger only (not *among* older adults) NR 
Bauer 26848633 Comparison with younger only (not *among* older adults)  
Choi 2017-49027-001 Duplicate 
 
Griffioen 2017-24682-006 Duplicate 
 
Han 2019-13421-016 Duplicate 
 
Larney 2015-00317-001 Duplicate 
 
Neutel 2014-05096-015 Duplicate 
 
Otten 2011-27935-004 Duplicate 
 
Park 2011-14318-002 Duplicate 
 
Shi 2012-15263-006 Duplicate 
 
Tevik 2018-18441-001 Duplicate 
 
Zedler 2014-51975-011 Duplicate 
 
Carew 29136566 Duplicate   
Wu 24163278 Duplicate 
 
Bedard 28413136 Mean age <65 and no other age info or analyses NR 
Campbell 26011277 Mean age <65 and no other age info or analyses 59 
Chang 29523356 Mean age <65 and no other age info or analyses 60.4 
Chang 31187888 Mean age <65 and no other age info or analyses NR 
Chenaf 27592608 Mean age <65 and no other age info or analyses 62.7 
Hakkinen 25447184 Mean age <65 and no other age info or analyses NR 
Kim 28844770 Mean age <65 and no other age info or analyses 62.4 
Knudsen 2011-04767-011 Mean age <65 and no other age info or analyses 62.2 
Maree 27567185 Mean age <65 and no other age info or analyses NR 
Pugely 29653244 Mean age <65 and no other age info or analyses NR 
Rose 26431852 Mean age <65 and no other age info or analyses 63 
Rosen 21237575 Mean age <65 and no other age info or analyses NR 
Schwarzkopf 26897490 Mean age <65 and no other age info or analyses 61 
Sing 27451080 Mean age <65 and no other age info or analyses 61 
E-6 
 
Author PMID Rejection Reason Mean age 
Turner 26785321 Mean age <65 and no other age info or analyses 64 
Von Korff 28113120 Mean age <65 and no other age info or analyses 64 
Wong 22059201 Mean age <65 and no other age info or analyses 52 
Tevik 30999872 No opioids 
 
Tevik 28886172 No opioids 
 
Tevik 30990815 No opioids 
 
Almeida 30029154 No opioids 
 
Arinzon 2006-05685-002 No opioids 
 
Blazer 105444706 No opioids 
 
Chhatre 28830504 No opioids 
 
Choi 25923291 No opioids 
 
Choi 29560840 No opioids 
 
Colliver 106460745 No opioids 
 
Goebel 21256706 No opioids 
 
Hawkins 22305658 No opioids 
 
Lau 106601191 No opioids 
 
Lay 105804666 No opioids 
 
Reynoso-Vallejo 28853974 No opioids 
 
Yee 16288080 No opioids 
 
Zarba 15667402 No opioids 
 
Zuckerman 16862033 No opioids 
 
Bosley 14728635 No opioids 75 
Gatti 21491171 No outcome of interest 
 
Glintborg 18344106 No outcome of interest 
 
Griffioen 27739258 No outcome of interest 
 
Hollingworth 25845470 No outcome of interest 
 
Hubbard 25877120 No outcome of interest 
 
Hwang 27079639 No outcome of interest 
 
Ilgen 20553655 No outcome of interest 
 
Jones 27387857 No outcome of interest 
 
Kann 24842594 No outcome of interest 
 
Kennedy 21134724 No outcome of interest 
 
Khalid 29253702 No outcome of interest 
 
Krantz 15771942 No outcome of interest 
 
Krebs 28893675 No outcome of interest 
 
Lewis 20624241 No outcome of interest 
 
Loughrey 12850423 No outcome of interest 
 
Malte 29287034 No outcome of interest 
 
McAlpine 18374970 No outcome of interest 
 
Minner 106496731 No outcome of interest 
 
Morasco 26516794 No outcome of interest 
 




Author PMID Rejection Reason Mean age 
Namba 29934272 No outcome of interest 
 
Nelson 22266156 No outcome of interest 
 
Pasquale 24268019 No outcome of interest 
 
Pergolizzi 2011-14318-003 No outcome of interest 
 
Tiet 2015 26075352 No outcome of interest  
Zhao 30653178 Not high-income country 
 
Safaei 19260339 Not high-income country 
 
Ping 27023332 Not high-income country 
 
Sharma 11868024 Not high-income country 
 
Mattson 28650597 Not primary study or SR 
 
Atkinson 24161287 Not primary study or SR 
 
Bush 26913328 Not primary study or SR 
 
Green 2017-39484-002 Not primary study or SR 
 
Licht 19947072 Not primary study or SR 
 
O'Neil 23036838 Not primary study or SR 
 
Pollice 18547496 Not primary study or SR 
 
Salmon 104515908 Not primary study or SR 
 
Taylor 23251860 Not primary study or SR 
 
 105902518 Not primary study or SR 
 
Joshi 30718033 Not primary study or SR 
 
Cherrier 2009-15780-001 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
da Costa 25229835 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Dauri 24567278 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Grieff 26943250 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Kaczocha 29486720 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Karlsson 19393841 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Leegaard 21099695 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Otten 22124189 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Roth 10737286 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Vorsanger 2011-18891-005 Opioid effectiveness study of pain control only (not misuse 
or decreasing opioid use) 
 
Abbreviaton: PMID = PubMed identifier.  
E-8 
 
Table E-2. Articles that did not report multivariable analyses or on interventions 














































































































Abbreviation: PMID = PubMed identifier. 
